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Synopsis
1Synopsis...
A comprehensive summary of the work to be incorporated in the thesis entitled
“Studies on synthesis of bioactive compounds and HPLC profile of some
pharmaceutical formulation” has been describe as under.
PART-[A]: HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME
PHARMACEUTICAL FORMULATION.
PART-[B]: STUDIES ON SYNTHESIS OF BIOACTIVE COMPOUNDS.
PART-[A]: HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME
PHARMACEUTICAL FORMULATION.
 The research work undertaken in these studies mainly addresses analysis and
validation protocol, development of stability indicating HPLC methods according to ICH
guidelines.  Our strategy for active pharmaceutical ingredient and formulation.
Aim of work
To develop stability indicating high performance liquid chromatographic methods
for the estimation of some active pharmaceutical ingredient from their single/combine
pharmaceutical dosage forms by HPLC and to perform the validation procedure for
same
Experimental Work
• Development of analytical method
Selection of mobile phase
Selection of stationary phase
Choice of flow-mode and flow rate
Selection of wave-length
Injection volume / Concentration
Selection of diluent
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• Validation of analytical method
Specificity study
Linearity and range study
Precision and Intermediate precision study
Accuracy study
Robustness study
Solution stability study
System suitability
Limit of detection and limit of quantification
We have undertaken the work on nebivolol, aspirin and clopidogrel and
aceclofenac and tramadol hydrochloride which are described as under
Section-I : HPLC Method Development and Validation of  Nebivolol
Nebivolol is an antihypertensive compound. It is chemically 1-(6-fluorochroman-
2-yl)-2-[(2-(6- fluorochroman-2-yl)-2-hydroxy-ethyl] amino] ethanol (Figure 1). Its
molecular formula is C22H25F2NO4 having molecular weight 405.435 g/mole. It is most
selective â1 receptor antagonist currently available for clinical use.
O N
OH
O
OH
F F
H
     (Figure 1)
Developed Chromatographic parameters are as under
Mobile phase: Buffer-ACN (65: 35, v/v)
Buffer: 50 mM phosphate buffer with 2 ml triethylamine, pH 3.5
with H3PO4
Column: Phenomenex, C8 (250 mm x  4.6 mm i.d., 5µ particle size)
Flow rate: 1 ml/min
Wavelength: 280 nm
Injection volume: 20 µl
Diluent: Mobile phase
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The developed procedure has been evaluated over the specificity, linearity,
accuracy, precision, limit of detection, limit of quantification and robustness in order to
ascertain the stability of the analytical method. It has been proved that it was specific,
linear, precise, accurate and robust and stability indicating. Hence, the method is
recommended for routine quality control analysis and also for stability of sample analysis.
Section-II: HPLC Method Development and Validation of Combine Dosage form
of Aspirin and Clopidogrel
Aspirin (Acetylsalicylic acid) (Figure 2) is a non-steroidal anti-inflammatory drug
that exhibits anti-inflammatory, analgesic and antipyretic activities. Clopidogrel [S-(a)(2-
chlorophenyl)-6,7-dihydrothieno (3,2-C) pyridine-5 (4H) acetic acid methyl ester
sulphate]  (Figure 3) is a platelet aggregation inhibitor and act as a an anticoagulant.
COOH
O
O
CH3
N
S
O OCH3
Cl
(Figure 2) (Figure 3)
Developed Chromatographic parameters are as under
Mobile phase:  Buffer-ACN(65: 35, v/v)
Buffer: 0.3% orthophosphoric acid
Column: Phenomenex, C8 (250 mm x  4.6 mm i.d., 5µ particle size)
Flow rate: 1 ml/min
Wavelength: 226 nm
Injection volume: 20 µl
Diluent: Mobile phase
The developed procedure has been evaluated over the specificity, linearity,
accuracy, precision, limit of detection, limit of quantification and robustness in order to
ascertain the stability of the analytical method. It has been proved that it was specific,
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linear, precise, accurate and robust and stability indicating. Hence, the method is suitable
for routine quality control analysis and also for stability sample analysis.
Section-III: HPLC Method Development and Validation  of Combine Dosage form
of  Tramadol hydrochloride and Aceclofenac
Tramadol hydrochloride and aceclofenac are available in combined tablet dosage
form. Aceclofenac (Figure 4) is 2-[(2,6-dichlorophenyl)amino] benzene acetic acid
carboxy methyl ester has analgesic and anti – inflammatory activity. Tramadol (Figure 5)
is (1R,2R)-rel-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol has
analgesic activity.
O
O COOH
NH
Cl Cl
OH
O
CH3
H
N
CH3 CH3
         (Figure 4)        (Figure 5)
Developed Chromatographic parameters are as under
Mobile phase: Buffer-ACN (65: 35, v/v)
Buffer: 0.01M ammonium acetate buffer with 2 ml triethylamine,
pH 6.5 with glacial Acetic acid
Column: Phenomenex, C18 (250 mm x  4.6 mm i.d., 5µ particle size)
Flow rate: 1 ml/min
Wavelength: 270 nm
Injection volume: 20 µl
Diluent: Water: ACN (50: 50, v/v)
The developed procedure has been evaluated over the specificity, linearity,
accuracy, precision, limit of detection, limit of quantification and robustness in order to
ascertain the stability of the analytical method. It has been proved that it was specific,
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linear, precise, accurate and robust and stability indicating. Hence, the method is very
useful for routine quality control analysis and also for stability sample analysis.
PART-[B]: STUDIES ON SYNTHESIS OF BIOACTIVE COMPOUNDS
Tetrahydropyrimidine and their derivatives represent one of the most active classes
of calcium channel blockers and it also possessing wide spectrum of biological activities.
In order to develop better medicinally important compounds, it was considered of interest
to synthesize some new dihydropyrimidinonthione and their derivatives as under.
SECTION-I: Synthesis, characterization and antimicrobial screening of N-(4-
chlorophenyl)-6-methyl-4-aryl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxamides.
This section covers literature survey, mechanistic studies, and different alternative
routes for the synthesis of parent compounds. DHPMs and their derivatives have attracted
interest in medicinal chemistry, exhibiting pharmacological and therapeutic properties
such as antiinflammatory, antiviral, antibacterial, antitumor, calcium channel antagonist
antihypertensive agent and anticancer. Recently DHPMs have been implicated in the
catabolism of pyrimidine base. Various catalyst for mild, rapid high yielding protocol,
several ionic liquids mediated synthesis, solid phase synthesis, microwave and ultrasound
assisted synthesis are described in detail in the introductory part of this section.
N-(4-chlorophenyl)-3-oxobutanamide react with thiourea and different aromatic
aldehydes to give tetrahydropyrimidines. General structure of synthesized compounds is
represented as under.
NH
N
H
O
NH
Cl
CH3 S
R
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SECTION-II: Synthesis, characterization and antimicrobial screening of N- (4-
chlorophenyl)-7-methyl-5-aryl-2,3-dihydro-5H-thiazolol [3,2-a]pyrimidine-6-
carboxamides.
In this section we have carried out the synthesis of N-(4-chlorophenyl)-7-methyl-
5-aryl-2,3-dihydro-5H-thiazolol[3,2-a]pyrimidine-6-carboxamides by the reaction of
N-(4-chlorophenyl)-6-methyl-4-aryl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxamides with 1,2-dibromoethane using DMF as a solvent.
N
N
O
NH
Cl
CH3 S
R
All the compounds are well characterized by 1H NMR, FT-IR and mass spectral
techniques. Selected compounds have been evaluated for their in vitro antimicrobial
activity towards gram positive, gram negative bacterial strains and fungi.
HPLC Method Development and Validation
of some Pharmaceutical Formulation
Part-[A]
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INTRODUCTION
1. History and Instrumentation
The year 2003 was the year of centenary of chromatography .In fact it was LC-
liquid chromatography/column chromatography from used by Tswett in 1903 and coined
a name of CHROMATOGRAPHY to this new technique. In column liquid
chromatography during last four decades, however, there has been an explosive spurt in
activity to revitalize this apparently passive technique. The tremendous advancements in
the researches in biochemistry, diagnostic medicine and pharmaceutical materials were
mainly responsible for triggering the explosive growth of LC, as many of the chemical
substances falling under these heads were nonvolatile, so that Gas Chromatography (GC)
could not be exploited to study them. It is worth mentioning here that, in spite of the
extraordinary success and wide applicability of GC, only about 15% of organic materials
are amenable to direct GC analysis. Among the remaining 85% can be included most
kinds of plastics and resins, and many pharmaceuticals, pollutants, biochemical materials,
dyes, pigments, etc. Insufficient volatility and thermal instability of such compounds are
mainly responsible for this unfortunate limitation imposed on GC.
On the contrary, LC does not suffer from the limitation of GC mentioned above.
It is ideally suited for the separation of nonvolatile or unstable materials. The clear aim,
therefore, in the surge of interest and activity in LC was to make it a complementary
technique to GC. Naturally, a prerequisite for success in this line turned out to be the
achievement for LC, many of the commendable and accepted features of GC, such as
high resolving power, fast analysis, continuous monitoring of column effluent, ease and
simplicity of operation, precise identification based on accurate measurement of retention
parameters, accurate quantitative measurement, repetitive analysis with the same column
and, finally, automation of the complete analysis and data handling operation.
During the last four decades, very fast development has been going on in what is
now being described as High Performance Liquid Chromatography (HPLC) in
columns. With the availability of pumps capable of producing pressures of a few thousand
psi, a typical HPLC analysis takes only a few minutes, compared to several hours required
by its “classical” form to achieve a similar result. This situation is essentially the
culmination of the efforts put forward by instrument manufacturers. As a result, HPL
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chromatographs have taken their rightful place beside the gas chromatographs in almost
every type of analytical laboratory.
HPLC today is the product of quarter century of refinement, driven by technical
advances and economic competition in a USD 2 Billon plus equipment market. Recently,
manufactures have improved HPLC’S performance easier. The proteomics researchers
need high resolution and small sample capabilities and the pharmaceutical industries
demand for high throughput screening for drug discovery. The HPLC instrumentation
took on the basis of these demands.
To increase the throughput, the systems with multi columns and more efficient
stationary phases are being developed. It appears that the advances in column
technology have significantly overtaken the advances in instrumental and hardware
aspects of HPLC.
The temperature programming of columns in HPLC is a new trend emerging.
The temperature programming adds a third dimension (in addition to mobile phase
and stationary phase) to HPLC. This increases the speed, selectivity and efficiency
of HPLC.
Lowering limits of detection and increasing method sensitivity have the goals
of analysts since the advent of liquid chromatography. It was soon recognized that
using smaller bore columns would improve sensitivity, but a lack of affordable and
suitable HPLC instrumentation meant that micro HPLC was the province of research
departments. Only recently has micro HPLC become popular, due mainly to the
increasing popularity of LCMS and to the improvements in instrument technology.
This demand was largely driven by chromatographers working with small complex
biological samples. It requires highly sensitive separation techniques.
The choice of multi detectors and diode array and mass spectrometers to analyze
the stream from the chromatography column means the results with more data per sample
and hence data handling and interpretation tools are required.
A schematic diagram of HPLC equipment is given in Figure 1 [1].
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Figer-1 Schematic diagram of HPLC equipment
The basic components of HPLC are: [2-6]
(i) Pumping System
(ii) Sample Introduction Device
(iii) Chromatographic Column
(iv) Detector
(v) Data handling Device
(i) Pumping System
The HPLC pump is very important component of the system. It delivers the
constant flow of the mobile phase or phases so that the separation of the components
of the mixture occur in a reasonable time.  Its performance directly affects retention
time, reproducibility and detector sensitivity. Three main types of pumps are used
in HPLC to propel the liquid mobile phase through the system are as under
a. Displacement pump: It produces a flow that tends to independent of viscosity
and backpressure and also output is pulse free. But it possesses limited capacity
(250 ml).
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b. Reciprocating pump: It has small internal volume (35 to 400 µl). It has high
output pressure (up to 10,000 psi) and constant flow rates. But it produces a
pulsed flow.
c. Pneumatic or constant pressure pump: They are pulse free, suffer from limited
capacity as well as a dependence of flow rate on solvent viscosity and column
backpressure. They are limited to pressure less than 2000 psi.
There are two type of elution process, i.e. isocratic and gradient,
Isocratic: In this system, the things are kept constant throughout the run. In the case of
pumping of mobile phase, the mobile phase composition is kept constant throughout the
run. The nominal flow rate accuracy required is ±1% of the set flow
Gradient: There is some change purposely incorporated during the particular sample
run to achieve a better or/and faster separation. In case of pumping mobile phase, the
composition of mobile phase is continuously varied during the particular run. The gradient
accuracy of  ±1% of the step gradient composition is typical.
(ii) Sample Introducing Device
It is not possible to use direct syringe injection on column like GC, as the inlet
pressure in LC is too high. Insertion of the sample onto the pressurized column must be
as a narrow plug so that the peak broadening attributable to this step is negligible. The
injection system itself should have no dead (void) volume. There are three important
ways of introducing the sample into injection port.
a. Loop injection: In which, a fixed amount of volume is introduced by making use
of fixed volume loop injector.
b. Valve injection: In which, a variable volume is introduced by making use of an
injection valve.
c. On column injection: In which, a variable volume is introduced by means of a
syringe through a septum.
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(iii) Chromatographic Column
Column is a heart of chromatography. The column is usually made up of heavy
glass or stainless steel tubing to withstand high pressure. The columns are usually 10-30
cm long and 4-10 mm inside diameter containing stationary phase at particle diameter of
25 µm or less. Columns with an internal diameter of 5 mm give good results because of
compromise between efficiency, sample capacity, and the amount of packing and solvent
required.
Column packing:
The packing used in modern HPLC consists of small, rigid particles having a
narrow particle size distribution. There are three main types of column packing in HPLC.
a. Porous, polymeric beds: Porous, polymeric beds based on styrene divinyl benzene
co-polymers used for ion exchange and size exclusion chromatography. For
analytical purpose these have now been replaced by silica based, packing which
are more efficient and more stable.
b. Porous layer beds: Consisting of a thin shell (1-3 µm) of silica or modified silica
on an spherical inert core (e.g. Glass). After the development of totally porous
micro particulate packings, these have not been used in HPLC.
c. Totally Porous silica particles (dia. < 10 µm): These packing have widely been
used for analytical HPLC in recent years. Particles of diameter > 20 µm are usually
dry packed. While particles of diameter < 20 µm are slurry packed in which particles
are suspended on a suitable solvent and the slurry so obtained is driven into the
column under pressure.
(iv) Detector
The function of the detector in HPLC is to monitor the mobile phase as it merges
from the column. There are several detectors available in the market. However UV-
Visible detector, photo diode array detector, fluorescence detector, conductometric and
coulometric detector are more commonly used. The new ELSD detector is proving to
be important detector, while the MS detector is outstanding. Detectors are usually of
two types:
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a. Bulk property detectors: It compares overall changes in a physical property of
the mobile phase with and without an eluting solute e.g. refractive index, dielectric
constant or density.
b. Solute property detectors: It responds to a physical property of the solute, which
is not exhibited by the pure mobile phase e.g. UV absorbance, fluorescence or
diffusion current.
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2. Drug Analysis
The number of drugs introduced into the market is increasing every year. These
drugs may be either new entities or partial structural modification of the existing one [7].
Very often there is a time lag from the date of introduction of a drug into the market to
the date of its inclusion in pharmacopoeias. This happens because of the possible
uncertainties in the continuous and wider usage of these drugs, reports of new toxicities
(resulting in their withdrawal from the market), development of patient resistance and
introduction of better drugs by competitors. Under these conditions, standard samples
and analytical procedures for these drugs may not be available in the pharmacopoeias.
It becomes necessary, therefore to develop newer analytical methods for such drugs.
Also quality is important in every product or service but it is vital in medicines as
it involves in human life. Quality control is a concept, which strives to produce a perfect
product by series of measures designed to prevent and eliminate errors at different stage
of production. The decision to release or reject a product is based on one or more type
of control action. With the growth of pharmaceutical industry during last several years,
there has been rapid progress in the field of pharmaceutical analysis involving complex
instrumentation. Providing simple analytical procedure for complex formulation is a matter
of most importance.
In brief, the reasons for the development of newer methods of drug analysis are:
• The drug or drug combination may not be official in any pharmacopoeias.
• A proper analytical procedure for the drug may not be available in the literature
due to patent regulations.
• Analytical methods may not be available for the drug in the form of a formulation
due to the interference caused by the formulation excipients.
• Analytical methods for the quantitation of the drug in biological fluids may not
be available.
• Analytical methods for a drug in combination with other drugs may not be
available.
• The existing analytical procedures may require expensive reagents and solvents. It
may also involve cumbersome extraction and separation procedures and these may
not be reliable.
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(I) Introduction to HPLC Methods of Analysis for Drugs [7-9]
Most of the drugs in single/multi component dosage forms can be analyzed
by HPLC method because of the several advantages like rapidity, specificity,
accuracy, precision and ease of automation in this method. HPLC method eliminates
tedious extraction and isolation procedures. Some of the advantages are:
• Speed (analysis can be accomplished in 20 minutes or less).
• Greater sensitivity (various detectors can be employed).
• Improved resolution (wide variety of stationary phases).
• Reusable columns (expensive columns but can be used for many analysis).
• Ideal for the substances of low volatility.
• Easy sample recovery, handling and maintenance.
• Instrumentation tends itself to automation and quantitation (less time and less
labour).
• Precise and reproducible.
• Calculations are done by integrator itself.
• Suitable for preparative liquid chromatography on a much larger scale.
There are different modes of separation in HPLC. They are normal phase mode,
reversed  phase  mode,  reverse  phase  ion  pa i r  chromatography,  a ff in i ty
chromatography and size exclusion chromatography (gel permeation and gel
filtration chromatography).
In the normal phase mode, the stationary phase is polar and the mobile phase is
nonpolar in nature. In this technique, nonpolar compounds travel faster and are
eluted first. This is because of the lower affinity between the nonpolar compounds
and the stationary phase. Polar compounds are retained for longer times because of
their higher affinity with the stationary phase. These compounds, therefore take
more times to elute. Normal phase mode of separation is therefore, not generally
used for pharmaceutical applications because most of the drug molecules are polar
in nature and hence takes longer time to elute.
Reversed phase mode is the most popular mode for analytical and preparative sepa-
rations of compound of interest in chemical, biological, pharmaceutical, food and bio-
medical sciences. In this mode, the stationary phase is nonpolar hydrophobic packing
with octyl or octa decyl functional group bonded to silica gel and the mobile phase is
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polar solvent. An aqueous mobile phase allows the use of secondary solute chemical
equilibrium (such as ionization control, ion suppression, ion pairing and complexation)
to control retention and selectivity. The polar compound gets eluted first in this mode
and nonpolar compounds are retained for longer time. As most of the drugs and phar-
maceuticals are polar in nature, they are not retained for longer times and hence elute
faster. The different columns used are Octa Decyl Silane (ODS) or C18, C8, C4, etc.
(in the order of increasing polarity of the stationary phase).
In ion exchange chromatography, the stationary phase contains ionic groups like NR3
+
or  SO3
- -, which interact with the ionic groups of the sample molecules. This is suitable
for the separation of charged molecules only. Changing the pH and salt concentration
can modulate the retention.
Ion pair chromatography may be used for the separation of ionic compounds
and this method can also substitute for ion exchange chromatography. Strong acidic
and basic compounds may be separated by reversed phase mode by forming ion
pairs (coulumbic association species formed between two ions of opposite electric
charge) with suitable counter ions. This technique is referred to as reversed phase
ion pair chromatography or soap chromatography.
Affinity chromatography uses highly specific biochemical interactions for
separation. The stationary phase contains specific groups of molecules which can
adsorb the sample if certain steric and charge related conditions are satisfied. This
technique can be used to isolate proteins, enzymes as well as antibodies from
complex mixtures.
Size exclusion chromatography separates molecules according to their molecular mass.
Largest molecules are eluted first and the smallest molecules last. This method is generally
used when a mixture contains compounds with a molecular mass difference of at least
10%. This mode can be further subdivided into gel permeation chromatography (with
organic solvents) and gel filtration chromatography (with aqueous solvents).
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(II) Method Development and Design of Separation Method
Methods for analyzing drugs in single or multi component dosage forms can be
developed, provided one has knowledge about the nature of the sample, namely, its
molecular weight, polarity, ionic character and the solubility parameter. An exact recipe
for HPLC, however, cannot be provided because method development involves
considerable trial and error procedures. The most difficult problem usually is where to
start, what type of column is worth trying with what kind of mobile phase. In general one
begins with reversed phase chromatography, when the compounds are hydrophilic in
nature with many polar groups and are water-soluble.
The organic phase concentration required for the mobile phase can be estimated
by gradient elution method. For aqueous sample mixtures, the best way to start is with
gradient reversed phase chromatography. Gradient can be started with 5-10% organic
phase in the mobile phase and the organic phase concentration (methanol or acetonitrile)
can be increased up to 100% within 30-45 min. Separation can then be optimized by
changing the initial mobile phase composition and the slope of the gradient according to
the chromatogram obtained from the preliminary run. The initial mobile phase composition
can be estimated on the basis of where the compounds of interest were eluted, namely
at what mobile phase composition.
Changing the polarity of mobile phase can alter elution of drug molecules.
The elution strength of a mobile phase depends upon its polarity, the stronger the
polarity, higher is the elution. Ionic samples (acidic or basic) can be separated, if
they are present in undissociated form. Dissociation of ionic samples may be
suppressed by the proper selection of pH.
The pH of the mobile phase has to be selected in such a way that the
compounds are not ionized. If the retention times are too short, the decrease of the
organic phase concentration in the mobile phase can be in steps of 5%. If the
retention times are too long, an increase of the organic phase concentration is needed.
In UV detection, good analytical results are obtained only when the wavelength
is selected carefully. This requires knowledge of the UV spectra of the individual
components present in the sample. If analyte standards are available, their UV spectra
can be measured prior to HPLC method development.
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The molar absorbance at the detection wavelength is also an important parameter.
When peaks are not detected in the chromatograms, it is possible that the sample quantity
is not enough for the detection. An injection of volume of 20 µl from a solution of 1 mg/
ml concentration normally provides good signals for UV active compounds around 220
nm. Even if the compounds exhibit higher λmax, they absorb strongly at lower wavelength.
It is not always necessary to detect compounds at their maximum absorbance. It is,
however, advantageous to avoid the detection at the sloppy part of the UV spectrum for
precise quantitation. When acceptable peaks are detected on the chromatogram, the
investigation of the peak shapes can help further method development.
The addition of peak modifiers to the mobile phase can affect the separation of
ionic samples. For examples, the retention of the basic compounds can be influenced by
the addition of small amounts of triethylamine (a peak modifier) to the mobile phase.
Similarly for acidic compounds small amounts of acids such as acetic acid can be used.
This can lead to useful changes in selectivity.
When tailing or fronting is observed, it means that the mobile phase is not
totally compatible with the solutes. In most case the pH is not properly selected
and hence partial dissociation or protonation takes place. When the peak shape
does not improve by lower (1-2) or higher (8-9) pH, then ion-pair chromatography
can be used. For acidic compounds, cationic ion pair molecules at higher pH and
for basic compounds, anionic ion-pair molecules at lower pH can be used. For
amphoteric solutes or a mixture of acidic and basic compounds, ion-pair
chromatography is the method of choice.
The low solubility of the sample in the mobile phase can also cause bad
peak shapes. It is always advisable to use the same solvents for the preparation of
sample solution as the mobile phase to avoid precipitation of the compounds in the
column or injector.
Optimization can be started only after a reasonable chromatogram has been
obtained. A reasonable chromatogram means that more or less symmetrical peaks on
the chromatogram detect all the compounds. By sight change of the mobile phase
composition, the position of the peaks can be predicted within the range of
investigated changes. An optimized chromatogram is the one in which all the peaks are
symmetrical and are well separated in less run time.
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The peak resolution can be increased by using a more efficient column (column
with higher theoretical plate number, N) which can be achieved by using a column of
smaller particle size, or a longer column. These factors, however, will increase the analysis
time. Flow rate does not influence resolution, but it has a strong effect on the analysis
time.
Unfortunately, theoretical predictions of mobile phase and stationary phase
interactions with a given set of sample components are not always accurate, but
they do help to narrow down the choices for method development. The separation
scientist must usually perform a series of trial and error experiments with different
mobile phase compositions until a satisfactory separation is achieved.
The parameters that are affected by the changes in chromatographic conditions are:
A. Resolution (RS ).
B. Capacity factor (k’).
C. Selectivity (α).
D. Column efficiency (N).
E. Peak asymmetry factor (AS ).
A. Resolution (RS ): Resolution is the parameter describing the separation power of
the complete chromatographic system relative to the particular components of the
mixture. The resolution (RS), of two neighboring peaks were defined as the ratio of
the distance between two peak maxima. It is the difference between the retention
times of two solutes divided by their average peak width. For baseline separation,
the ideal value of RS is 1.5 It is calculated by using the formula,
RS = Rt2 - Rt1 / 0.5 (W1 + W2)
Where, Rt1 and Rt2 are the retention times of components 1 and 2.
       W1 and W2 are peak width of components 1 and 2.
B.  Capacity factor (k’): Capacity factor is the ratio of the reduced retention volume
to the dead volume. Capacity factor (k’), is defined as the ratio of the number of
molecules of solute in the stationary phase to the number of molecules of the same in
the mobile phase. Capacity factor is a measure of how well the sample molecule is
retained by a column during an isocratic separation. The ideal value of k’ ranges
from 2-10. Capacity factor can be determined by using the formula,
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k’=  V1 - V0 / V0
Where, V1 = retention volume at the apex of the peak (solute) and
           V0 = void volume of the system.
The values of k’ of individual bands increase or decrease with changes in
solvent strength. In reversed phase HPLC, solvent strength increases with the
increase in the volume of organic phase in water/ organic mobile phase. Typically
an increase in percentage of the organic phase by 10% by volume will decrease k’ of
the bands by a factor of 2-3.
C. Selectivity (α): The selectivity, (or separation factor) is a measure of relative
retention of two components in a mixture. Selectivity is the ratio of the capacity
factors of both peaks, and the ratio of its adjusted retention times. Selectivity
represents the separation power of particular adsorbent to the mixture of these
particular components.
This parameter is independent of the column efficiency, it only depends
on the nature of the components, eluent type, eluent composition and adsorbent
surface chemistry. In general, if the selectivity of two components is equal to 1,
then there is no way to separate them by improving the column efficiency.
The ideal value of α is 2. It can be calculated by using formula,
α = V2 – V1 / V1 – V0     = k1’/ k2’
Where, V0 = the void volume of the column,
V1 and V2= the retention volumes of the second and the first peak
       respectively.
D. Column efficiency (N): Efficiency, of a column is measured by the number of
theoretical plates per meter. It is a measure of band spreading of a peak. Similar
the band spread, higher is the number of theoretical plates, indicating good
column and system performance. Columns with N ranging from 5,000 to 100,000
plates/meter are ideal for a good system. Efficiency is calculated by using the formula,
N = 16 Rt
2 / W2
Where, Rt is the retention time.
W is the peak width.
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E. Peak asymmetry factor (AS ): Peak asymmetry factor, can be used as a criterion of
column performance. The peak half width, b, of a peak at 10 % of the peak height,
divided by the corresponding front half width, a, gives the asymmetry factor.
AS = b / a
For a well-packed column, an asymmetry factor of 0.9 to 1.1 should be achievable.
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(III) Validation of Analytical Method
HPLC method validation is the process used to confirm that the HPLC procedure
employed for a specific test is suitable for its intended use. Results from method validation
can be used to judge the quality, reliability and consistency of HPLC results, and it is an
integral part of any good analytical practice.
Method validation has received considerable attention in literature and from
industrial committees and regulatory agencies. The International Conference on
Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals
for Human Use [10] has developed a consensus text on the validation of analytical
procedures. The document includes definitions for eight validation characteristics. ICH
has also developed appendices with more detailed methodology [11].
The United States Food and Drug Administration (US FDA) has proposed
guidelines on submitting samples and analytical data for methods validation [12,13].
The United States Pharmacopoeia (USP) has published specific guidelines for method
validation for compound evaluation [14].
The US FDA has added section 211.222 on ‘methods validation’ to cGMP(Current
Good Manufacturing Practices)regulations [15]. This requires the manufacturer to
establish and document the accuracy, sensitivity, specificity, reproducibility and any other
attribute necessary to validate test methods. The validation is also required to meet the
existing requirements for laboratory records provided at Sec. 211.194 (a). These
requirements include a statement of each method used in testing the sample to meet
proper standards of accuracy and reliability, as applied to the tested product.
Representatives of the pharmaceutical and chemical industry have published
papers on the validation of analytical methods. Hokanson [16,17] applied the life
cycle approach, developed for computerized systems, to the validation and revalidation
of methods. Green [18] gave a practical guide for analytical method validation, with a
description of a set of minimum requirements for a method. Renger and his colleagues
[19] described the validation of a specific analytical procedure, for the analysis of
theophylline in a tablet using High Performance Thin Layer Chromatography (HPTLC).
The validation procedure in this particular article is based on requirements for European
Union multi-state registration. Winslow and Meyer [20] recommend the definition of a
master plan for validating analytical methods.
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A. Scope of the method and validation parameters
The scope of the method and its validation parameters and acceptance criteria
should be defined early in the process. These includes:
? What analytes should be detected?
? What are the expected concentration levels?
? What are the sample matrices?
? Are there interfering substances expected and, if so, should they be detected
and quantified?
? Are there any specific legislative or regulatory requirements?
? Should information be qualitative or quantitative?
? What are the required detection and quantitation limits?
? What is the expected concentration range?
? What precision and accuracy is expected?
? How robust should the method be? For example, should the method work at a
specific room temperature or should it run independent from room temperatures?
? Which type of HPLC should be used, is the method for one specific model from a
specific vendor or should it be used by all models from all vendors. This is especially
important for HPLC gradient methods, because different instrument may have different
delay volumes ranging from 0.5 up to 8 ml. This can have a tremendeous impact the
separation and elution order of the compounds.
? Will the method be used in one specific laboratory or should it be applicable in
all laboratories in your organization?
? What skills should the anticipated users of the HPLC method have?
The method’s performance characteristics and acceptance criteria should be
based on the intended use of the method. It is not always necessary to validate all
parameters that are available for HPLC. For example, if the method is to be used
for qualitative trace level analysis, there is no need to test and validate the method’s
limit of quantitation, or the linearity, over the full dynamic range of the equipment.
Initial parameters should be chosen according to the chromatographer’s experience and
best judgment. Final parameters should be agreed between the lab or analytical chemist
performing the validation and the lab or individual applying the method.
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Before an HPLC is used to validate a method, its performance specifications
should be verified using generic chemical standards. Satisfactory results for a method
can only be obtained with HPLC equipment that is performing well. Special attention
should be paid to those equipment characteristics that are critical for the method.
For example, if detection limit is critical for a specific method, the instrument’s
specification for baseline noise and, for certain detectors, also the response to
specified compounds, should be verified.
Any chemicals used to determine critical validation parameters, such as
reagents and reference standards, should be
? Available in sufficient quantities
? Accurately identified
? Sufficiently stable and
? Checked for exact composition and purity.
Any other materials and consumables, for example HPLC columns, should be
new. This ensures that one set of consumables can be used for most experiments and
avoids unpleasant surprises during method validation.
If there is little or no information on the method’s performance characteristics, it
is recommended to prove the suitability of the method for its intended use in initial
experiments. These studies should include the approximate precision, working range
and detection limits. If the preliminary validation data appear to be inappropriate, the
method itself, the HPLC equipment or the acceptance limits should be changed. HPLC
method development and validation is therefore an iterative process. For example,
selectivity is achieved through selection of mobile phase composition. For quantitative
measurements, the resolution factor between two peaks should be 2.5 or higher. If this
value is not achieved, the mobile phase composition needs further optimization.
B. Sequence of validation experiments [21-24]
There are no official guidelines on the correct sequence of validation experiments
and the optimal sequence may depend on the method itself. Based on our experience,
for a liquid chromatographic method, the various validation parameters are as under:
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Bi . Specificity
Bii. Linearity
Biii . Precision
a) Repeatability
b) Intermediate Precision
c) Reproducibility
Biv. Accuracy
Bv. Solution Stability
Bvi. Limit of detection (LOD)
Bvii. Limit of quantitation (LOQ)
Bviii . Robustness
All the work covered under current research topic have method development for
some pharmaceutical formulation including validation of the developed method .A common
method validation protocol was followed for all the method developed during the research
work (FDA, ICH Q2A & Q2B, 2005).
Bi. Specificity
The evaluation of the specificity of the method was determined against placebo.
The interference of the excipients of the claimed placebo present in pharmaceutical dosage
form was derived from placebo solution. Further the specificity of the method toward
the drug was established by means of checking the interference of the degradation
products in the drug quantification for assay during the forced degradation study. The
peak purity of analyte peak was evaluated in each degraded sample with respect to total
peak purity and three point peak purity. The peak purity value must be more than 0.9999
in every case.
Force degradation study
These study were undertaken to elucidate inherent stability characteristics. Such
testing is part of the development strategy and is normally carried out under more sever
condition than those used for accelerated stability studies. Force degradation of the
drug substance can help identify the likely degradation products, which can in turn help
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establish the degradation pathways and the intrinsic stability of the molecule and validate
the stability indicating power of the analytical procedures used. The nature of the stress
testing will depend on the individual drug substance and the type of drug product involved.
Stress testing is likely to be carried out on a single batch of the drug substance.
It should include the effect of temperatures (in 10°C increments (e.g., 50°C, 60°C,
etc.) above that for accelerated testing), humidity where appropriate, oxidation,
and photolysis on the drug substance. The testing should also evaluate the
susceptibility of the drug substance to hydrolysis across a wide range of pH values.
Photo stability testing should be an integral part of stress testing. Examining degradation
products under stress conditions is useful in establishing degradation pathways and
developing and validating suitable analytical procedures.
So, as per the guidelines the tress studies for all the drug under investigation
were done in the same conditions, the only difference were in temperature and the time
required for each drug to degrade up to 10-15% level. In general, the drug were kept at
solution and solid state stability in the following manner,
Solution state stability:
? Acidic hydrolysis: - Drug solution in 1-5N HCl solution
? Alkaline hydrolysis: - Drug solution in 1-5N NaOH solution
? Oxidative degradation: - Drug solution in 3-5% H2O2 (aqueous)
Solid state stability
? Thermal degradation: - Solid drug were exposed at 80 0C for 72 h.
? Photolytic degradation: - Solid drug were exposed in UV-light for 72 h.
All the above mentioned sample were used for method development trials to
develop a stability indicating assay method and also used to evaluated the specificity
of the method.
Bii. Linearity
The linearity of an analytical procedure is its ability (within a given range)
to obtain test results, which are directly proportional to the concentration (amount)
of analyte in the sample.
A linear relationship should be evaluated across the range of the analytical
procedure. It was demonstrated directly on the drug substance by dilution of a standard
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stock solution of the drug product components, using the proposed procedure. For the
establishment of linearity, minimum of five concentrations are recommended by ICH
guideline. Here, linearity test solutions for the assay method were prepared at seven
concentration levels from 40, 60, 80, 100, 120, 140 and 160% of assay analyte
concentration. The peak areas versus concentration data were evaluated by linear
regression analysis.  Intercept and correlation coefficient (r2) was evaluated. The Value
of r2 should fall around 0.9999.
Biii. Precision
The precision of an analytical procedure expresses the closeness of agreement
(degree of scatter) between a series of measurements obtained from multiple
sampling of the same homogeneous sample. Precision may be considered at three
levels: repeatability, intermediate precision and reproducibility. The precision of
an analytical procedure is usually expressed as the variance, standard deviation or
coefficient of variation of a series of measurements.
a) Repeatability: Repeatability study was performed by preparing a minimum of 6
determinations at 100% of the test concentration and analyzed as per the respective
methodology. The assay values were evaluated for %RSD, which should not more
than 2%.
b) Intermediate Precision: The extent to which intermediate precision should be
established depends on the circumstances under which the procedure is intended to
be used. The applicant should establish the effects of random events on the precision
of the analytical procedure. Typical variations to be studied include days, analysts,
equipment, etc. It is not considered necessary to study these effects individually.
Here, Intermediate precision of the method was checked by carrying out six
independent assays of test sample preparation on the different day by another person
under the same experimental condition and calculated the %RSD of assays. It  should
not be more than 2%.
c) Reproducibility: Reproducibility is assessed by means of an inter-laboratory trial.
Reproducibility should be considered in case of the standardization of an analytical
procedure, for instance, for inclusion of procedures in pharmacopoeias. These data are
not part of the marketing authorization dossier.
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Biv. Accuracy
The accuracy of an analytical procedure expresses the closeness of agreement
between the value, which is accepted either as a conventional true value or an
accepted reference value and the value found. The evaluation of accuracy has got
very prime importance as it deliberately force the method to extract the drug in
higher and lower level. Here the known amount of drug(s) was/were spiked with identical
amount of placebo preparation. The drug spiking was done at three different concentration
levels, that is 50, 100 and 150% of assay concentration level. The spike placebos were
then treated as per sample procedure and assay of the synthetic mixture was performed
in triplicate. The mean recovery at each concentration level was evaluated and it should
be lie between the range of 98-102%. The % RSD of % recovery at each level should
not be more than 2.0.
Bv. Solution Stability
The stability of solution for test preparation was evaluated. The solution was
stored at ambient temperature and 2-8 0C and tested at interval of 12 h, 24 h, 36 h and
48 h. The assays for the aged solution were evaluated using a freshly prepared standard
solution. The assay value of initial time point was compared with the assay of the aged
solution. The difference between assays should not be more than 2% from the initial
value for formulations. Overall %RSD of peak area of standard preparation injected at
initial at stage and injected after different time intervals should not be more than 2.0.
Bvi. Limit of detection (LOD)
The detection limit of an individual analytical procedure is the lowest amount
of analyte in a sample, which can be detected but not necessarily quantitated as an
exact value. Determination of the signal-to-noise ratio is performed by comparing
measured signals from samples with known low concentrations of analyte with those
of blank samples and establishing the minimum concentration at which the analyte can
be reliably detected. A signal-to-noise ratio between 3 or 2:1 is generally considered
acceptable for estimating the detection limit. The limit of detection was evaluated by
serial dilutions of analyte stock solution in order to obtain signal to noise ratios of 3:1.
Bvii. Limit of quantitation (LOQ)
The quantitation limit of an individual analytical procedure is the lowest amount
of analyte in a sample, which can be quantitatively determined with suitable precision
2 8I n t r o d u c t i o n . . .
Par t -A
and accuracy. The quantitation limit is a parameter of quantitative assays for low levels
of compounds in sample matrices. Determination of the signal-to-noise ratio is performed
by comparing measured signals from samples with known low concentrations of analyte
with those of blank samples and by establishing the minimum concentration at which the
analyte can be reliably quantified. A typical signal-to-noise ratio is 10:1. The limit of
quantification was evaluated by serial dilutions of analyte stock solution in order to obtain
signal to noise ratios of 10:1.
Bviii. Robustness
The robustness of an analytical procedure is a measure of its capacity to
remain unaffected by small, but deliberate variations in method parameters and
provides an indication of its reliability during normal usage.
In the case of liquid chromatography, examples of typical variations are:
? Influence of variations of pH in a mobile phase;
? Influence of variations in mobile phase composition;
? Different columns (different lots and/or suppliers);
? Temperature;
? Flow rate.
The factors chosen for all the drugs under investigation were the flow rate,
mobile phase composition, pH of a mobile phase and using different lot of LC
column. The observation shall be summarized and critical parameters shall be listed
out in the validation report. System suitability parameter must be within the limit
of acceptance criteria as mentioned in the method.
C. Advantages of Analytical method Validation
? The biggest advantage of method validation is that it builds a degree of confidence,
not only for the developer but also to the user.
? Although the validation exercise may appear costly and time consuming, it results
inexpensive, eliminates frustrating repetitions and leads to better time
management in the end.
? Minor changes in the conditions such as reagent supplier or grade, analytical setup
are unavoidable due to obvious reasons but the method validation absorbs the shock
of such conditions and pays for more than invested on the process.
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3. Current Trend
The Reverse Phase High Performance Liquid Chromatography (RP-HPLC)
analysis has stolen the show from all other techniques. It finds more acceptability with
regulatory authorities. The RP-HPLC has got very large application in current
pharmaceuticals growth towards the generic market due to its versatility for the
determination of purity of the compound and its related impurities (degradation of
products) as well. RP-HPLC is versatile for the detectors also as various types of
detectors can be attached as per the chemical nature of the components. Various detectors
like UV-Visible, Photo Diode Array (PDA), RI, Fluoresce, ELSD and MS detectors
are applied to determine the assay and related impurities formed during the stressed and
routine stability study.
The development and sales of combined dosage form in Indian pharmaceutical
market is promising. The methods suggested and published for the combined dosage
forms are, in many cases, suitable only for the quantification of each component. In
another major approach, the pharmaceutical giants are trying to develop the generic
version of the innovator formulation in the USA, UK and other developed countries. In
this regard the method developed for quality equation of the proposed formulation should
have capability to resolve all the major degradation products formed during the routine
stability study designed as per ICH guidelines. The routine stability study takes more
time to evaluate the formulation for its quality parameters at each time interval using the
developed method.
Forced degradation (Stress): Study of the drug component has become an integral
part of method development. Forced degradation or stress testing is undertaken to
demonstrate specificity when developing stability-indicting methods, particularly when
little information is available about potential products. These studies also provide
information about the degradation pathways and degradation products that could be
formed during storage. Forced degradation studies may help facilitate pharmaceutical
development as well in areas such as formulation development, manufacturing and
packaging, in which knowledge of chemicals behavior can be used to improve quality of
the product.
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These studies established the inherent stability characteristics of the molecules,
such as degradation pathways and lead to identification of degradation products, which
renders support to the suitability of the proposed analytical procedure. The detailed
nature of the studies will depend on the individual drug substances and type of drug
product.
It is recognized that some degradation may useful in developing and
validating suitable analytical method, but it may not always be necessary to examine
specifically for all degradation products, if it has been demonstrated that in practice
these are not forced.
This method development using the forced degradation study of each component
present in the formulation is very useful and it saves time to judge the major degradation
products in a very short time. These methods, which are developed and tested for their
robustness and specificity by studying post degradation samples, can be uniformly applied
for all the analysis involving the API. This though seems to be consuming and expensive,
is, in reality, very advantageous as there will be no need to further modify the method
whenever a new impurity is detected.
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4. Objective
The specific and main objectives of the work are:
? Development and validation of a stability indicating HPLC assay method for
determination of nebivolol in tablet formulation.
? Development and validation of HPLC assay method for determination of aspirin and
clopidogrel in combined dosage form in presence of degradation product formed
under ICH recommended stress condition.
? Development and validation of stability indicating HPLC assay method for the
simultaneous determination of tramadol HCl and aceclofenac components from
combine dosage form.
5. Instrument Used for Whole Research Work
A. Chromatographic system:
The chromatographic system used to perform development and validation
of this assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp
photo diode array detector and a rheodyne manual injector model 7725i with 20ìl
loop (Shimadzu, Kyoto, Japan) connected to a multi-instrument data acquisition
and data processing system (Class-VP 6.13 SP2, Shimadzu).
B. Other instruments:
? UV-Visible Spectrophotometer (Phamaspec-UV-1700, Shimadzu, Kyoto, Japan).
? Ultrasonic Bath (SONICA, Spincotech Pvt. Ltd., Mumbai).
? pH-Meter (Li-610, Elico Ltd. India).
? Hot Air Oven (Nova Instruments, India).
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HPLC METHOD DEVELOPMENT AND VALIDATION OF NEBIVOLOL
1. Introduction
In Western societies, 15-20% of the adult population has hypertension [1].
According to the 1996 health survey, 23% of all adults in England had high blood pressure.
Among those subjects who had hypertension, 59% were receiving anti-hypertensive
medication [2]. Of the populations on antihypertensive medication 64% had their blood
pressure under control, but the other 36% were inadequately treated [2]. Untreated,
sustained hypertension is a risk factor for the development of cardiovascular diseases
heart failure, stroke, coronary heart disease and its sequelae, and renal failure.
Beta-blockers are a well-established class of drugs for treating hypertension. There is a
substantial amount of evidence from randomized controlled trials demonstrating their
benefit in reducing morbidity and mortality in hypertensive patients.
Nebivol first introduced in the UK in 1999. Third generation, nebivolol is highly
selective â1-adrenoceptor antagonist indicated for the treatment of essential hypertension.
In addition to its â-blocking effects, nebivolol also has an endothelium dependent mild
vasodilatory action that may slow or prevent some of the vascular complications
associated with hypertension [3]. This review examines the pharmacological properties
of nebivolol and its efficacy in controlled clinical trials, particularly when compared with
the other available treatments for hypertension, including other â -blockers, angiotensin
converting enzyme (ACE) inhibitors and calcium channel blockers.
1.1 Description
Nebivolol is chemically 1-(6-fluorochroman-2-yl)-2-[(2-(6- fluorochroman-
2-yl)-2-hydroxy-ethyl] amino] ethanol (Figure 1). Its molecular formula is
C22H25F2NO4 having molecular weight 405.435 g/mole [4].
O N
OH
O
OH
F F
H
Figure 1: Chemical structure of nebivolol
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1.2 Pharmacology
Chemistry: Nebivolol is structurally distinct from older â-blockers and is highly lipophilic
[5]. The therapeutic formulation of nebivolol is a racemic mixture containing equal
proportions of the D-and L-enantiomers [6]. The pharmacological properties of the
enantiomers differ, with D-nebivolol largely responsible for the â -adrenergic blocking
effects of the drug whilst both enantiomers are associated with its mild vasodilatory
properties [5-7].
Mechanism of action: Nebivolol is the most selective â1-adrenoceptor antagonist
currently available in the UK for clinical use and has no á 1-blocking action at
therapeutic doses [8,9]. In addition to its classical â-blocking effects upon the
sympathetic nervous system, heart rate and cardiac contractility, nebivolol has
additional mild vasodilatory properties that cannot simply be ascribed to â1-
adrenoceptor.
Vasodilatory effects: Affinities of various â-blockers for â1- and â2-adrenergic
receptors from lung tissue There is considerable experimental evidence to suggest
that the vasodilatory effect of nebivolol results from its ability to stimulate the
release of the potent vasodilator, NO(nitric oxide), from endothelial cells [10-14]. One
of the key studies implicating NO release determined that the endothelium must be intact
for nebivolol induced relaxation of canine coronary artery strips to occur and this effect
was blocked by the NO synthesis inhibitor, NG-monomethyl-L-arginine (L-NMMA)
[15]. Although the exact mechanism is still under investigation, in vitro studies have
suggested a number of possible mechanisms: the involvement of ATP efflux, a nebivolol
mediated increase in endothelial free calcium ions leading to an increase in NO production
by NO synthase, the involvement of endothelial 5-HT1A receptors, interaction with
oestrogen receptors, a free radical scavenging effect of nebivolol [10,12,14,16,17].
Studies in humans: Human studies in small numbers of healthy volunteers where
nebivolol was infused into phenylephrine preconstricted superficial hand veins of
eleven volunteers [18] or into the brachial artery in five groups of eight volunteers
[19] have confirmed that nebivolol has nitric oxide mediated venodilator effects.
These studies were extended in a series of eight patients with essential hypertension,
and similar results were obtained.
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1.3 Pharmacokinetics
The rate of metabolism of nebivolol to its active hydroxyl metabolites is dependent
on the presence or absence of a genetic polymorphism in the gene encoding the
cytochrome P450 (CYP) 2D6 isoenzyme, leading to two distinct metaboliser phenotypes,
‘poor’ and ‘extensive’ [5,6]. At steady state, the peak plasma concentration of unchanged
nebivolol is 23 times higher in poor metabolisers than in extensive metabolisers. However,
when plasma concentrations of unchanged nebivolol and its hydroxylated metabolites
are considered together, plasma levels are comparable between phenotypes, which
explains the similar clinical effects observed in both groups and also excludes the need
for dosage adjustment.
Although the pharmacokinetic profile of nebivolol is not affected by the age
of the patient, the recommended starting dose in patients aged over 65 years is half
that of the normal starting dose (i.e.2.5 mg vs. 5 mg) [6]. This is consistent with
similar recommendations for prescribing other antihypertensives to the elderly. The
recommended starting dose of nebivolol in patients with renal insufficiency is also
2.5 mg, whilst a lack of data precludes the use of nebivolol in patients with hepatic
insufficiency or impaired liver function [6]. Despite its relatively high lipophilicity,
nebivolol demonstrates limited distribution in adipose tissue and consequently, there
is no need for dosage adjustment in obese patients [20].
1.4 Efficacy
In a multicenter, double blind, randomized, parallel group dose finding study in
509 patients with primary essential hypertension, nebivolol 2.5, 5 and 10 mg, but not
0.5 or 1mg, for 4 weeks significantly reduced mean supine diastolic BP (by 7.1 to 10.2
mmHg; p<0.05) at trough drug levels (23-25 h post dosing), compared with placebo.
There was no significant difference between the nebivolol 5 mg and 10 mg groups.
The trough-to-peak ratio for supine diastolic BP with nebivolol 5 mg once daily
was 0.894 [21]. In a non-comparative study nebivolol 5 mg was given once daily to 37
patients with mild to moderate essential hypertension (diastolic BP between 95 and 114
mmHg). Significant (p<0.0001 vs baseline) reductions were maintained during therapy
over 12 months [22]. Other comparative studies found a similar reduction in 24 h
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ambulatory BP with nebivolol 2.5 to 10 mg daily compared with lisinopril 10 to 40 mg
daily, enalapril 10 mg daily, atenolol 100 mg daily and nifedipine 20 mg bd for up to 12
weeks (p<0.01 for systolic and diastolic BP for all drugs vs baseline or placebo) [23].
1.5 Adverse Effect
Nebivolol has been studied in over 3000 patients with hypertension, who
have received the drug for at least one month, and some for 3 years [24]. The most
frequent adverse events (incidence between 1-10%) were headache, dizziness,
tiredness and paraesthesia. Other adverse events reported by at least 1% of patients
were: diarrhoea, constipation, nausea, dyspnoea and oedema [25]. Other adverse
events have been reported with a frequency of less than 1%.
Generally, in comparative trials there were no statistically significant differences
reported between the severity and frequency of adverse events in patients receiving
once daily nebivolol 5 mg (20 to 48.6% of patients reported adverse events), placebo
(25 to 36%), atenolol 50 mg (13%) or enalapril 10mg (55%). [24] To date, no significant
adverse effects on plasma lipids or glucose metabolism have been demonstrated in patients
with hypertension, although rare cases of raised triglyceride levels have been reported
[23].
1.6 Contraindications
The use of nebivolol (and â-blockers in general) is contra indicated in patients with:
? Cardiogenic shock
? Uncontrolled heart failure
? Sick sinus syndrome
? Second and third degree heart block
? History of bronchospasm and bronchial asthma
? Untreated phaeochromocytoma
? Metabolic acidosis
? Hepatic insufficiency or impaired liver function
? Bradycardia
? Hypotension
38
Part -A (Seect ion-I )
N e b i v o l o l . . .
? Pregnancy or lactation
? Severe peripheral circulatory disturbances
Furthermore, nebivolol should be used with caution in patients with:
? Peripheral circulatory disorders (e.g. Raynaud’s disease)
? First degree heart block
? Prinzmetal’s angina
? Diabetes (treatment may mask symptoms of hypoglycaemia)
? Hyperthyroidism (treatment may mask symptoms of tachycardia)
? COPD
? History of psoriasis
1.7 Dosing
The dose is one tablet daily, preferably at the same time of the day. Tablet may
be taken with meals.
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2. Literature Review
The literature reviews regarding nebivolol suggest that various analytical methods
were reported for its determination as drug, in pharmaceutical formulation and in various
biological fluids. The literature reviews for analysis of nebivolol are as under
2.1 M. M. Kamila, N. Mondal, L. K. Ghosh, B. K. Gupta have developed and
validated a simple UV spectrophotometric method for the determination of assay of
nebivolol hydrochloride in raw material and tablets. The absorbance was measured
at 282 nm for nebivolol hydrochloride tablet solution. The developed method was
applied directly and easily to analyze bulk and pharmaceutical formulations [26].
2.2 N. V. S. Ramkrishna, K. N. Vishwottam, M. Koteshwara, S. Manoj, M. Santosh,
D. P. Varma have developed and validated a rapid liquid chromatographic /electro
spray ionization tandem mass spectrometric method for the quantification of nebivolol
in human plasma. The method involved a simple single step liquid-liquid extraction
with diethyl ether/dichloromethane (70/30). The analyte was chromatograph on C18
column by isocratic elution with water-acetonitrile-formic acid (30:70:0.03,v/v/v)
and analyzed by mass spectrometry. The method can be considered suitable for
application to pharmacokinetic studies of nebivolol [27].
2.3 K. R. Rajeswari, G. G. Sankar, A. L. Rao, D. B. Raju, J. V. L. N. Seshagiri
Rao have developed and validated RP-HPLC method for the estimation of nebivolol
in bulk drug and pharmaceutical formulation. Nebivolol was chromatograph on C18
column in a mobile phase consisting of acetonitrile and 30 mM KH2PO4 buffer (pH 3.1)
in the ratio of 55: 45 (v/v). Flow rate was 0.8 ml/min and the eluent were monitored
at 286 nm. The method can be used for the routine quality control analysis of nebivolol
formulation [28].
2.4 T. S. Reddy, P. S. Devi have been established and validated a quantitative
densitometric high performance thin layer chromatographic method for
determination of nebivolol hydrochloride in pharmaceutical preparations.
Nebivolol hydrochloride from the formulations was separated and identified on
silica gel 60 F254 HPTLC plates with toluene-ethyl acetate-methanol-formic acid
(8:6:4:1,v/v/v), as mobile phase. The plates were developed to a distance of 8 cm.
Densitometric quantification was performed at 285 nm by reflectance scanning. The
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method could find application in routine quality control analysis of pharmaceutical
formulations [29].
2.5 P. S. Selvan, K. V. Gowda, U. Mandal, W. D. S. Solomon, T. K. Pal have
developed liquid chromatographic tandem mass spectrometry method for the
simultaneous determination of nebivolol and valsartan in human plasma. Nebivolol
and valsartan were extracted from plasma using acetonitrile and separated on a C18
column. The mobile phase consisting of a mixture of acetonitrile - 0.05 mM formic
acid (50:50 v/v, pH 3.5) was delivered at a flow rate of 0.25 ml/min. This method
can be applied to the pharmacokinetic study of fixed dose combination (FDC) of
nebivolol and valsartan formulation product [30].
2.6 L. J. Patel, B. N. Suhagia, P. B. Shah developed HPLC and HPTLC method for
the estimation of nebivolol hydrochloride in tablet formulation. In HPLC method
they have used C18 column and mobile phase consisting of 50 mM KH2PO4 buffer
(pH 3.0)- acetonitrile (45:55,v/v). The flow rate was 1.0 ml/min and effluent was
monitored at 282 nm. For HPTLC method, precoated silica gel 60F254 used as a
stationary phase and mobile phase consisting of ethyl acetate-toluene-methanol-
ammonium hydroxide (1:6:2:0.1,v/v/v/v) were used. The detection of spot was carried
out at 282 nm. The method can be used for estimation of nebivolol hydrochloride in
tablet dosage form [31].
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3. Aim of Present Work
As per discussion in the literature review, one UV, two HPTLC, two LC-MS
and two HPLC methods for the determination of nebivolol in pharmaceutical dosage
forms or in biological fluids are reported. UV, HPLC and HPTLC methods simply used
for estimation of nebivolol from pharmaceutical formulation and LC-MS methods applied
to the pharmacokinetic studies of nebivolol. So far to our present knowledge, no validated
stability indicating HPLC assay method for the determination of nebivolol in
pharmaceutical formulation was available in literature. Our work deals with the forced
degradation of nebivolol under stress condition like acid hydrolysis, base hydrolysis,
oxidation, thermal and photolytic stress. This work also deals with the validation of the
developed method for the assay of nebivolol from its dosage form (tablets). Hence, the
method is recommended for routine quality control analysis and also stability sample
analysis.
The aim and scope of the proposed work are as under
? To developed suitable HPLC method for nebivolol.
? Forced degradation study of nebivolol under stress condition.
? To resolve all major impurities generated during the force degradation studies
of nebivolol.
? Perform the validation for the developed method.
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4. Experimental
4.1 Materials
Nebivolol hydrochloride standard of was provided by Cadila Pharmaceuticals
Ltd., (India). Nebivolol tablets and the inactive ingredient used in drug matrix were
obtained from market. Each tablet contains 5 mg nebivolol as label claim. Analytical
grade potassium dihydrogen orthophosphate and triethylamine were purchased from Sisco
Research Pvt. Ltd., Mumbai (India) and Spectrochem Pvt. Ltd., Mumbai (India)
respectively. HPLC grade acetonitrile, methanol and water were obtained from
Spectrochem Pvt. Ltd., Mumbai (India). Analytical grade hydrochloric acid, sodium
hydroxide pellets, orthophosphoric acid and 30% v/v hydrogen peroxide solution were
obtained from Ranbaxy Fine Chemical, New Delhi (India).
4.2 Instrumentation
LC-10ATvp HPLC system was used as describe as  Part-[A] (5.A).
4.3 Mobile Phase Preparation
The mobile phase consisted of acetonitrile-50mM phosphate buffer pH 3.5
(35: 65, v/v). To prepare the buffer solution, 6.8 g potassium dihydrogen phosphates
was weighed and dissolved in 1000 ml HPLC grade water, 2 ml triethylamine was added
and then adjusted to pH 3.5 with orthophosphoric acid. Mobile phase was filtered through
a 0.45 ìm nylon membrane (Millipore Pvt. Ltd. Benglore, India) and degassed in an
ultrasonic bath (Spincotech Pvt. Ltd., Mumbai).
4.4 Diluent Preparation
Mobile phase used as a diluent.
4.5 Standard Preparation
A nebivolol standard solution containing 0.1 mg/ml, was prepared in a 250
ml volumetric flask by dissolving 27.25 mg of nebivolol hydrochloride (equivalent
to 25 mg nebivolol) in 10 ml methanol and then diluted to volume with mobile
phase.
4.6 Test Preparation
Twenty tablets were weighed and the average weight of tablet was determined.
From these, five tablets were weighed and transfered into a 250 ml volumetric flask.
About 10 ml methanol and 150 ml mobile phase was added and sonicated for a
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minimum 30 min with intermittent shaking. Then content was brought back to room
temperature and diluted to volume with mobile phase. The sample was filtered through
0.45 µm nylon syringe filter. The concentration obtained was 0.1 mg/ml of nebivolol.
4.7 Chromatographic Conditions
Chromatographic analysis was performed on a Phenomenex Luna C8 (2) (250 mm
×  4.6 mm i.d., 5 ìm particle size) column. The mobile phase consisted of acetonitrile-
50 mM phosphate buffer pH 3.5 (35: 65, v/v). The flow rate of the mobile phase was
adjusted to 1.0 ml/min and the injection volume was 20 µl. Detection was performed at
280 nm.
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5. Result and Discussion
5.1 Development and Optimization of the HPLC Method
Proper selection of the methods depends upon the nature of the sample, (ionic or
ionisable or neutral molecule) its molecular weight and solubility. Nebivolol is dissolved
in polar solvent hence RP-HPLC was selected to estimate them. To develop a rugged
and suitable HPLC method for the quantitative determination of nebivolol, the analytical
condition were selected after testing the different parameters such as diluents, buffer,
buffer concentration, organic solvent for mobile phase and mobile phase composition
and other chromatographic conditions. Our preliminary trials using different composition
of mobile phases consisting of water with methanol or acetonitrile, did not give good
peak shape. By using 50 mM KH2PO4 buffer with addition of 2 ml triethylamine per
1000 ml of buffer, adjusted to pH 3.5 with orthophosphoric acid and keeping mobile
phase composition as acetonitrile-phosphate buffer (35: 65, v/v), best peak shape was
obtained. Triethylamine was added to buffer to lower the peak asymmetry. For the
selection of organic constituent of mobile phase, acetonitrile was chosen to reduce the
longer retention time and to attain good peak shape. Figure 2 and Figure 3 represent the
chromatograms of standard and test preparation respectively.
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Figure 2: Chromatogram of standard preparation
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Figure 3: Chromatogram of test preparation
5.2 Degradation Study
The degraded samples were prepared by transferring powdered tablets, equivalent
to 25 mg nebivolol into a 250 ml round bottom flask. Then prepared samples were
employed for acidic, alkaline and oxidant media and also for thermal and photolytic
conditions. After the degradation treatments were completed, the stress content solutions
were allowed to equilibrate to room temperature and diluted with mobile phase to attain
0.1 mg/ml concentration. Specific conditions were described as follows.
5.2.1 Acidic condition: Acidic degradation study was performed by heating the drug
content in 5 N HCl(50 ml) at 80 0C for 3 h and mixture was neutralized with
5 N NaOH solutions. Nebivolol was found to be degrading up to 10% in acidic
condition. (Figure 4).
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Figure 4: Chromatogram of acidic forced degradation study
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5.2.2 Alkaline condition: Alkaline degradation study was performed by heating the
drug content in 5 N NaOH(50 ml) at 80 0C for 3 h and mixture was neutralized
with 5 N HCl solutions. In alkali degradation, it was found that around 8-10% of
the drug degraded (Figure 5).
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Figure 5: Chromatogram of alkali forced degradation study
5.2.3 Oxidative condition: Oxidation degradation study was performed by heating
the drug content in 3% v/v H2O2(50 ml) at 80 
0C for 3 h. Major degradation was
found in oxidative condition that product was degraded up to 50%. The major
impurity peaks were found at 8.63 min and 53.46 min (Figure 6).
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Figure 6: Chromatogram of oxidative forced degradation study
5.2.4 Thermal condition: Thermal degradation was performed by exposing solid drug
at 80 0C for 72 h. Nebivolol was found to be stable under thermal degradation
condition (Figure 7).
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Figure 7: Chromatogram of thermal degradation study
5.2.5 Photolytic condition: Photolytic degradation study was performed by exposing
the drug content in UV-light for 72 h. There was no degradation observed in
above specific photolitic condition. Nebivolol was found to be stable in UV-light
(Figure 8).
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Figure 8: Chromatogram of UV-light degradation study
48
Part -A (Seect ion-I )
N e b i v o l o l . . .
5.3 Method Validation
5.3.1 Specificity: The specificity of the method was determined by checking the
interference of placebo with analyte and the proposed method was eluted by
checking the peak purity of nebivolol during the force degradation study. The
peak purity of the nebivolol was found satisfactory (0.9999) under different stress
condition. There was no interference of any peak of degradation product with
drug peak.
5.3.2 Linearity: Seven points calibration curve were obtained in a concentration range
from 0.04-0.16 mg/ml for nebivolol. The response of the drug was found to be
linear in the investigation concentration range and the linear regression equation
was y =16749949.98x +3974.44 with correlation coefficient 0.9999. (Figure 9)
Chromatogram obtain during linearity study were shown in Figure 10-16.
Linearity Study for nebivolol
y = 16749949.98x + 3974.44
R2 = 0.9999
0
500000
1000000
1500000
2000000
2500000
3000000
0 0.05 0.1 0.15 0.2
Concentration (mg/ml)
Pe
ak
 a
re
a
Figure 9: Linearity curve for nebivolol
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Figure 10: Linearity study chromatogram of level-1 (40%)
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Figure 11: Linearity study chromatogram of level-2 (60%)
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Figure 12: Linearity study chromatogram of level-3 (80%)
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Figure 13: Linearity study chromatogram of level-4 (100%)
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Figure 14: Linearity study chromatogram of level-5 (120%)
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Figure 15: Linearity study chromatogram of level-6 (140%)
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Figure 16: Linearity study chromatogram of level-7 (160%)
5.3.3 Precision: The result of repeatability and intermediate precision study are shown
in Table 1. The developed method was found to be precise as the %RSD values
for the repeatability and intermediate precision studies were < 0.69% and < 1.39
%, respectively, which confirm that method was precise.
Table 1: Evaluation data of precision study
Set Intraday (n = 6) Interday (n = 6) 
1 100.5 99.9 
2 100.9 98.8 
3 102.1 101.8 
4 101.1 99.7 
5 101.2 102.3 
6 102.3 99.5 
Mean 101.4 100.3 
Standard deviation 0.70 1.39 
% RSD 0.69 1.39 
 
5.3.4 Accuracy: The HPLC area responses for accuracy determination are depicted
in Table 2. The result shown that best recoveries (98.57-99.55 %) of the spiked
drug were obtained at each added concentration, indicating that the method was
accurate. Chromatogram obtain during accuracy study were shown in Figure 17-19.
52
Part -A (Seect ion-I )
N e b i v o l o l . . .
Table 2: Evaluation data of accuracy study
Level (%) 
 
Amount Added 
Concentration a 
(mg/ml) 
Amount Found 
Concentration a 
(mg/ml) 
% Recovery % RSD 
50 0.05387 0.05362 99.55 0.60 
100 0.10707 0.10554 98.57 0.09 
150 0.16187 0.16102 99.48 0.53 
 
a Each value corresponds to the mean of three determinations.
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Figure 17: Accuracy study chromatogram of level-1 (50%)
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Figure 18: Accuracy study chromatogram of level-2 (100%)
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Figure 19: Accuracy study chromatogram of level-3 (150%)
5.3.5 Solution stability study: Table 3 shows the results obtain in the solution stability
study at different time intervals for test preparation. It was concluded that the
test preparation solution was found stable up to 48 h at 2-5 0C and ambient
temperature, as during this time the result was not decrease below the minimum
percentage.
Table 3: Evaluation data of solution stability study
Intervals 
% Assay for Test 
Preparation Solution 
Stored at 2-5 0C 
% Assay for Test Preparation 
Solution Stored at Ambient 
Temperature 
Initial 99.2 99.2 
12 h 99.0 99.1 
24 h 98.6 98.5 
36 h 98.3 98.1 
48 h 98.1 98.0 
 
5.3.6 Robustness: The result of robustness study of the developed assay method was
established in Table 4. The result shown that during all variance conditions, assay
value of the test preparation solution was not affected and it was in accordance
with that of actual. System suitability parameters were also found satisfactory,
hence the analytical method would be concluded as robust. Chromatogram obtain
during robustness study were shown in figure 20-26.
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Table 4: Evaluation data of robustness study
System Suitability Parameters 
Robust conditions % Assay 
Theoretical Plates Asymmetry 
Flow 0.9 ml/min 101.0 7657 1.68 
Flow 1.1 ml/min 100.4 7803 1.66 
Buffer pH 3.3 100.0 9062 1.72 
Buffer pH 3.7 99.8 7534 1.70 
Buffer-ACN (63: 37,v/v) 100.3 7723 1.70 
Buffer-ACN (67: 33,v/v) 99.8 7937 1.60 
Column change 99.9 6993 1.69 
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Figure 20: Standard chromatogram (0.9 ml/min flow rate)
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 Figure 21: Standard chromatogram (1.1 ml/min flow rate)
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 Figure 22: Standard chromatogram [Buffer-ACN (63: 37,v/v)]
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 Figure 23: Standard chromatogram [Buffer-ACN (67: 33, v/v)]
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 Figure 24: Standard chromatogram (pH 3.7)
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 Figure 25: Standard chromatogram (pH 3.3)
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Figure 26: Standard chromatogram (Column change)
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5.3.7 System suitability: A system suitability test of the chromatographic system was
performed before each validation run. Five replicate injections of standard
preparation were injected and asymmetry, theoretical plate and % RSD of peak
area were determined for same. Acceptance criteria for system suitability,
Asymmetry not more than 2.0, theoretical plate not less then 5000 and % RSD
of peak area not more then 2.0, were full fill during all validation parameters.
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6. Calculation and Data
Calculation formula used:
1. Calculation formula for % assay of nebivolol
94.441
48.405
250
WeightStandard
AreaStandardMean
AreaTestMean
Assay% ××=
StandardofPotency
ClaimLable
WeightAverage
WeightTest
250 ×××
2. Relative standard deviation
100
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD% ×=
3. Recovery
100
AddedAmount
foundAmount
erycovRe% ×=
4. Amount found
ionConcentratStandard
AreaStandardMean
AreaTestMean
)ml/mg(FoundAmount ×=
5. Amount added
Volume
Weight)ml/mg(AddedAmount =
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Specificity Study for Analytical Method Validation of Nebivolol Tablets
Standard Weight (mg) 26.8      
Standard Dilution 250     
Standard Potency 98.59 %     
Factor 1 405.48     
Factor 2 441.94     
Standard Concentration 
(mg/ml) 0.0984     
      
Replicate 1 2 3 4 5 
Standard Area 1654331 1649549 1653034 1653003 1653616 
Mean Standard Area 1652707     
Stdev. 1846.02     
% RSD 0.11     
 
Replicate Test Area 
1 1744413 
2 1813285 
Mean Test Area 1778849 
Test Weight (mg) 1041.2  
Label claim (mg) 5  
Mean Test Weight (mg) 204.1 
% Assay 102.2 % 
 
Calculation:
Prototype calculation for one set:
94.441
48.405
250
8.26
1652707
1778849Assay% ××= 59.98
5
1.204
2.1041
250 ×××
     = 102.2 %
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Linearity Study for Analytical Method Validation of Nebivolol Tablets
 
Standard Weight (mg) 26.8          
Standard Dilution 250     
Standard Potency 98.59 %     
Factor 1 405.48     
Factor 2 441.94     
Standard Concentration (mg/ml) 0.0984     
Concentration of Linearity Stock 
Solution (mg/ml) 0.5460     
      
Replicate 1 2 3 4 5 
Standard Area 1686152 1681540 1682487 1679841 1680488 
Mean Standard Area 1682102         
Stdev 2217.37         
% RSD 0.13         
 
Concentration  
Level (%) 
Volume of 
Linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final Concentration 
(mg/ml) Mean Area 
40 2.0 25 0.0401 673255 
60 3.0 25 0.0601 1001175 
80 4.0 25 0.0802 1347328 
100 5.0 25 0.1002 1701055 
120 6.0 25 0.1202 2024118 
140 7.0 25 0.1403 2345866 
160 8.0 25 0.1603 2683441 
  Correlation co-efficient 0.9999 
  Slope 16749949.98 
  Intercept 3974.44 
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Precision Study for Analytical Method Validation of Nebivolol Tablets
Standard Weight (mg) 26.8      
Standard Dilution 250   
Standard Potency 98.59 %     
Label Claim (mg) 5    
Mean Test Weight (mg) 204.1    
Factor 1 405.48     
Factor 2 441.94     
Standard Concentration (mg/ml) 0.0984     
    
Replicate 1 2 3 
Standard Area 1651094 1650113 1643
Mean Standard Area 1647724     
Stdev. 3238.79     
% RSD 0.20   
 
Description Mean area Test Weight (mg) % Assay 
Set 1 1722946 1029.2 100.5 
Set 2 1713205 1019.8 100.9 
Set 3 1714246 1008.2 102.1 
Set 4 1698890 1009.4 101.1 
Set 5 1736411 1030.1 101.2 
Set 6 1752798 1028.9 102.3 
  Mean 101.4 
  Stdev 0.70 
  % RSD 0.69 
  Confidence Level (95.0%) 0.74 
 
Calculation:
Prototype calculation for one set:
94.441
48.405
250
 26.8
1647724
1722946Assay% ××= 59.98
5
1.204
2.1029
250 ×××
     =  100.5 %
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IntermediatePrecision Study for Analytical Method Validation of Nebivolol Tablet
Standard Weight (mg) 26.9          
Standard Dilution 250     
Standard Potency 98.59 %         
Label Claim (mg) 5      
Mean Test weight (mg) 204.1      
Factor 1 405.48         
Factor 2 441.94         
Standard Concentration (mg/ml) 0.1076         
      
Replicate 1 2 3 4 5 
Standard Area 1642429 1641707 1645698 1644263 1646619 
Mean Standard Area 1644143         
Stdev. 2087.76         
% RSD 0.13       
 
Description Mean area Test Weight (mg) % Assay 
Set 1 1700283 1027.8 99.9 
Set 2 1649225 1008.4 98.8 
Set 3 1734995 1030.1 101.8 
Set 4 1664862 1008.7 99.7 
Set 5 1707946 1008.4 102.3 
Set 6 1661793 1009.4 99.5 
  Mean 100.3 
  Stdev 1.39 
  % RSD 1.39 
  Confidence Level (95.0%) 1.46 
 
Calculation:
Prototype calculation for one set:
94.441
48.405
250
9.26
1644143
1700283Assay% ××= 59.98
5
1.204
8.1027
250 ×××
     =  99.9 %
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Comparison for Precision and Intermediate Precision Study for Analytical Method
Validation for Nebivolol Tablets
 Set %Assay 
1 100.5 
2 100.9 
3 102.1 
4 101.1 
5 101.2 
Precision study 
6 102.3 
1 99.9 
2 98.8 
3 101.8 
4 99.7 
5 102.3 
Intermediate precision study 
6 99.5 
 Mean 100.8 
 Stdev 1.18 
 % RSD 1.17 
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Accuracy Study for Analytical Method Validation of Nebivolol Tablets
Standard Weight (mg) 28.5          
Standard Dilution 250     
Standard Potency 98.59 %         
Factor 1 405.48         
Factor 2 441.94         
Standard Concentration (mg/ml) 0.1046         
      
Replicate 1 2 3 4 5 
Standard Area 1644642 1638915 1637776 1635107 1634085 
Mean Standard Area 1638105         
Stdev 4142.62         
% RSD 0.25       
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Solution Stability Study for Analytical Method Validation of Nebivolol Tablets
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1678207 1662724 1687950 1697508 1667885 
2 1676828 1661210 1688152 1685856 1666619 
3 1677108 1658816 1687480 1688203 1662877 
4 1672384 1662791 1694160 1690180 1664324 
5 1675192 1663227 1681072 1695345 1671921 
Mean 1675944 1661754 1687763 1691418 1666725 
Stdev 2263.66 1810.65 4635.66 4881.45 3497.40 
%RSD 0.14 0.11 0.27 0.29 0.21 
 
Solution stability for standard preparation at 2 -8°C 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1678207 1678207 1678207 1678207 
2 1676828 1676828 1676828 1676828 
3 1677108 1677108 1677108 1677108 
4 1672384 1672384 1672384 1672384 
5 1675192 1675192 1675192 1675192 
1 1675603 1675731 1673748 1678891 
2 1672995 1671705 1681093 1674779 
Mean 1675474 1675308 1676366 1676198 
Stdev 2151.06 2438.52 2903.63 2239.25 
%RSD 0.13 0.15 0.17 0.13 
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 Solution stability for standard preparation at room temperature 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1678207 1678207 1678207 1678207 
2 1676828 1676828 1676828 1676828 
3 1677108 1677108 1677108 1677108 
4 1672384 1672384 1672384 1672384 
5 1675192 1675192 1675192 1675192 
1 1672051 1670649 1671078 1677944 
2 1671502 1675685 1673611 1670266 
Mean 1674753 1675150 1674915 1675418 
Stdev 2752.47 2713.93 2652.41 3022.22 
%RSD 0.16 0.16 0.16 0.18 
Solution stability for test preparation 
 Initial After 12 hours 
After 24 
hours 
 Standard Standard Standard
Replicate Peak area Peak area Peak area
1 1678207 1662724 1687950 
2 1676828 1661210 1688152 
3 1677108 1658816 1687480 
4 1672384 1662791 1694160 
5 1675192 1663227 1681072 
Replicate Test Area Test Area Test Area
1 1618776 1614362 1614791 
2 1616214 1610975 1614011 
Mean 1617495 1612669 1614401 
% Assay 99.2 99.0 98.6 
Standard weight 
(mg) 28.1 27.9 28.2 
Test weight (mg) 1009.9 1009.9 1009.9 
% Absolute 
difference compare 
to that of initial 
 0.2 0.6 
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Solution stability for test preparation at room temperature 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1678207 1662724 1687950 1697508 1667885 
2 1676828 1661210 1688152 1685856 1666619 
3 1677108 1658816 1687480 1688203 1662877 
4 1672384 1662791 1694160 1690180 1664324 
5 1675192 1663227 1681072 1695345 1671921 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1618776 1615279 1612824 1616163 1616471 
2 1616214 1614736 1613258 1612157 1620568 
Mean 1617495 1615008 1613041 1614160 1618520 
% Assay 99.2 99.1 98.5 98.1 98.0 
Standard weight 
(mg) 28.1 27.9 28.2 28.1 27.6 
Test weight (mg) 1009.9 1009.9 1009.9 1009.9 1009.9 
% Absolute 
difference 
compare to that 
of initial 
 0.1 0.7 1.1 1.2 
 
Calculation:
Prototype calculation for one set:
94.441
48.405
250
1.28
1675944
1617495Assay% ××= 49.98
5
1.204
9.1009
250 ×××
        =  99.2 %
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Aspirin and Clopidogrel...
HPLC METHOD DEVELOPMENT AND VALIDATION OF COMBINE DOSAGE
FORM OF ASPIRIN AND CLOPIDOGREL
1. Introduction to Drug
Platelet aggregation and thrombus formation play a critical role in the initiation
and development of key complications of acute coronary syndromes (ACSs). Antiplatelet
therapy and antithrombotic therapy have been demonstrated to favorably modify clinical
outcome, and recent trials of revascularization in ACSs have demonstrated a reduction
in the frequency of major cardiac events [1-13]. Antiplatelet and antithrombin therapy
can have synergistic actions that reduce the risk of spontaneous or revascularization,
especially percutaneous coronary intervention (PCI)-related events. Yet, all effective
antithrombotic agents also increase the risk of bleeding, especially bleeding that results
from vascular accessor associated with surgery, including coronary artery bypass grafting
(CABG). The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events
(CURE) trial demonstrated that the combination of clopidogrel and aspirin was superior
to aspirin alone for patients hospitalized with non-ST-elevation ACSs.
1.1 Aspirin
Aspirin is chemically acetylsalicylic acid (Figure 1) Its molecular formula is
C9H8O4 having molecular weight 180 g/mole [14]. It is slightly soluble in water, freely
soluble in alcohol, soluble in chloroform and ether, sparingly soluble in absolute ether.
COOH
O
O
CH3
Figure 1: Chemical structure of aspirin
Aspirin, one of the first drugs to come into common usage, is still the most widely
used drug in the world, is a non-steroidal anti-inflammatory drug that exhibits anti-
inflammatory, analgesic and antipyretic activities. Aspirin is now accepted as an important
weapon in the prevention of heart disease. A single dose of 300 mg is now recommended
for patients in the acute stages of a heart attack followed by a daily dose of 75-100 mg.
A similar low dose treatment regime is recommended for patients with angina, a history
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Aspirin and Clopidogrel...
of heart problem or who have undergone coronary by-pass surgery. Major use of aspirin
is as an anti-platelet aggregating agent.
1.1.1 Pharmacology
Mechanism of Action: Aspirin is an inhibitor of the enzyme cyclooxygenase, the
reaction being considered to be due to an irreversible acetylation process. In blood
platelets such enzyme inhibition prevents the synthesis of thromboxane A2, a
compound that is a vasoconstrictor, causes platelet aggregation and is thus
potentially thrombotic. Thus aspirin inhibits platelet inhibition. Aspirin is an
effective antithrombotic at doses as low as 80 mg, but the rapid, acute effect probably
requires 162.5 mg.
Combination: The combination of clopidogrel with aspirin provides enhanced
prevention of atherothrombotic events by blocking the platelet aggregation by both
ways. (ADP Pathway and collagen induced pathway) and it shows a synergistic
antiplatelet action in controlling the ischemic events.
1.1.2 Pharmacokinetics
Absorption: Aspirin is absorbed rapidly from the gastrointestinal tract. Following
oral administration, absorption of nonionised aspirin occurs in the stomach and
intestine. Some aspirin is hydrolyzed to salicylate in the gut wall. After absorption
is rapidly converted to salicylate but during the first 20 minutes following oral
administration. Aspirin is the predominant from of the drug in the plasma.
Distribution: Aspirin is 80 to 90% bound to plasma proteins and is widely distributed
its volume of distribution is reported to be 170 ml per kg body weight in adults. As
plasma drug concentrations increase, the binding sites on the proteins become saturated
and the volume of distribution increases. Both aspirin and salicylate have pharmacological
activity; only aspirin has an antiplatelet effect. Salicylate is extensively bound to plasma
proteins and is rapidly distributed to all body parts. Salicylate appears in breast milk
and crosses the placenta.
Metabolism and Excretion: Salicylate is mainly eliminated by hepatic metabolites
include salicyluric acid, salicyl phenolic glucuronide, salicyclic acyl glucuronide,
gentisic acid and gentisuric acid. Steady state plasma-salicylate concentrations increase
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disproportionately with dose. Following a 325 mg aspirin dose, elimination is a first
order process and the plasma salicylate half-life is about 2 to 3 hours. At high aspirin
doses, the half-life increases to 15 to 30 hours. Salicylate is also excreted unchanged in
the urine; the amount excreated by this route increasing dose and also depends on urinary
pH, about 30% of a dose being extracted in alkaline in urine compared with 2% of a
dose in acidic urine. Renal excretion involves glomerular filtration, active renal tubular
secretion, and passive tubular reabsorption. Salicylate is removed by heamodialysis.
1.1.3 Indications
It is indicated for the prevention of secondary events after the carotid stents.
It is also indicated in the prevention of ischemic stroke and unstable angina.
1.1.4 Contraindications
• It should not be given to any patients with a history of sensitivity reactions
to aspirin, which includes those in whom attacks of a asthma, angioedema,
urticari, or rhinitis have been precipitated by aspirin.
• It should be avoided in severe renal or hepatic impairment.
• It should not be administered to patients with hemonhagic disorders or to
patients with gout since low doses increase urate concentrations.
1.1.5 Drug Interactions
• Aspirin may enhance the activity of coumarin anticoagulants,sulphonylurea,
hypoglycemic drugs, methotrexate, phenytoin, and valproic acid.
• Concurrent administration of aspirin with dypyridamole, metoprolol may increase
peak plasma-salicylate concentrations.
• The risk of gastro intestinal bleeding and ulceration associated with aspirin is
increased when used with corticosteroids.
• Antacids and adsorbents may increase the excretion of aspirin in alkaline urine.
• Aspirin diminishes the effect of uricosurics such as probenecid and sulphinpyrazone.
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1.1.6 Adverse Reaction
The adverse reactions reported with aspirin are gastro intestinal disturbances
such as nausea and vomiting, urticaria, skin eruptions like angioedema, rhinitis
and severe paroxysmal bronchospasm and dyspnoea may be provoked in persons with
asthma, chronic rhinitis and hepatotoxicity in patients with juvenile chronic arthritis or
other connective disorders and blood disorders like thrombocytopenia.
1.2 Clopidogrel
Clopidogrel bisulfate,  chemically it  is [S- (a)(2-chlorophenyl)-6,7-
dihydrothieno (3,2-C) pyridine-5 (4H) acetic acid methyl ester sulphate] (Figure
2). The empirical formula of clopidogrel bisulfate is C16H16ClNO2S•H2SO4 and its
molecular weight is 419.9 g/mole [14]. It is a white to off-white powder. It is
practically insoluble in water at neutral pH but freely soluble at pH 1. It also
dissolves freely in methanol, dissolves sparingly in methylene chloride and is
practically insoluble in ethyl ether. It has a specific optical rotation of about +56°.
The structural formula is as follows:
 
N
S
O OCH3
Cl
Figure 2: Chemical Structure of clopidogrel
1.2.1 Pharmacology
Mechanism of Action: Clopidogrel is an inhibitor of platelet aggregation. A variety
of drugs that inhibit platelet function have been shown to decrease morbid events
in people with established cardiovascular atherosclerotic disease as evidenced by
stroke or transient ischemic attacks, myocardial infarction, unstable angina or the need
for vascular by-pass or angioplasty. This indicates that platelets participate in the initiation
and/or evolution of these events and that inhibiting them can reduce the event rate.
Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to
its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein
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GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Biotransformation of
clopidogrel is necessary to produce inhibition of platelet aggregation, but an active
metabolite responsible for the activity of the drug has not been isolated. Clopidogrel
also inhibits platelet aggregation induced by agonists other than ADP by blocking the
amplification of platelet activation by released ADP. Clopidogrel does not inhibit
phosphodiesterase activity.
Clopidogrel acts by irreversibly modifying the platelet ADP receptor.
Consequently, platelets exposed to clopidogrel are affected for the remainder of
their lifespan. Dose dependent inhibition of platelet aggregation can be seen 2 hours
after single oral doses of clopidogrel bisulfate. Repeated doses of 75 mg clopidogrel
bisulfate per day inhibit ADP-induced platelet aggregation on the first day and
inhibition reaches steady state between day 3 and day 7. At steady state, the average
inhibition level observed with a dose of 75 mg clopidogrel bisulfate per day was
between 40% and 60%. Platelet aggregation and bleeding time gradually return to
baseline values after treatment is discontinued, generally in about 5 days.
1.2.2 Pharmacokinetics
After repeated 75 mg oral doses of clopidogrel (base), plasma concentrations of
the parent compound, which has no platelet inhibiting effect, are very low and are generally
below the quantification limit (0.00025 mg/L) beyond 2 hours after dosing. Clopidogrel
is extensively metabolized by the liver. The main circulating metabolite is the carboxylic
acid derivative, and it too has no effect on platelet aggregation. It represents about 85%
of the circulating drug related compounds in plasma.
Following an oral dose of 14C-labeled clopidogrel in humans, approximately 50%
was excreted in the urine and approximately 46% in the feces in the 5 days after dosing.
The elimination half-life of the main circulating metabolite was 8 hours after single and
repeated administration. Covalent binding to platelets accounted for 2% of radiolabel
with a half-life of 11 days.
Effect of food: Administration of clopidogrel bisulfate with meals did not significantly
modify the bioavailability of clopidogrel as assessed by the pharmacokinetics of the
main circulating metabolite.
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Absorption and distribution: Clopidogrel is rapidly absorbed after oral administration
of repeated doses of 75 mg clopidogrel (base), with peak plasma levels (3 mg/L) of the
main circulating metabolite occurring approximately 1 hour after dosing. The
pharmacokinetics of the main circulating metabolite are linear (plasma concentrations
increased in proportion to dose) in the dose range of 50 to 150 mg of clopidogrel.
Absorption is at least 50% based on urinary excretion of clopidogrel related metabolites.
Clopidogrel and the main circulating metabolite bind reversibly in vitro to human
plasma proteins (98% and 94%, respectively). The binding is nonsaturable in vitro up
to a concentration of 100 µg/ml.
Metabolism and elimination: In vitro and in vivo, clopidogrel undergoes rapid
hydrolysis into its carboxylic acid derivative. In plasma and urine, the glucuronide
of the carboxylic acid derivative is also observed.
1.2.3 Indications and Usage for Clopidogrel
Clopidogrel bisulfate is indicated for the reduction of a t h e r o t h r o m b o t i c
events as follows:
• Recent Myocardial Infarction (MI), Recent Stroke or Established Peripheral
Arterial Disease:
For patients with a history of recent  MI, recent stroke or established peripheral
arterial disease, clopidogrel bisulfate has been shown to reduce the rate of a
combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not)
and other vascular death.
• Acute Coronary Syndrome:
For patients with acute coronary syndrome (unstable angina/non-Q-wave MI)
including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or
CABG, clopidogrel bisulfate has been shown to decrease the rate of a combined
endpoint of cardiovascular death, MI or stroke as well as the rate of a combined
endpoint of cardiovascular death, MI stroke or refractory ischemia.
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1.2.4 Contraindications
The use of clopidogrel bisulfate is contraindicated following conditions:
• In the hypersensitivity to the drug substance or any component of the product.
• Active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
1.2.5 Dosing
The recommended dose of the combination of clopidogrel 75 mg and aspirin
75 mg or combination of clopidogrel 75 mg and aspirin 150 mg  is one tablet daily.
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2. Literature Review
There are many reported method for the determination of either aspirin or
clopidogrel alone or in combination with other drug in pharmaceutical dosage forms
or individually in biological fluids are as under:
2.1 Literature Review for Aspirin
2.1.1 J. T. Franeta, D. Agbaba, S. Eric, S. Pavkov, M. Aleksic, S. Vladimirov
have developed a method for the simultaneous determination of acetylsalicylic
acid, paracetamol, caffeine and phenobarbital in tablets. Separation was achieved
using C18 column (250 mm × 4.6 mm i.d, 5µm particle size). Mixture of
acetonitrile-water (25:75, v/v) adjusted to pH 2.5 with phosphoric acid was used
as a mobile phase at a flow rate of 2.0 ml/min UV detection was at 207 nm. The
method could find application in routine quality control analysis of pharmaceutical
formulations [15].
2.1.2 A. Verstraeten, E. Roets, J. Hoogmartens have developed a quantitative high-
performance liquid chromatographic method for the determination of aspirin and
releted substances in tablets using C 8 column. Methanol-water-1M phosphoric
acid (59:36:5,v/v/v) as the mobile phase has been used for the analysis of several
naturally aged batches of fourteen brands of acetylsalicylic acid tablets.
Comparison is made with classical spectrophotometric method [16].
2.1.3 J. Fogel, P. Epstein, P. Chen have developed a reversed phase high-
performance liquid chromatography method for the simultaneous assay of
acetylsalicylic acid and salicylic acid in film coated aspirin tablet using a 5 µm C
18 column with water-acetonitrile-phosphoric acid (76:24:0.5, v/v/v) as the mobile
phase enabled the chromatographic separation to be completed in 4 min [17].
2.1.4 M. Gandhimathi, T. K. Ravi, A. Abraham, R. Thomas have developed a
simple reversed phase high-performance liquid chromatography method for the
simultaneous estimation of aspirin and isosorbide 5-mononitrate in combined
formulation. The method was carried out on a Thermo Quest C18 column using
a mixture of water-methanol (water pH adjusted to 3.4 using dilute
orthophosphoric acid) and detection was carried out at 215 nm using
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chlorzoxazone as internal standard. Propose method can be use in routine quality
control analysis of pharmaceutical formulations [18].
2.1.5 Y. Dong, Y. Z. Zhao, Y. N. Zhang have developed determination method of
aspirin and free salicylic acid in lysinipirine injection by high performance liquid
chromatography. A Hypersil BDS C18 column was used with the mobile phase
of methanol-water-acetic acid (35:65:3, v/v/v) and the detection wavelength of
280 nm. Method can be used for the qualitative analysis of aspirin and salicylic
acid in lysinipirine injection formulation [19].
2.1.6 M. Sawyer, V. Kumar have developed a rapid reversed phase HPLC procedure
and validated for the simultaneous quantitation of aspirin, salicylic acid and caffeine
extracted from an effervescent tablet. The method uses a Hypersil C18 column
(150 mm × 4.6 mm i.d.,5 µm particle size) for an isocratic elution in a water-
methanol-acetic acid mobile phase at a wavelength of 275 nm. The method could
find application in routine quality control analysis of pharmaceutical tablet
formulations [20].
2.1.7 R. Thomis, E. Roets, J. Hoogmartens have reported analysis method of tablets
containing aspirin, acetaminophen and ascorbic acid by high-performance liquid
chromatography. Method enables the quantitation of the components and the
main impurities of tablets containing aspirin, acetaminophen and ascorbic acid. A
C 8 reverse phase column was used; the mobile phase was methanol-0.2 M
phosphate buffer (pH 3.5)-water (20:10:70, v/v/v). Method was used for the
stability sample analysis [21].
2.1.8 A. W. Abu-Qare, M. B.  Abou-Donia have developed method for the separation
and quantification of the pyridostigmine bromide, acetaminophen, aspirin and
caffeine in rat plasma and urine. The compounds were extracted using C18 Sep-
Pak(R) cartridges then analyzed by high-performance liquid chromatography
(HPLC) with reversed phase C18 column and UV detection at 280 nm. The
compounds were separated using gradient of 1-85 % acetonitrile in water (pH
3.0) at a flow rate ranging between 1 and 1.5 ml/min in a period of 14 min [22].
2.1.9 C. Akay, B. Gümüsel, T. Degim, S. Tartilmis, S. Cevheroglu have developed
simple and accurate high-performance liquid chromatography method to
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measure the amount of acetaminophen, acetylsalicylic acid and ascorbic acid in
tablet formulation. Three drugs, acetaminophen, aspirin and ascorbic acid, were
analyzed simultaneously. A commercial pharmaceutical effervescent tablet was
examined and the amount of each of these agents successfully determined [23].
2.1.10 R. Pirola, S. R. Bareggi, G. De Benedittis have reported determination of
acetylsalicylic acid and salicylic acid in skin and plasma by high-performance
liquid chromatography. Separation of acetylsalicylic acid and salicylic acid
achieved on C18 column using a water-phosphate buffer (pH 2.5)-acetonitrile
(35:40:25, v/v/v) as mobile phase at 1 ml/min flow rate [24].
2.1.11 F. Kees, D. Jehnich, H. Grobecker have reported simultaneous determination
of acetylsalicylic acid and salicylic acid in human plasma by high-
performance liquid chromatography. Aspirin and salicylic acid determined by
reversed phase C18 column (150 mm × 4.0 mm i.d., 4 µm particle size) using
mobile phase water-85% orthophosphoric acid-acetonitrile (740:0.9:180,v/v/v)
and photometric detection (237 nm). 2-Methylbenzoic acid was used as internal
standard [25].
2.1.12 P. P. Ascione, G. P. Chrekian have developed an automated high-pressure liquid
chromatographic method for the separation and determination of aspirin,
phenacetin and caffeine in pharmaceutical dosage forms. Separation of these
compounds for quantitation was achieved on a controlled pore glass support,
utilizing a mixture of acetic acid and chloroform as the mobile phase. The feasibility
of determining free salicylic acid in analgesics also was established [26].
2.1.13 G. Alibrandi, S. Coppolino, S. D’Aliberti, R. Ficarra, N. Micali, A. Villari
reported fast drug stability determination by LC variable parameter kinetic
experiments. Variable parameter kinetic experiments were carried out using
HPLC as analytical instrument. The hydrolysis of aspirin was followed both at
variable temperature and at variable pH conditions [27].
2.1.14 G. P. McMahon, S. J. O’Connor, D.  J. Fitzgerald, S. le Roy, M. T. Kelly
have developed a high-performance liquid chromatographic method for the
simultaneous determination of aspirin and salicylic acid in transdermal perfusates.
The compounds were separated on a C8 Nucleosil column (250 mm × 4.6 mm
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i.d., 5 µm particle size) using a mobile phase containing a mixture of water-
acetonitrile-orthophosphoric acid (650:350:2, v/v/v) and a flow rate of 1 ml/min.
The method has been applied to the determination of aspirin and salicylic acid in
phosphate-buffered saline following in vitro application of the compounds to mouse
skin samples [28].
2.1.15 Z. Kokot, K. Burda have developed simple assay procedure for simultaneous
analysis of aspirin and salicylic acid in aspirin delayed release tablet
formulation by ‘zero crossing’ second derivative UV spectrophotometry [29].
2.1.16 S. H. Hansen, M. E. Jensen, I. Bjørnsdottir have reported the separation of
aspirin and three of its metabolites salicylic acid, salicyluric acid and gentisic
acid  demonstrated in a non-aqueous capillary electrophoresis system with reversed
electroosmotic flow. Solvent mixtures of methanol and acetonitrile were used for
the electrophoresis media and different electrolytes have been investigated. The
separation method was applied to the assay of aspirin and its major metabolites
in plasma and urine [30].
2.1.17 S. Torrado, S. Torrado, R. Cadórniga have compared second derivative
spectroscopy, colorimetry and fluorescence spectroscopy with a high-
performance liquid chromatographic method for the assay of salicylic acid
in preparations of aspirin [31].
2.1.18 I. M. Jalal, S. I. Sa’sa’ has published the official compendial method for
the determination of dextropropoxyphene napsylate, caffeine, aspirin and
salicylic acid involves a lengthy extraction by gas chromatography and
spectrophotometry. The analytical scheme reported here provides a fast,
sensitive and stability-indicating reversed-phase HPLC assay for all these
components concurrently [32].
2.1.19 G. Santoni, L. Fabbri, P. Gratteri, G. Renzi and S. Pinzauti has developed a
reversed phase HPLC method for the simultaneous determination of aspirin,
propyphenazone and codeine phosphate in an analgesic tablet formulation. The
elution was isocratic using two C 8 columns and methanol-water (45:55, v/v) as
mobile phase with 1.4% acetic acid and 5 mM tetramethylammonium bromide
[33].
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2.1.20 S. L. Ali has reported application of gas-liquid chromatography and high-
performance liquid chromatography to the analysis of trace amounts of
salicylic acid, acetylsalicylic anhydride and acetylsalicylsalicylic acid in
aspirin samples and aspirin formulations [34].
2.1.21 V. Kmetec has reported simultaneous determination of acetylsalicylic,
salicylic, ascorbic and dehydroascorbic acid by high performance liquid
chromatography [35].
2.2. Literature Review for Clopidogrel
2.2.1 H. Agrawal, N. Kaul, A. R. Paradkar, K. R. Mahadik have developed and
validated stability indicating high-performance thin layer chromatographic
method of analysis of clopidogrel bisulphate both as a bulk drug and in
formulations. The method employed TLC aluminium plates precoated with silica
gel 60F254 as the stationary phase. The solvent system consisted of carbon
tetrachloride-chloroform-acetone (6:4:0.15, v/v/v). Clopidogrel bisulphate was
subjected to acid and alkali hydrolysis, oxidation, photo degradation and dry
heat treatment. The method could be employed as a stability indicating one [36].
2.2.2 E. Souri, H. Jalalizadeh, A. Kebriaee-Zadeh, M. Shekarchi, A. Dalvandi
have developed reproducible method for determination of carboxylic acid
metabolite of clopidogrel in human plasma. After liquid-liquid extraction in
acidic medium with chloroform, samples were quantified on a C8, 5 mm
column using a mixture of 30 mm dipotassium hydrogen phosphate (pH 3)-
tetra hydro furan-acetonitrile  (79:2:19, v/v/v) as mobile phase with UV
detection at 220 nm. The flow rate was set at 0.9 ml/min. Ticlopidine was
used as internal standard and the total run time of analysis was about 12 min. The
method was used to study the pharmacokinetics of clopidogrel [37].
2.2.3 S. S. Singh, K. Sharma, D. Barot, P. R. Mohan, V. B. Lohray have developed
a high-performance liquid chromatographic method for the estimation of
carboxylic acid metabolite of clopidogrel bisulfate in rat plasma using atorvastatin
as internal standard. Plasma samples were extracted with a mixture of ethyl
acetate-dichloro methane (80:20, v/v) followed by subsequent reconstitution in
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a mixture of water: methanol: acetonitrile (40:40:20, v/v/v). The chromatographic
separation was achieved with gradient elution on Kromasil ODS (250 mm x
4.6 mm i.d., 5 µm particle size) analytical column maintained at 30 °C. Carboxylic
acid metabolite of clopidogrel as well as the internal standard were detected at a
wavelength of 220 nm. The method was applied to the pharmacokinetic study of
the two different polymorphs of clopidogrel bisulfate in wister rat [38].
2.2.4 A. Robinson, J. Hillis, C. Neal, A. C. Leary have developed and validated
LC-MS/MS bio-analytical method for the determination of unchanged
clopidogrel in human plasma. Analysis was performed using a C 8 column
(temperature controlled to 50 °C) by gradient elution at a flow rate of 0.9 ml/min
over a 3 min run time. Detection was achieved using a Sciex API 4000, triple
quadrupole mass spectrometer, in positive turboionspray (electrospray) ionization
mode. This validated method was used to support a pharmacokinetic study in
healthy volunteers [39].
2.2.5 R. V. Nirogi, V. N. Kandikere, M. Shukla, K. Mudigonda, S. Maurya, R.
Boosi have reported high-performance liquid chromatography/positive
electrospray ionization tandem mass spectrometry method for the quantification
of clopidogrel in human plasma. The analytes were separated using an isocratic
mobile phase on a reversed-phase column and analyzed by mass spectrometry in
the multiple reaction-monitoring mode. The validated method has been used to
analyze human plasma samples for application in pharmacokinetic, bioavailability
or bioequivalence studies [40].
2.2.6 H. Ksycinska, P. Rudzki, M. Bukowska-Kiliszek have reported a method
for determination of clopidogrel metabolite (SR26334) in human plasma. Samples
were quantified using reversed phase high performance liquid chromatography
with mass detection. The determination was performed on a Luna C18, (75 mm
x 4.6 mm i.d., 3 µm particle size) column with an acetonitrile-water-formic acid
mixture (60:40:0.1, v/v/v) as a mobile phase. The flow rate was set at 0.2 ml/min.
The method has been used to study clopidogrel metabolite pharmacokinetics in
healthy volunteers [41].
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2.2.7 A. Mitakos, I. Panderi have documented a reversed phase HPLC method for
the determination of clopidogrel in pharmaceutical dosage forms. The
determination was performed on a semi-micro column BDS C8 (250 mm x 2.1
mm i.d., 5 µm particle size). The mobile phase consisted of a mixture of 0.010 M
sodium dihydrogen phosphate (pH 3.0)-acetonitrile (35:65, v/v), pumped at a
flow rate 0.3 ml/min. The UV detector was operated at 235 nm. The method
was applied in the quality control of commercial tablets and content uniformity
test [42].
2.2.8 P. Lagorce, Y. Perez, J. Ortiz, J. Necciari, F. Bressolle haved eveloped GC-
MS method for the analysis of the carboxylic acid metabolite clopidogrel in
plasma and serum. The analytical procedure involves a robotic liquid-liquid
extraction with diethyl ether followed by a solid-liquid extraction on C18
cartridges. The derivatization process was performed using n-ethyl
diisopropylethylamine and alpha-bromo-2,3,4,5,6-pentafluoro toluene. The
method use for the pharmacokinetic studies [43].
2.3 Literature Review for Aspirin and Clopidogrel
Some method reported for the simultaneous determination of aspirin and
clopidogrel in pharmaceutical formulation and biological fluids are as under:
2.3.1 Y. Tomoko, N. Mihoko, W. Mitsuhiro, N. Kentchiro have developed a semi-
micro column HPLC-UV method for simultaneous determination of
clopidogrel metabolite, aspirin and salicylic acid in rat plasma. These
compounds in rat plasma simply extracted by liquid-liquid extraction with 10%
n-hexane/ethyl acetate. The separation of these compounds was achieved within
22 min by a C18 column (250 mm x 1.5 mm) with a mixture of 10 mM phosphate
buffer (pH 2.5) and acetonitrile as an eluant [44].
2.3.2 P. Mishra, A. Dolly have developed two simple spectrophotometric methods
for the simultaneous determination of aspirin and clopidogrel in pharmaceutical
formulation. First method was based on the aditivity of the absorbance. Second
method was based on the determination of graphical absorbance ratio at two
selected wavelengths, one being the isoabsorptive point for the two drugs (225 nm)
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and the other being the absorption maximum of hydrolyzed aspirin (235.7 nm).
Method can be use for the analysis of pharmaceutical formulation [45].
2.3.3 M. Gandhimathi, T. K. Ravi have developed a HPLC to determine aspirin and
clopidogrel in combined dosage form. The chromatographic resolution of aspirin
and clopidogrel was obtained in a mobile phase consisting of 0.1%(v/v)
triethylamine (pH 4.0)-acetonitrile in the ratio (25: 75, v/v) in an isocratic elution.
A detection wavelength of 225 nm and flow rate of 1 ml/min was used. Method
can be used for the simultaneous determination of aspirin and clopidogrel in
pharmaceutical formulation [46].
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3. Aim of Present Work
In recent times, there is increased tendency towards the development of stability-
indicating assays [47-49], using the approach of stress testing as enshrined in the
International Conference on Harmonization (ICH) guideline Q1A (R2) [50]. Even this
approach is being extended to drug combinations [51,52] to allow accurate and precise
quantitation of multiple drugs in presence of their degradation products and interaction
product if any.
Various publications are available regarding determination method of aspirin and
clopidogrel but most of the methods are applicable to alone aspirin or clopidogrel in
pharmaceutical dosage form or in bilogical fluids. Only three method are reported for
the simulteneous determination of apirin and clopidogrel. One is semi-micro column
HPLC-UV method for simultaneous determination of clopidogrel metabolite, aspirin and
salicylic acid in rat plasma. Second is a spectrophotometric method, which is able to
determine aspirin and clopidogrel in combine dosage form and third is simple high
performance liquid chromatography, which applicable to routine quality control sample
analysis. The separation is performed by high performance liquid chromatography for
reasons of robustness and familiarity of analysts with this technique. To our knowledge,
no stability-indicating analytical method for the determination of aspirin and clopidogrel
in combine dosage forms has been published. The previous published methods are not
directly applicable for this issue and need more investigation for method development
and validation.
Consequently, the focus in the present study was to develop a validated stability
indicating HPLC method for the combination, by degrading the drugs together under
various stress conditions like acid hydrolysis, base hydrolysis, oxidation, thermal and
photolytic stress which is recommended by ICH guideline.
The aim and scope of the proposed work are as under
¾ To developed suitable HPLC method for simultaneous determination aspirin
and clopidogrel in tablet formulation.
¾ Forced degradation study of aspirin and clopidogrel under stress condition.
¾ To resolve all major impurities generated during the force degradation studies of
aspirin and clopidogrel.
¾ Perform the validation for the developed method.
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4. Experimental
4.1 Materials
Pharmacopoeial grade standards of aspirin and clopidogrel bisulphate were
provided by reputed pharma company. A tablet containing 150 mg aspirin and 75 mg
clopidogrel was commercially available. HPLC grade acetonitrile, methanol and water
were obtained from Spectrochem Pvt. Ltd., Mumbai (India). Analytical grade hydrochloric
acid, sodium hydroxide pellets, orthophosphoric acid and hydrogen peroxide solution
(30% v/v) were obtained from Ranbaxy Fine Chemical, New Delhi (India).
4.2 Instrumentation
LC-10ATvp HPLC system was used as describe as Part-[A] (5.A).
4.3 Mobile Phase Preparation
The mobile phase was consisted of 0.3% ortho phosphoric acid (v/v)- acetonitrile
(65:35, v/v). Mobile phase was filtered through a 0.45 µm nylon membrane (Millipore
Pvt. Ltd. Bangalore, India) and degassed in an ultrasonic bath (Spincotech Pvt. Ltd.,
Mumbai).
4.4 Diluent Preparation
Mobile phase used as a diluent.
4.5 Standard Preparation
Standard solution containing aspirin (0.075 mg/ml) and clopidogrel (0.0375 mg/
ml) were prepared by dissolving 37.5 mg aspirin and 24.46 mg clopidogrel bisulphate
(equivalent to 18.5 mg clopidogrel) in 100 ml volumetric flask by mobile phase (stock
standard solution). Pipette out 10 ml stock solution into 50 ml volumetric flask and
dilute up to mark with mobile phase (standard solution).
4.6 Test Preparation
Twenty tablets were weighed and the average tablet weight was determined.
Tablets were crushed by mortar and pastel. Tablet powder was weighed equivalent to
five times of average weight and transfer in to 200 ml volumetric flask. About 170 ml
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mobile phase was added and sonicated for of 30 min time interval with intermittent
shaking. Content was brought back to room temperature and dilute to volume with mobile
phase (stock solution). The stock solution was filtered through 0.45 µm nylon syringe
filter. Pipette out 2 ml filtered stock solution in to 100 ml volumetric flask and diluted
with mobile phase (test solution). The concentration obtain was 0.075 mg/ml of aspirin
and 0.0375 mg/ml of clopidogrel.
4.7 Chromatographic Conditions
Chromatographic analysis was performed on a Phenomenex Luna C8(2)
(250 mm  4.6 mm i.d., 5 µm particle size) column. The mobile phase was consisted of
0.3% orthophosphoric acid (v/v) - acetonitrile (65:35, v/v). The flow rate of the mobile
phase was adjusted to 1.0 ml/min and the injection volume was 20 µl. Detection was
performed at 226 nm.
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5. Result and Discussion
5.1 Development and Optimization of the HPLC Method
In the presence work, an analytical method based on LC using UV detection
was developed and validated for assay determination of aspirin and clopidogrel in tablet
formulation. The analytical conditions were selected, keeping in mind the different chemical
nature of aspirin and clopidogrel. The development trials were taken by using the
degraded sample of each component was done, by keeping them in various extreme
conditions.
The column selection has been done on the basis of backpressure, resolution,
peak shape, theoretical plates and day-to-day reproducibility of the retention time and
resolution between aspirin and clopidogrel peak. After evaluating all these factors, C8
(2) (250 mm  4.6 mm i.d., 5 µm particle size) column was found to be giving satisfactory
results. The selection of buffer based on chemical structure of both the drugs. The acidic
pH range was found suitable for solubility, resolution, stability, theoretical plates and
peak shape of both components. Best results were obtained with 0.3% orthophosphoric
acid solution improved the peak shape of aspirin and clopidogrel. Finally, by fixing 0.3%
orthophosphoric acid (v/v) and mobile phase composition consisting of a mixture of
0.3% orthophosphoric acid (v/v)-acetonitrile (65:35, v/v). Optimized mobile phase
proportion was provide good resolution between aspirin and clopidogrel and also for
degradation product which is generated during force degradation study. For the selection
of organic constituent of mobile phase, acetonitrile was chosen to reduce the longer
retention time and to attain good peak shape. Figure 3 and Figure 4 represent the
chromatograms of standard and test preparation respectively.
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Figure 3: Chromatogram of standard preparation
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Figure 4: Chromatogram of test preparation
5.2 Degradation Study
In order to determine whether the analytical method or assay were stability-
indicating, aspirin and clopidogrel combine tablets were stressed under various conditions
to conduct forced degradation studies. Regulatory guidance in ICH Q2A, Q2B, Q3B
and FDA 21 CFR section 211 all require the development and validation of stability-
indicating potency assays. Unfortunately, the current guidance documents do not indicate
detailed degradation conditions in stress testing. However, the used forced degradation
conditions, stress agent concentration and time of stress, were found to effect a
degradation and not complete degradation of active materials. The discovery of such
conditions was based on development trial.
The degradation samples were prepared by transferring powdered tablets,
equivalent to 150 mg aspirin and 75 mg clopidogrel into a 250 ml round bottom flask.
Then prepared samples were employed for acidic, alkaline and oxidant media and also
for thermal and photolytic stress conditions. After the degradation treatments were
completed, the stress content solutions were allowed to equilibrate to room temperature
and diluted with mobile phase to attain 0.075 mg/ml of aspirin and 0.0375 mg/ml of
clopidogrel concentration. Specific degradation conditions were described as follows.
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5.2.1 Acidic condition: Acidic degradation study was performed by heating the drug
content in 1 N HCl (50 ml)at 80 0C for 1 h and mixture was neutralized with 1 N
NaOH solution. The drug content was found to be degrading up to 16.93% in
acidic condition (Figure 5).
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 Figure 5: Chromatogram of acidic forced degradation study
5.2.2 Alkaline condition: Alkaline degradation study was performed by heating the
drug content in 1 N NaOH (50 ml) at 80 0C for 1 h and mixture was neutralized
with 1 N HCl solutions. In alkali degradation, it was found that around 22.00%
of the drug degraded (Figure 6).
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Figure 6: Chromatogram of alkali forced degradation study
93
Part -A (Seect ion-II )
Aspirin and Clopidogrel...
5.2.3 Oxidative condition: Oxidation degradation study was performed by heating
the drug content in 3% v/v H2O2(50 ml) at 80 
0C for 30 min. In oxidative
degradation, it was found that around 15.84% of the drug degraded (Figure 7).
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Figure 7: Chromatogram of oxidative forced degradation study
5.2.4 Thermal condition: Thermal degradation was performed by exposing solid drug
at 80 0C for 72 h. Resultant chromatogram of thermal degradation study (Figure 8)
indicate that nebivolol is found to be slightly stable under thermal degradation
condition. Only 7.0% drug content were degraded.
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Figure 8: Chromatogram of thermal degradation study
5.2.5 Photolytic condition: Photolytic degradation study was performed by exposing
the drug content in sun-light for 72 h. There is 5.0% degradation observed in
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above specific photolitic condition. Drug content was found to be more stable
than other stress condition stable in UV-light (Figure 9).
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Figure 9: Chromatogram of UV-light degradation study
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5.3 Method Validation
5.3.1 Specificity: The specificity of the method was determined by checking the
interference of placebo with analyte and the proposed method were eluted
by checking the peak purity of aspirin and clopidogrel during the force degradation
study. The peak purity of the aspirin and clopidogrel were found satisfactory
under different stress condition. There was no interference of any peak of
degradation product with drug peak.
5.3.2 Linearity: For linearity seven points calibration curve were obtained in a
concentration range from 0.030-0.120 mg/ml for aspirin and 0.015-0.060 mg/ml
for clopidogrel. The response of the drug was found to be linear in the investigation
concentration range and the linear regression equation for aspirin was
y= 60026378.57x + 51410.11 with correlation coefficient 0.9999(Figure 10) and
for clopidogrel was y = 44544414.03x - 1890.29 with correlation coefficient 0.9999
(Figure 11). Where x is the concentration in mg/ml and y is the peak area in
absorbance unit. Chromatogram obtain during linearity study were shown in Figure
12-18.
Linearity study for aspirin
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Figure 10: Linearity curve for aspirin
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Linearity study for clopidogrel
y = 44544414.03x - 1890.29
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Figure 11: Linearity curve for clopidogrel
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Figure 12: Linearity study chromatogram of level-1 (40%)
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Figure13: Linearity study chromatogram of level-2 (60%)
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Figure14: Linearity study chromatogram of level-3 (80%)
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Figure 15: Linearity study chromatogram of level-4 (100%)
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Figure 16: Linearity study chromatogram of level-5 (120%)
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 Figure 17: Linearity study chromatogram of level-6 (140%)
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Figure 18: Linearity study chromatogram of level-7 (160%)
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5.3.3 LOD and LOQ: The limit of detection and limit of quantification were evaluated
by serial dilutions of aspirin and clopidogrel stock solution in order to obtain
signal to noise ratio of 3:1 for LOD and 10:1 fro LOQ. The LOD value for
aspirin and clopidogrel were found to be 0.05 ppm and 0.15 ppm, respectively
and the LOQ value 0.2 ppm and 0.3 ppm, respectively. Chromatogram of LOD
and LOQ study were shown in Figure 19-22.
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Figure 19: Chromatogram of LOD study of aspirin
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Figure 20: Chromatogram of LOD study of clopidogrel
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Figure 21: Chromatogram of LOQ study of aspirin
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Figure 22: Chromatogram of LOQ study of clopidogrel
5.3.4 Precision: Data obtain from precision experiments are given in Table 1 for
intraday and interday precision study for both aspirin and clopidogrel. The RSD
values for intra day precision study and interday precision study was < 2.0% for
aspirin and clopidogrel. Which confirm that the method was precise.
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Table 1: Results of precision study
Aspirin (%Assay) Clopidogrel (%Assay) 
Set Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Intraday 
(n = 6) 
1 99.1 100.2 99.3 99.6 
2 100.0 99.9 98.7 99.6 
3 99.6 100.5 98.6 100.1 
4 99.5 100.3 99.0 100.1 
5 100.3 101.0 100.0 100.6 
6 99.1 100.8 99.5 100.7 
Mean 99.6 100.5 99.2 100.1 
Standard deviation 0.48 0.40 0.53 0.47 
% RSD 0.48 0.40 0.53 0.47 
 
5.3.5 Accuracy: Recovery of aspirin and clopidogrel were determined at three
different concentration levels. The mean recovery for aspirin was 99.12-99.83
% and 98.20-100.35 % for clopidogrel (Table 2). The result indicating that
the method was accurate. Chromatogram obtain during accuracy study were
shown in Figure 23-25.
Table 2: Results of accuracy study
 Level 
(%) 
 
Amount Added 
Concentrationa 
(mg/ml) 
Amount Found 
Concentrationa 
(mg/ml) 
% 
Recoverya 
% 
RSDa 
50 0.03751 0.03721 99.22 0.07 
100 0.07497 0.07432 98.12 0.23 Aspirin 
150 0.11250 0.11232 99.83 0.05 
50 0.01874 0.01840 98.20 0.19 
100 0.03748 0.03695 98.59 0.14 Clopidogrel 
150 0.05627 0.05647 100.35 0.24 
 a Each value corresponds to the mean of three determinations.
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Figure 23: Accuracy study chromatogram of level-1 (50%)
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Figure 24: Accuracy study chromatogram of level-2 (100%)
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Figure 25: Accuracy study chromatogram of level-3 (150%)
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5.3.6 Solution stability study: Table 3 shows the results obtain in the solution stability
study at different time intervals for test preparation. It was concluded that the
test preparation solution was found stable up to 48 h at 2-5 0C and 36 h at
ambient temperature with the consideration of < 2.0% in %assay value difference
of inteval value against initial value.
Table 3: Evaluation data of solution stability study
% Assay for Test Solution 
Stored at 2 –5 0C 
% Assay for Test Solution 
Stored at Ambient Temperature Intervals 
Aspirin Clopidogrel Aspirin Clopidogrel 
Initial 101.3 100.0 101.3 100.0 
12 h 100.9 99.3 100.1 99.5 
24 h 100.3 99.6 99.8 99.0 
36 h 100.1 99.0 99.8 98.6 
48 h 99.9 98.7 98.1 98.7 
 
5.3.7 Robustness: The result of robustness study of the developed assay method was
established in Table 4 and Table 5. The result shown that during all variance
conditions, assay value of the test preparation solution was not affected and it
was in accordance with that of actual. System suitability parameters were also
found satisfactory, hence the analytical method would be concluded as robust.
Chromatogram obtain during robustness study were shown in Figure 26-32.
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Table 4: Evaluation data of robustness study of aspirin
% 
Assay 
System Suitability Parameters 
Robust Conditions 
 
Theoretical 
Plates 
Asymmetry % RSD 
Flow 0.9 ml/min 100.5 6460 1.05 0.22 
Flow 1.1 ml/min 100.3 5661 1.05 0.09 
0.28 % H3PO4-ACN (65:35, v/v) 100.0 6117 1.00 0.40 
0.32 % H3PO4-ACN (65:35, v/v) 99.7 5588 1.02 0.30 
0.3% H3PO4-ACN (63:37,v/v) 100.2 5475 1.12 0.19 
0.3% H3PO4-ACN  (67:33,v/v) 100.1 5838 1.04 0.20 
Column change 100.4 5425 1.05 0.34 
 
Table 5: Evaluation data of robustness study for clopidogrel
System Suitability Parameters 
Robust Conditions 
%  
Assay Theoretical 
Plates 
Asymmetry 
% 
RSD 
Resolution 
Flow 0.9 ml/min 98.5 6975 1.07 0.67 5.75 
Flow 1.1 ml/min 100.0 5992 1.06 0.39 5.14 
0.28 % H3PO4-ACN(65:35,v/v) 98.8 6899 1.03 1.03 6.35 
0.32 % H3PO4-ACN(65:35,v/v) 99.2 6113 1.03 0.69 5.62 
0.3% H3PO4-ACN(63:37,v/v) 99.5 5850 1.11 0.70 4.31 
0.3% H3PO4-ACN (67:33,v/v) 99.0 6185 1.04 0.30 5.71 
Column change 100.0 5996 1.04 0.25 4.97 
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Figure 26: Standard chromatogram (0.9 ml/min flow rate)
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Figure 27: Standard chromatogram (1.1 ml/min flow rate)
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Figure 28: Standard chromatogram [0.3% H3PO4-ACN (63:37,v/v)]
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Figure 29: Standard chromatogram [0.3% H3PO4-ACN (67:33,v/v)]
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Figure 30: Standard chromatogram [0.28% H3PO4-ACN (65:35, v/v)]
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Figure 31: Standard chromatogram [0.32% H3PO4-ACN (65:35, v/v)]
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Figure 32: Standard chromatogram (Column change)
5.3.8 System suitability: A system suitability test of the chromatographic system was
performed before each validation run. Five replicate injections of standard
preparation were injected and asymmetry, theoretical plate, resolution and %
RSD of peak area were determined for same. Acceptance criteria for system
suitability, asymmetry should not be more than 2.0, theoretical plate should not
be less then 4000 and  %RSD of peak area should not be more then 2.0, were
full fill during all validation parameters.
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6. Calculation and Data
Calculation formula used:
1. Calculation formula for aspirin
WeightTest
200
50
10
100
WeightStandard
AreaStandardMean
AreaTestMean
Assay% ×××=
StandardofPotency
ClaimLable
WeightAverage
2
100 ×××
2.Calculation formula for clopidogrel
83.419
83.321
50
10
100
WeightStandard
AreaStandardMean
AreaTestMean
Assay% ×××=
StandardofPotency
ClaimLable
WeightAverage
2
100
WeightTest
200 ××××
3. Relative standard deviation
100
 tsMeasuremenofValueMean
 tsMeasuremenofDeviationStandard
RSD% ×=
4. Recovery
100
AddedAmount
FoundAmount
erycovRe% ×=
5. Amount Found
ionConcentratStandard
AreaStandardMean
AreaTestMean
)ml/mg(FoundAmount ×=
6. Amount added
Volume
Weight)ml/mg(AddedAmount =
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Specificity Study for Analytical Method Validation of Aspirin Clopidogrel Tablets
¾ For Aspirin
Standard Weight (mg) 37.5     
Standard Dilution 100 10 50   
Standard Potency 99.97 %     
Factor 1 -     
Factor 2 -     
Standard Concentration 
(mg/ml) 0.0750     
      
Replicate 1 2 3 4 5 
Standard Area 4600786 4604792 4601538 4598274 4603409 
Mean Standard Area 4601760     
Stdev 2238.86     
% RSD 0.05     
 
Replicate Test Area 
1 4666587 
2 4662838 
Mean Test Area 4664713 
Test Weight (mg) 2007.5 
Label Claim (mg) 150  
Average Test Weight (mg) 400.1 
% Assay 101.0 % 
 
Calculation:
Prototype calculation for one set:
5.2007
200
50
10
100
5.37
4601760
4664713Assay% ×××= 97.99
150
1.400
2
100 ×××
     = 101.0 %
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¾ For Clopidogrel
Standard Weight (mg) 25.2      
Standard Dilution 100 10 50   
Standard Potency 99.38 %     
Factor 1 321.83     
Factor 2 419.83     
Standard Concentration 
(mg/ml) 0.0386     
      
Replicate 1 2 3 4 5 
Standard Area 1655001 1660845 1662939 1662004 1666323 
Mean Standard Area 1661422     
Stdev. 3693.83     
% RSD 0.22     
 
Replicate Test Area 
1 1638562 
2 1638424 
Mean Test Area  1638493 
Test Weight (mg) 2007.5 
Label Claim (mg) 75  
Mean Test weight (mg) 400.1 
% Assay 100.6 % 
 
Calculation:
Prototype calculation for one set:
5.2007
200
83.419
83.321
50
10
100
2.25
1661422
1638493Assay% ××××= 38.99
75
1.400
2
100 ×××
     = 100.6 %
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Linearity Study for Analytical Method Validation of Aspirin Clopidogrel Tablets
¾ For Aspirin
 
Standard Weight (mg) 37.5            
Standard Dilution 100 10 50   
Standard Potency 99.97 %     
Factor 1 -     
Factor 2 -     
Standard Concentration (mg/ml) 0.0750     
Concentration of Linearity Stock 
Solution (mg/ml) 0.3750     
      
Replicate 1 2 3 4 5 
Standard Area 4651479 4643757 4621922 4607507 4582449 
Mean Standard Area 4621423         
Stdev 27906.30         
% RSD 0.60         
Concentration 
Level (%) 
Volume of 
Linearity stock 
solution taken (ml) 
Diluted to 
(ml) 
Fi
Conce
(mg
40 4.0 50 0.0
60 6.0 50 0.0
80 8.0 50 0.0
100 10.0 50 0.0
120 12.0 50 0.0
140 14.0 50 0.1
160 16.0 50 0.1
  Correlation co-effic
  Slope 
  Intercept 
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¾ For Clopidogrel
 
Standard Weight (mg) 24.5            
Standard Dilution 100 10 50   
Standard Potency 99.38 %     
Factor 1 321.83     
Factor 2 419.83     
Standard Concentration (mg/ml) 0.0375     
Concentration of Linearity Stock 
Solution (mg/ml) 0.1875     
      
Replicate 1 2 3 4 5 
Standard Area 1693789 1688587 1683886 1683619 1679066 
Mean Standard Area 1685789         
Stdev 5598.17         
% RSD 0.33         
Concentration 
Level (%) 
Volume of 
Linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
F
Conce
(m
40 4.0 50 0.
60 6.0 50 0.
80 8.0 50 0.
100 10.0 50 0.
120 12.0 50 0.
140 14.0 50 0.
160 16.0 50 0.
  Correlation co-eff
  Slope 
  Intercept 
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Precision Study for Analytical Method Validation of Aspirin Clopidogrel Tablets
¾ For Aspirin
Standard Weight (mg) 37.5          
Standard Dilution 100 10 50   
Standard Potency 99.97 %         
Label Claim (mg) 150      
Mean Test Weight (mg) 400.1      
Factor 1 -         
Factor 2 -         
Standard Concentration (mg/ml) 0.0750         
      
Replicate 1 2 3 4 5 
Standard Area 4570460 4556977 4527249   4537188 4529478 
Mean Standard Area 4544270         
Stdev 18748.71         
% RSD 0.41       
 
Description Mean Area Test Weight (mg) % Assay 
Set 1 4505006 2000.2 99.1 
Set 2 4541669 1998.2 100.0 
Set 3 4529604 2000.9 99.6 
Set 4 4532550 2004.1 99.5 
Set 5 4614090 2025.5 100.3 
Set 6 4499658 1998.6 99.1 
  Mean 99.60 
  Stdev 0.48 
  % RSD 0.48 
  Confidence Level (95.0%) 0.51 
 
Calculation:
Prototype calculation for one set:
2.2000
200
50
10
100
5.37
4544270
4505006Assay% ×××= 97.99
150
1.400
2
100 ×××
     = 99.1 %
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 ¾ For Clopidogrel
Standard Weight (mg) 25.3          
Standard Dilution 100 10 50   
Standard Potency 99.38 %         
Label claim (mg) 75      
Mean Test Weight (mg) 400.1      
Factor 1 321.83         
Factor 2 419.83         
Standard Concentration (mg/ml) 0.0388         
      
Replicate 1 2 3 4 5 
Standard Area 1645676 1642399 1625264 1611740 1627881 
Mean Standard Area 1630592         
Stdev 13766.51         
% RSD 0.84       
 
  
Description Mean Area Test weight (mg) % Assay 
Set 1 1574146 2000.2 99.3 
Set 2 1563472 1998.2 98.7 
Set 3 1564660 2000.9 98.6 
Set 4 1573421 2004.1 99.0 
Set 5 1605971 2025.5 100.0 
Set 6 1576470 1998.6 99.5 
  Mean 99.2 
  Stdev 0.53 
  % RSD 0.53 
  Confidence Level (95.0%) 0.55 
 
Calculation:
Prototype calculation for one set:
2.2000
200
83.419
83.321
50
10
100
3.25
1630592
1574146Assay% ××××= 38.99
75
1.400
2
100 ×××
     = 99.3 %
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Intermediate Precision Study for Analytical Method Validation of Aspirin
Clopidogrel Tablet
¾ For Aspirin
Standard Weight (mg) 37.5          
Standard Dilution 100 10 50   
Standard Potency 99.97 %         
Label Claim (mg) 150      
Mean Test Weight (mg) 400.1      
Factor 1 -         
Factor 2 -         
Standard Concentration (mg/ml) 0.0750         
      
Replicate 1 2 3 4 5 
Standard Area 4581410 4597915 4604993 4610703 4609156 
Mean Standard Area 4600835         
Stdev 11934.85         
% RSD 0.26       
 
Description Mean Area Test Weight (mg) % Assay 
Set 1 4656542 2020.2 100.2 
Set 2 4631669 2015.3 99.9 
Set 3 4634482 2003.9 100.5 
Set 4 4627280 2004.4 100.3 
Set 5 4646497 1999.4 101.0 
Set 6 4631718 1998.2 100.8 
  Mean 100.5 
  Stdev 0.40 
  % RSD 0.40 
  Confidence Level (95.0%) 0.42 
 
Calculation:
Prototype calculation for one set:
2.2020
200
50
10
100
5.37
4600835
4656542Assay% ×××= 97.99
150
1.400
2
100 ×××
     = 100.2 %
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¾ For Clopidogrel
Standard Weight (mg) 25.2          
Standard Dilution 100 10 50   
Standard Potency 99.38 %         
Label Claim (mg) 75      
Mean Test Weight (mg) 400.1      
Factor 1 321.83         
Factor 2 419.83         
Standard Concentration (mg/ml) 0.0386         
      
Replicate 1 2 3 4 5 
Standard Area 1666514 1664669 1660945 1662983 1664353 
Mean Standard Area 1663893         
Stdev 2073.78         
% RSD 0.12       
 
Description Mean Area Test weight (mg) % Assay 
Set 1 1633699 2020.2 99.6 
Set 2 1631190 2015.3 99.6 
Set 3 1628789 2003.9 100.1 
Set 4 1630551 2004.4 100.1 
Set 5 1633870 1999.4 100.6 
Set 6 1633828 1998.2 100.7 
  Mean 100.1 
  Stdev 0.47 
  % RSD 0.47 
  Confidence Level (95.0%) 0.49 
 
Calculation:
Prototype calculation for one set:
2.2020
200
83.419
83.321
50
10
100
2.25
1683893
1633699Assay% ××××= 38.99
75
1.400
2
100 ×××
    = 99.6 %
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 Comparison for Precision and Intermediate Precision Study for Analytical
Method Validation for Aspirin Clopidogrel Tablets
¾ For Aspirin
 Set %Assay 
1 99.1 
2 100.3 
3 99.6 
4 99.5 
5 101.0 
Precision study 
6 99.1 
1 101.2 
2 100.8 
3 100.7 
4 100.4 
5 101.1 
Intermediate precision study 
6 100.7 
 Mean 100.3 
 Stdev 0.77 
 % RSD 0.77 
 
¾ For Clopidogrel
 Set % Assay 
1 99.3 
2 99.0 
3 98.6 
4 99.0 
5 100.7 
Precision study 
6 99.5 
1 100.5 
2 100.5 
3 100.2 
4 100.2 
5 100.7 
Intermediate precision study 
6 100.6 
 Mean 99.9 
 Stdev 0.77 
 % RSD 0.77 
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Accuracy Study for Analytical Method Validation of Aspirin Clopidogrel Tablets
¾ For Aspirin
Standard Weight (mg) 37.7          
Standard Dilution 100 10 50   
Standard Potency 99.97 %         
Factor 1 -         
Factor 2 -         
Standard Concentration (mg/ml) 0.0754         
      
Replicate 1 2 3 4 5 
Standard Area 4631817 4595351 4573625 4606829 4619422 
Mean Standard Area 4605409         
Stdev 22400.61         
% RSD 0.49       
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¾ For Clopidogrel
Standard Weight (mg) 24.9          
Standard Dilution 100 10 50   
Standard Potency 99.38 %         
Factor 1 321.83         
Factor 2 419.83         
Standard Concentration 
(mg/ml) 0.0382         
      
Replicate 1 2 3 4 5 
Standard Area 1696020 1683394 1678190 1682439 1693078 
Mean Standard Area 1686624         
Stdev 7566.68         
% RSD 0.45       
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Solution Stability Study for Analytical Method Validation of Aspirin
Clopidogrel Tablets
¾ For Aspirin
System suitability of standard preparation for solution stability 
 
Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 4590829 4595107 4578851 4586051 4604645 
2 4568423 4592801 4577832 4593989 4624750 
3 4568097 4577366 4582843 4612737 4625372 
4 4592898 4591664 4555542 4597328 4615701 
5 4568068 4600193 4571090 4593089 4622415 
Mean 4577663 4591426 4573232 4596639 4618577 
Stdev 12984.59 8515.29 10754.40 9891.30 8680.15 
%RSD 0.28 0.19 0.24 0.22 0.19 
 
Solution stability for standard preparation at 2-8 °C 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 4590829 4590829 4590829 4590829 
2 4568423 4568423 4568423 4568423 
3 4568097 4568097 4568097 4568097 
4 4592898 4592898 4592898 4592898 
5 4568068 4568068 4568068 4568068 
1 4580963 4552862 4578125 4568463 
2 4560334 4559105 4556889 4580056 
Mean 4575659 4571469 4574761 4576691 
Stdev 12632.41 15084.85 13211.31 11240.89 
%RSD 0.28 0.33 0.29 0.25 
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Solution stability for standard preparation at room temperature 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 4590829 4590829 4590829 4590829 
2 4568423 4568423 4568423 4568423 
3 4568097 4568097 4568097 4568097 
4 4592898 4592898 4592898 4592898 
5 4568068 4568068 4568068 4568068 
1 4529151 4503255 4465031 4441407 
2 4515593 4493929 4466973 4427586 
Mean 4561866 4555071 4545760 4536758 
Stdev 29250.60 40103.27 55509.71 70770.56 
%RSD 0.64 0.88 1.22 1.56 
Solution stability for test preparation at
 Initial After 12 hours 
After 24 
hours 
 Standard Standard Standard 
Replicate Peak area Peak area Peak area 
1 4590829 4595107 4578851 
2 4568423 4592801 4577832 
3 4568097 4577366 4582843 
4 4592898 4591664 4555542 
5 4568068 4600193 4571090 
Replicate Test Area Test Area Test Area
1 4633289 4614247 4589238 
2 4613030 4599953 4585954 
Mean 4623160 4607100 4587596 
% Assay 101.3 100.9 100.3 
Standard weight (mg) 37.6 37.7 37.5 
Test weight (mg) 2000.1 2000.1 2000.1 
%Absolute difference 
compare to that of 
initial 
 0.4 1.0 
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Solution stability for test preparation at room temperature 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 4590829 4595107 4578851 4586051 4604645 
2 4568423 4592801 4577832 4593989 4624750 
3 4568097 4577366 4582843 4612737 4625372 
4 4592898 4591664 4555542 4597328 4615701 
5 4568068 4600193 4571090 4593089 4622415 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 4633289 4564891 4542451 4487609 4455559 
2 4613030 4564260 4527236 4482632 4449981 
Mean 4623160 4564576 4534844 4485121 4452770 
% Assay 101.3 100.1 99.8 99.8 98.1 
Standard weight (mg) 37.6 37.7 37.7 38.2 37.9 
Test weight (mg) 2000.1 2000.1 2000.1 2000.1 2000.1 
% Absolute difference 
compare to that of 
initial 
 1.2 1.4 1.4 3.2 
 
Calculation:
Prototype calculation for one set:
1.2000
200
50
10
100
6.37
4577663
4623160Assay% ×××= 97.99
150
1.400
2
100 ×××
     = 101.3 %
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¾ For Clopidogrel
System suitability of standard preparation for solution stability 
 
Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1638380 1659679 1670899 1664590 1667806 
2 1637594 1660579 1660183 1663458 1677669 
3 1640913 1662667 1658794 1663701 1673047 
4 1646765 1663436 1655880 1661151 1669403 
5 1638080 1662128 1655210 1672996 1670406 
Mean 1640346 1661698 1660193 1665179 1671666 
Stdev 3811.12 1538.91 6324.71 4550.37 3858.48 
%RSD 0.23 0.09 0.38 0.27 0.23 
 
Solution stability for standard preparation at 2 -8 °C 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1638380 1638380 1638380 1638380 
2 1637594 1637594 1637594 1637594 
3 1640913 1640913 1640913 1640913 
4 1646765 1646765 1646765 1646765 
5 1638080 1638080 1638080 1638080 
1 1655363 1652956 1654426 1653554 
2 1652007 1650203 1646895 1657608 
Mean 1644157 1643556 1643293 1644699 
Stdev 7278.95 6352.80 6303.82 8143.27 
%RSD 0.44 0.39 0.38 0.50 
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Solution stability for standard preparation at room temperature 
After 12 hours After 24 hours After 36 hours After 48 hours  
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1638380 1638380 1638380 1638380 
2 1637594 1637594 1637594 1637594 
3 1640913 1640913 1640913 1640913 
4 1646765 1646765 1646765 1646765 
5 1638080 1638080 1638080 1638080 
1 1653617 1647434 1646010 1649559 
2 1656717 1643628 1646155 1647690 
Mean 1644581 1641828 1641985 1642712 
Stdev 7923.48 4158.15 4185.55 5127.39 
%RSD 0.48 0.25 0.25 0.31 
Solution stability for test preparation at
 Initial After 12 hours 
After 24
hours 
 Standard Standard Standard
Replicate Peak area Peak area Peak area
1 1638380 1659679 1670899
2 1637594 1660579 1660183
3 1640913 1662667 1658794
4 1646765 1663436 1655880
5 1638080 1662128 1655210
Replicate Test Area Test Area Test Area
1 1608749 1610497 1619269
2 1606925 1612528 1609494
Mean 1607837 1611513 1614382
% Assay 100.0 99.3 99.6 
Standard weight (mg) 25.1 25.2 25.2 
Test weight (mg) 2000.1 2000.1 2000.1 
% Absolute difference 
compare to that of 
initial 
 0.7 0.4 
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Solution stability for test preparation at room temperature 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1638380 1659679 1670899 1664590 1667806 
2 1637594 1660579 1660183 1663458 1677669 
3 1640913 1662667 1658794 1663701 1673047 
4 1646765 1663436 1655880 1661151 1669403 
5 1638080 1662128 1655210 1672996 1670406 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1608749 1618655 1606974 1603043 1602744 
2 1606925 1609690 1603593 1602378 1606073 
Mean 1607837 1614173 1605284 1602711 1604409 
% Assay 100.0 99.5 99.0 98.6 98.7 
Standard weight (mg) 25.1 25.2 25.2 25.2 25.3 
Test weight (mg) 2000.1 2000.1 2000.1 2000.1 2000.1 
% Absolute difference 
compare to that of 
initial 
 0.5 1.0 1.4 1.3 
 
Calculation:
Prototype calculation for one set:
1.2000
200
83.419
83.321
50
10
100
1.25
1640346
1607837Assay% ××××= 38.99
75
1.400
2
100 ×××
     = 100.0 %
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HPLC METHOD DEVELOPMENT AND VALIDATION OF COMBINE DOSAGE
FORM OF TRAMADOL HYDROCHLORIDE AND ACECLOFENAC
1. Introduction to Drug
1.1 Tramadol Hydrochloride
Tramadol hydrochloride, (1,2)–2-[(dimethylamino)-methyl]–1-(3-methoxy-
phenyl) cyclohexanol hydrochloride (Figure 1) Its molecular formula is C16H25NO2HCl
having molecular weight 299.24 g/mole. It white crystalline powder and soluble in
water [1].
N
CH3
CH3
OH
H3CO .HCl
Figure 1: Chemical structure of tramadol hydrochloride
Tramadol is a centrally acting analgesic agent, which has been shown to be a
synthetic analogue of codeine [2]. It is metabolized by the cytochrome P450 enzyme
system in the liver to form 11 metabolites of which M1                                             (O-
desmethyltramadol) predominates and possesses analgesic properties [3]. It has been
used since 1977 for the relief of strong physical pain and has been the most widely sold
opioid analgesic drug in the world [4]. Tramadol was developed by the German
pharmaceutical company Grünenthal GmbH and marketed under the trade name Tramal.
Grünenthal has also cross licensed the drug to many other pharmaceutical companies
that market it under various names.Tramadol is usually marketed as the hydrochloride
salt (tramadol hydrochloride) and is available in both injectable (intravenous and/or
intramuscular) and oral preparations. It is also available in conjunction with paracetamol
(acetaminophen) and aceclofenac.
1.1.1 Pharmacodynamics
Tramadol hydrochloride is a centrally acting synthetic opioid analgesic in an orally
disintegrating tablet form. Although its mode of action is not completely understood,
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from animal tests, at least two complementary mechanisms appear applicable. Binding
of parent and M1 metabolite to µ-opioid receptors and weak inhibition of re-uptake of
norepinephrine and serotonin.
Opioid activity is due to both low affinity binding of the parent compound
and higher affinity binding of the O-demethylated metabolite M1 to µ-opioid
receptors. In animal models, M1 is up to 6 times more potent than tramadol in
producing analgesia and 200 times more potent in µ-opioid binding. Tramadol
induced analgesia is only partially antagonized by the opiate antagonist naloxone
in several animal tests. The relative contribution of both tramadol and M1 to human
analgesia is dependent upon the plasma concentrations of each compound.
Tramadol has been shown to inhibit re-uptake of norepinephrine and serotonin
in vitro, as have some other opioid analgesics. These mechanisms may contribute
independently to the overall analgesic profile of tramadol. Analgesia in human begins
approximately within one hour after administration and reaches a peak in approximately
two to three hours.
Apart from analgesia, tramadol administration may produce a constellation
of symptoms (including dizziness, somnolence, nausea, constipation, sweating and
pruritus) similar to that of other opioids. In contrast to morphine, tramadol has not
been shown to cause histamine release. At therapeutic doses, tramadol has no effect
on heart rate, left-ventricular function or cardiac index. Orthostatic hypotension
has been observed.
1.1.2 Pharmacokinetics
The analgesic activity of tramadol is due to both parent drug and the M1
metabolite.  Tramadol is administered as a racemate and both the [-] and [+] forms
of both tramadol and M1 are detected in the circulation. Tramadol is well absorbed
orally with an absolute bioavailability of 75%. Tramadol has a volume of distribution of
approximately 2.7 L/kg and is 20% bound to plasma proteins. Tramadol is extensively
metabolized by a number of pathways, including CYP2D6 and CYP3A4, as well as by
conjugation of parent and metabolites. One metabolite, M1, is pharmacologically active
in animal models. The formation of M1 is dependent upon CYP2D6 and as such is
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subject to inhibition, which may affect the therapeutic response. Tramadol and its
metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3
and 7.4 hours for tramadol and M1, respectively. Linear pharmacokinetics have been
observed following multiple doses of 50 and 100 mg to steady state.
No difference has been identified in systemic exposure (AUC), peak exposure
(Cmax), time to peak exposure (Tmax) and apparent elimination half-life (tÂ½) of
tramadol and metabolites M1 and M5 between administration of tramadol
hydrochloride with and without water and tablet.
Absorption: Racemic tramadol is rapidly and almost completely absorbed after oral
administration. The mean absolute bioavailability of a 100 mg oral dose is approximately
75%. The mean peak plasma concentration of racemic tramadol and M1 occurs at two
and three hours, respectively, after administration in healthy adults. In general, both
enantiomers of tramadol and M1 follow a parallel time course in the body following
single and multiple doses although small differences (~ 10%) exist in the absolute amount
of each enantiomer present.
Food Effects: Oral administration of tramadol hydrochloride with food does not
significantly affect its extent of absorption, however, food does delay tmax by about
30 minutes compared to fasting conditions. The clinical significance of this delay
is not known.
Distribution: The volume of distribution of tramadol was 2.6 and 2.9 L/kg in male and
female subjects, respectively, following a 100 mg intravenous dose. The binding of
tramadol to human plasma proteins is approximately 20% and binding also appears to
be independent of concentration up to 10 µg/ml. Saturation of plasma protein binding
occurs only at concentrations outside the clinically relevant range.
Metabolism: Tramadol is extensively metabolized after oral administration.
Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas
60% of the dose is excreted as metabolites. The remainder is excreted either as
unidentified or as unextractable metabolites. The major metabolic pathways appear
to be N - and O - demethylation and glucuronidation or sulfation in the liver. One
metabolite (O -desmethyltramadol, denoted M1) is pharmacologically active in animal
models. Formation of M1 is dependent on CYP2D6 and as such is subject to inhibition,
which may affect the therapeutic response.
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Approximately 7% of the population has reduced activity of the CYP2D6
isoenzyme of cytochrome P-450. These individuals are “poor metabolizers” of
debrisoquine, dextromethorphan, tricyclic antidepressants, among other drugs.
Based on a population PK analysis of phase-I studies in healthy subjects,
concentrations of tramadol were approximately 20 % higher in “poor metabolizers”
versus “extensive metabolizers,” while M1 concentrations were 40% lower. Concomitant
therapy with inhibitors of CYP2D6 such as fluoxetine, paroxetine and quinidine could
result in significant drug interactions. In vitro drug interaction studies in human liver
microsomes indicate that inhibitors of CYP2D6 such as fluoxetine and its metabolite
norfluoxetine, amitriptyline and quinidine inhibit the metabolism of tramadol to various
degrees, suggesting that concomitant administration of these compounds could result in
increases in tramadol concentrations and decreased concentrations of M1. The full
pharmacological impact of these alterations in terms of either efficacy or safety is
unknown. Concomitant use of SEROTONIN re-uptake INHIBITORS and MAO
INHIBITORS may enhance the risk of adverse events, including seizure and serotonin
syndrome.
Elimination: Tramadol is eliminated primarily through metabolism by the liver
and the metabolites are eliminated primarily by the kidneys. The mean terminal
plasma elimination half-lives of racemic tramadol and racemic M1 are 6.3 ± 1.4
and 7.4 ± 1.4 hours, respectively. The plasma elimination half-life of racemic
tramadol increased from approximately six hours to seven hours upon multiple
dosing.
1.2 Aceclofenac
Aceclofenac, 2-[(2,6-dichlorophenyl) amino]-phenylacetoxyacetic acid
(Figure 2). The molecular formula of aceclofenac is C16H13Cl2NO4 and its molecular
weight is 354.19 g/mole [1]. It is a white or almost white powder. It is practically insoluble
in water, freely soluble in acetone and  soluble in alcohol.
137Tramado l  Hydroch lo r ide  and  Acec l o f enac . .
Part -A (Seect ion-III )
O
NH
O COOH
Cl Cl
Figure 2: Chemical structure of aceclofenac
That shows analgesic properties and good tolerability profile in a variety of
painful conditions [5, 6]. It is used in the treatment of rheumatic disorders and soft
tissue injuries. Aceclofenac inhibits the cyclooxygenase enzyme and thus exerts its
anti-inflammatory activity by inhibition of prostaglandin synthesis. This effect seems
to be correlated to the appearance of acute protocolitis associated with nonsteroidal
anti-inflammatory drug therapy [7-9].
1.2.1 Pharmacology
Mechanism of Action: The mode of action of aceclofenac is largely based on the
inhibition of prostaglandin synthesis. Aceclofenac is potent inhibiter of the enzyme
cyclo-oxygenase, which is involved in the production of prostaglandins. Aceclofenac
has been shown to exert effects on a variety of mediators of inflammation. The
drug inhibits synthesis of the inflammatory cytokines interleukin (IL)-1â and tumour
necrosis factor and inhibits prostaglandin E2 (PGE2) production. Effects on cell
adhesion molecules from neutrophils have also been noted. In vitro data indicate inhibition
of cyclo-oxygenase (COX)-1 and 2 by aceclofenac in whole blood assays, with
selectivity of COX-2 being evident.
In contrast to some other NSAIDs, aceclofenac has shown stimulatory effects
on cartilage matrix synthesis, which may be linked to the ability of the drug to
inhibit IL-1â activity. In vitro data indicates stimulation by the drug of synthesis of
glycosaminoglycan in osteoarthritic cartilage. There is also evidence that aceclofenac
stimulates the synthesis of IL-1 receptor antagonist in human articular chondrocytes
subjec ted  to  inf lammatory  s t imul i  and  tha t  4’ -hydroxyaceclofenac  has
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chondroprotective properties attributable to suppression of IL-1â mediated promatrix
metalloproteinase production and proteoglycan release.
In patients with osteoarthritis of the knee, aceclofenac decreases pain, reduces
disease severity and improves the functional capacity of the knee. It reduce joint
reduces inflammation, pain intensity and the duration of morning stiffness in patients
with rheumatoid arthritis. The duration of morning stiffness and pain intensity are
reduced and spinal mobility improved, by aceclofenac in patients with ankylosing
spondylitis.
1.2.2 Pharmacokinetics
Aceclofeanc is rapidly and completely absorbed after oral adiminstration. Peak
plasma concetrations are reached to 1 to 3 hours after an oral dose. The drug is highly
protient bound (99%). The presence of food does not alter the extent of absorption of
aceclofenac but the absorption rate is reduced. The plama concentration of aceclofenac
was approximately twice that in synovial fluid after multiple doeses of the durg in patients
with knee pain and slynovial fludie effusiton.
Aceclofeance is metabolised to a major metabolite, 4’-hydroxyaceclofenac and
to  a  number  of  o ther  metabol i tes  inc luding  5-hydroxyaceclofenac ,  4’ -
hydroxydiclofenac, diclofenac and 5-hydroxydiclofenac. These other metabolites
account for the fate of approximatlely 20 % of each does of aceclofenac. Renal
excretion is the main route of elemination of aceclofenac with 70 to 80% of an adminstred
does found in the urine, mainly as the glucuronides of aceclofenac and its metabolites.
Of each dose of aceclofenac, 20% is extreted in the faeces. The plasma elimination half
life of the drug is approximately 4 hours.
1.2.3 Indication
Aceclofenac is indicated for the relied of pain and inflammation associated with
rheumatoid arthrits, osteoarthritis or ankylosing spondylitis.
1.2.4 Contraindcations
Aceclofenac shoud not be administreted to patients hypersensititve to aceclofenac
of other NSAIDs or patients with a history of aspirin of NSAID related allergic or
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anaphylatic reactions of with peptic ulcers of GI bleeding, moderate of sever renal
impairment.
1.2.5 Drug Interactions
? Drug interactions associated with aceclofenac are similar to those observed with
other NSAIDs.
? Aceclofenac may increase plasma concentrations of lithium, digoxin and
methotrexate, increase the activity of anticoagulatns, inhibite the activity of
diuretics, enhance cyclosporin  nephrotoxicity and precipitate convulsions when
coadministered with quinolone antibiotics.
? When concomitant administration with potassium sparing diuretics is empployed,
serum potassium shoud be monitored.
? Furthermore, hypo or hyperglycamia may result for the concomitant administration
of acelofenac and antidiabetic drugs, although this is rare. The condministration of
acelofenac with other NSAIDs of corticosteroids may result in increased frequency
of adverse events.
? Cautions shuold be exercised if NSAIDs and methoterxate are administred wthinin
2-4 hours of each other, since NSAIDs may increase methotrexate plasma levels,
resulting in increased toxicity.
1.2.6 Dosage and Administration
The usual dose of acelofenac is 100 mg given tiwice daily by mouth. One tablet
in the morning and one in the evening.
There is no evidence that the dosage of aceclofenac needs to be modified in
patients with mild renal impairment but as with other NSAIDs cautins should be
excercised. There is some evidence that the dose of aceclofenac should be reduced
in patients with hepatic impairment and it is suggested that an intial daily dose of
100 mg be used.Aceclofenac tablets should be swallowed whole with a sufficient
quantity of liquid. When aceclofenac was administred to fasting and fed healthy
volunteers only the rate and not the extent of aceclofenac absorption was affected
and as such aceclofenac can be taken with food.
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2. Literature Review
There are many reported method for the determination of either tramadol
hydrochloride and aceclofenac alone or in combination with other drug in
pharmaceutical dosage forms or individually in biological fluids are as under:
2.1 Literature Review for Tramadol Hydrochloride
2.1.1 Y. H. Ardakani, M. R. Rouini have developed liquid chromatographic method
for the simultaneous determination of tramadol and its three main metabolites
in human plasma, urine and saliva. Chromatographic separation was achieved
with a Chromolith Performance RP-18e (100 mm x 4.6 mm) column, using
a mixture of methanol-water (19:81, v/v) adjusted to pH 2.5 by phosphoric
acid, in an isocratic mode at flow rate of 2 ml/min. Fluorescence detection
(ë ex 200 nm/ ë em 301 nm) was used. The developed procedure was applied to
assess the pharmacokinetics of tramadol and its main metabolites [10].
2.1.2 R. Mehvar, K. Elliott, R. Parasrampuria, O. Eradiri have reported a
stereospecific method for simultaneous quantitation of the enantiomers of
tramadol and its active metabolites O-demethyl tramadol and O-demethyl-
N-demethyl tramadol in human plasma The separation was achieved using a
Chiralpak AD column with a mobile phase of hexanes-ethanol-diethylamine
(94:6:0.2, v/v/v) and a flow rate of 1 ml/min. The fluorescence of analytes was
then detected at excitation and emission wavelengths of 275 and 300 nm,
respectively. The application of the assay was demonstrated by simultaneous
measurement of plasma concentrations of tramadol, O-demethyl tramadol and
O-demethyl-N-demethyl tramadol enantiomers in a healthy volunteer [11].
2.1.3 M. Zeceviæ, Z. Stankoviæ, Lj. Zivanoviæ, B. Jociæ have developed and
validated a high performance liquid chromatographic method for the determination
of tramadol hydrochloride and its three impurities. The method can simultaneously
assay potassium sorbate, used as preservative and saccharin sodium, used as
sweetener in tramadol pharmaceutical formulation. The separation was carried
out on a C18 XTerra (150 mm x 4.6 mm i.d., 5 µm particle size) column using
acetonitrile-0.015 M Na2HPO4 buffer (2:8, v/v) as mobile phase (pH value 3.0
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was adjusted with orthophosphoric acid) at a flow rate 1.0 ml/ min, temperature
of the column 20 0C and UV detection at 218 nm mother method can be use in
routine quality control analysis [12].
2.1.4  A. Küçük, Y. Kadioðlu have reported a determination method of tramadol
hydrochloride in ampoule dosage forms by using UV spectrophotometric and
HPLC-DAD methods in methanol and water media. Measurements for
spectrophotometric method were performed using UV-Vis Spectrophotometer
in ranges of 200-400 nm. The solutions of standard and the samples were prepared
in methanol and water media and the UV absorption spectrums of tramadol were
monitored with maximum absorptions at 275 and 271 nm for both mediums,
respectively. Reversed phase chromatography for HPLC method was conducted
using a Phenomenex Bondclone C18 column with an isocratic mobile phase
consisting of acetonitrile- 0.01 M phosphate buffer, pH 3 (25:75,v/v). The effluent
was monitored on a DAD detector at 218 nm. The methods were applied to
pharmaceutical ampoule forms [13].
2.1.5 A. Küçük, Y. Kadýoðlu, F. Çelebi have reported a determination method of
tramadol concentration in rabbit plasma using simple liquid-liquid extraction
and high-performance liquid chromatography. The method was applied to a
pharmacokinetic study of intravenous tramadol injections in rabbits [14].
2.1.6 Y. Gu, J. P. Fawcett have developed an HPLC method for the determination of
tramadol and its major active metabolite, O-desmethyltramadol, in human plasma.
Tramadol, O-desmethyltramadol and the internal standard, sotalol, were separated
by reversed phase HPLC using 35 % acetonitrile and an aqueous solution
containing 20 mM sodium phosphate buffer, 30 mM sodium dodecyl sulphate
and 15 mM tetraethylammonium bromide pH 3.9. Detection was by fluorescence
with excitation and emission wavelengths of 275 and 300 nm, respectively. The
method can apply to a pharmacokinetic study of tramadol in human volunteers. [15].
2.1.7 L. M. Zhao, X. Y. Chen, J. J. Cui, M. Sunita, D. F. Zhong have documented
a determination of tramadol and its active metabolite O-desmethyl tramadol in
plasma and amniotic fluid using LC/MS/MS. Samples containing tramadol, O-
desmethyltramadol and diphenhydramine (internal standard, IS) were extracted
using liquid-liquid extraction, followed by liquid chromatographic separation and
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online MS/MS using atmospheric pressure chemical ionization as an interface
detection. The analytes were detected in the selected reaction-monitoring mode.
Method can be suitable for clinical pharmacokinetics studies of tramadol and
O-desmethyltramadol [16].
2.1.8 A. Medvedovici, F. Albu, A. Farca, V. David have validated HPLC
determination of 2-[(dimethylamino) methyl] cyclohexanone, an impurity in
t ramadol ,  us ing  a  precolumn der iva t i sa t ion  reac t ion  wi th  2 ,4-
dinitrophenylhydrazine. The method is based on the derivatisation of 2-
[(dimethylamino) methyl] cyclohexanone with 2,4-dinitrophenylhydrazine (2,4-
DNPH) in acidic conditions followed by a reversed-phase liquid chromatographic
separation with UV detection [17].
2.1.9 M. A. Campanero, E. Garcia-Quetglas, B. Sadaba, J. R. Azanza have
reported a bioanalytical method involving a simple liquid–liquid extraction for
the simultaneous HPLC determination of the enantiomers of tramadol, the active
metabolite O-desmethyltramadol and the other main metabolite N-
desmethyltramadol in biological samples. Chromatography was performed at 5 °C
on a  Chirace l  OD-R column conta in ing  ce l lu lose  t r i s  (3 ,5-
dimethylphenylcarbamate) as chiral selector, preceded by an achiral end-
capped  C 8 column (250 mm × 4 mm i.d., 5 µm particle  size). The mobile
phase was a mixture of phosphate buffer containing sodium perchlorate (1 M)
adjusted to pH 2.5-acetonitrile-N, N-dimethyloctylamine (74.8:25:0.2, v/v/v).
The flow rate was 0.5 ml/min. Fluorescence detection (ëex 200 nm/ ëem 301 nm)
was used [18].
2.1.10 V. Kmetec, R. Roskar hav reported HPLC determination of tramadol in human
breast milk. They chose the liquid-liquid extraction procedure using n-hexane as
an organic phase with back extraction into aqueous phase since it was considered
the most suitable and the most compatible with the subsequent HPLC analysis.
The developed method is suitable for monitoring of tramadol in human breast
milk [19].
2.1.11 S. H. Gan, R. Ismail, W. A. Wan Adnan, Z. Wan have been developed and
validated a method for the determination of tramadol concentration in human
plasma by using a simple liquid-liquid extraction and HPLC with UV detection.
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The method has been applied to determine tramadol concentrations in human
plasma samples for a pharmacokinetic study [20].
2.1.12 M. Nobilis, J. Kopecký, J. Kvetina, J. Chládek, Z. Svoboda, V. Vorísek,
F. Perlík, M. Pour, J. Kunes have developed and validated  simultaneous HPLC
determination of the tramadol, its major pharmacodynamically active metabolite
O-desmethyltramadol in human plasma. HPLC analysis was performed on a
chromatographic column with LiChrospher 60 RP-selectB (250 mm x 4 mm i.d.,
5 µm particle size) and consists of an analytical period where the mobile phase
acetonitrile-0.01 M phosphate buffer, pH 2.8 (3:7, v/v) was used. Detection
was carried out by  fluorescence detectore. The validated analytical method was
applied to pharmacokinetic studies of tramadol in human volunteers [21].
2.1.13 H. E. Abdellatef has reported kinetic spectrophotometric determination of
tramadol hydrochloride in pharmaceutical formulation. The results obtained
are  compared  s ta t i s t ica l ly  wi th  those  g iven  by  the  reference
spectrophotometric method. [22]
2.1.14 S. H. Gan, R. Ismail has been developed and validated a solid-phase extraction
and HPLC with UV detection method in order to determine tramadol and
O-desmethyltramadol concentrations in human plasma. The system has been
applied to determine tramadol concentrations in human plasma samples for a
pharmacokinetic study [23].
2.1.15 F. Vanderbist Ceccato, J. Y. Pabst, B. Streel has reported enantiomeric
determination of tramadol and its main metabolite O-desmethyltramadol in
human plasma by liquid chromatography tandem mass spectrometry. The
method developed can used to investigate plasma concentration of
enantiomers of tramadol and O-desmethyltramadol in a pharmacokinetic
study [24].
2.1.16 M. A. Campanero, B. Calahorra, M. Valle, I.F. Troconiz, J. Honorato have
been reported a stereo selective HPLC assay for the quantitative determination
of the analgesic tramadol and O-demethyltramadol, an active metabolite. The
assay involved liquid chromatography analysis with fluorescence detection.
Chromatography was performed at 20 ºC on a Chiracel OD-R column containing
cellulose tris- (3,5-dimethylphenylcarbamate) as stationary phase, preceded by
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an achiral end-capped C18 column. The mobile phase was a mixture of phosphate
buffer [containing sodium perchlorate (0.2 M) and triethylamine (0.09 M) adjusted
to pH 6] - acetonitrile (80:20, v/v). Applicability of the method was demonstrated
by a pharmacokinetic study in normal volunteers [25].
2.1.17 G. C. Yeh, M. T. Sheu, C. L. Yen, Y. W. Wang, C. H. Liu, H. O. Ho have
developed HPLC method using UV detection for determination of tramadol
concentration in human plasma. Separation was performed on a reversed
phase LiChrospher 60 RP-select B column with a particle size of 5 µm. The
mobile phase consisted of 0.05 M KH2PO4 aqueous solution (pH 3.5) -
acetonitrile  (90:10, v/v). Metoprolol was used as the internal standard and
UV detection at 225 nm was employed. This validated method was applied
to the determination of tramadol concentrations in healthy volunteers [26].
2.1.18 M. Valle, J. M. Pavon, R. Calvo, M. A. Campanero, I. F. Troconiz have
developed method for simultaneous determination of tramadol and its main
active metabolite O-demethyltramadol in rat plasma. The method involves a
single step extraction procedure and a specific determination by HPLC with
electrochemical detection, using an ethoxy analogue of tramadol (L-233) as
internal standard. The dual-electrode detector was operated in the oxidation-
screening mode [27].
2.1.19 P. Overbeck, G. Blaschke have developed a reversed phase HPLC method for
the direct determination of three glucuronides of the centrally acting analgesic
tramadol. Separation of these glucuronides into their diastereomers was achieved
by HPLC using ion pair chromatography with nonanesulfonic acid sodium salt
and LiChrospher 100 RP 18 as stationary phase. Fluorescence detector performed
detection [28].
2.1.20 A. Ceccato, P. Chiap, P. Hubert, J. Crommen have reported automated method
for the separation and individual determination of tramadol enantiomers in plasma
using solid-phase extraction on disposable extraction cartridges in combination
with chiral liquid chromatography. The enantiomeric separation of tramadol was
achieved using a Chiralcel OD-R column containing cellulose tris-(3,5-
dimethylphenylcarbamate) as chiral stationary phase. The mobile phase was a
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mixture of phosphate buffer, pH 6.0, containing sodium perchlorate (0.2 M) -
acetonitrile (75:25, v/v) [29].
2.1.21 I. Y. Zaghloul, M. A. Radwan, J. Liq have developed a HPLC method for
determination of tramadol in pharmaceutical dosage forms. Reversed phase
chromatography was conducted using ì-Bondapak C18 column (3.9 mm x
150 nm) with an isocratic mobile phase consisting of 0.005 M triethylamine
in 0.01 M sodium phosphate buffer (pH 5.5) containing 17% acetonitrile.
The effluent was monitored on a UV detector at 230 nm [30].
2.1.22 M. Nobilis, J. Pastera, P. Anzenbacher, D. Svoboda, J. Kopecký, F. Perlík
have determined tramadol in human plasma samples using a sensitive HPLC
method. Separation performed on reversed phase silica gel using ion-pair
chromatography (verapamil as an internal standard) and fluorescence detection.
The method was applied to the determination of tramadol levels in healthy
volunteers [31].
2.1.23 B. Elsing, G. Blaschke have been developed a reversed phase HPLC method
for the simultaneous determination of tramadol and its major metabolites
O-demethyltramadol and N-demethyltramadol in urine. The determination
of the enantiomeric ratios of the three compounds was achieved using a
Chiralpak AD column and a Chiralcel OD column, respectively [32].
2.2 Literature Review for Aceclofenac
2.2.1 P. Musmade, G. Subramanian, K. K.Srinivasan have developed a simple
HPLC method for quantification of aceclofenac in rat plasma. Ibuprofen was
used as an internal standard. Separation was carried out on reversed-phase C18
column (250 mm x 4.6 mm, 5 µm particle size) and the column effluent was
monitored by UV detector at 282 nm. The mobile phase used was methanol-
0.3%(v/v) triethylamine, pH 7.0, (60:40, v/v) at a flow rate of 1.0 ml/min. The
method was applied for pharmacokinetic study of aceclofenac in rats [33].
2.2.2 A. Zinellu, C. Carru, S. Sotgia, E. Porqueddu, P. Enrico, L. Deiana have
reported a fast-free zone capil lary electrophoresis  method for  the
simultaneous determination of aceclofenac and diclofenac in human plasma. A
separation was achieved using a 40 cm × 75 µm uncoated silica capillary,
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300 mM/L sodium borate buffer, 200 mM/l N-methyl-d-glucamine, pH 8.9, in
about 3 min. method is efficient mean for the comprehensive determination of
aceclofenac and diclofenac in human plasma when pharmacokinetics studies are
required [34].
2.2.3 Y. Jin, H. Chen, S. Gu, F. Zeng has established a reversed phase HPLC method
for the determination of aceclofenac in human plasma. Chromatography was
performed on a C18 column with methanol-0.1 M/L ammonium acetate, pH 6.0,
(7:3, v/v) as the mobile phase. The flow rate was 1.0 ml/min. The UV- detector
was set at 275 nm. This method can be used for clinical pharmacokinetic study
of aceclofenac [35].
2.2.4 N. Y. Hasan, M. Abdel-Elkawy, B. E. Elzeany, N. E. Wagieh have established
five new methods for the determination of aceclofenac in the presence of its
degradation product diclofenac. Method-A util izes third derivative
spectrophotometry at 242 nm. Method-B was RSD1 spectrophotometric
method based on the simultaneous use of the first derivative of ratio spectra
and measurement at 245 nm. Method-C was a Ph induced difference (ÄA)
spectrophotometry using UV measurement at 273 nm. Method-D was a
spectrodensitometric one, which depends on the quantitative densitometric
evaluation of thin layer chromatogram of aceclofenac at 275 nm. Method-E
was RP-HPLC that depends on using methanol- water (60:40, v/v) as mobile
phase at a flow rate of 1 ml/min and UV detection at 275 nm. The methods
could be applied for the analysis of the drug in its pharmaceutical formulation [36].
2.2.5 B. Hinz, D. Auge, T. Rau, S. Rietbrock, K. Brune, U. Werner have been
reported a method for the simultaneous determination of aceclofenac and
three of its metabolites in human plasma by HPLC. The analytes were
separated using an acetonitrile-phosphate buffer gradient at a flow rate of 1
ml/min and UV- detection at 282 nm. The developed procedure was applied to
assess the pharmacokinetics of aceclofenac and its metabolites [37].
2.2.6 N. H. Zawilla, M. A. A. Mohammad, N. M. El Kousy, S. M. El-Moghazy
Aly have reported three sensitive and reproducible methods for quantitative
determination of aceclofenac in pure form and in pharmaceutical formulation.
The first method is based on Beer’s law. Absorption measurements were carried
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out at 665.5 nm. The other two methods are high performance liquid
chromatography and densitometric methods by which the drug was determined
in the presence of its degradation products [38].
2.2.7 H. S. Lee, C. K. Jeong, S. J. Choi, S. B. Kim, M. H. Lee, G. Il Ko and D.
H. Sohn have developed a narrow bore HPLC with column-switching for the
simultaneous determination of aceclofenac and diclofenac from human
plasma samples. Plasma sample (100 µl) was directly introduced onto a
Capcell Pak MF Ph-1 column (20 mm × 4 mm i.d.) primary separation was
occurred to remove proteins and concentrate target substances using
acetonitrile- 0.1 M potassium phosphate, pH 7, (14:86, v/v). The drug
molecules eluted from MF Ph-1 column were focused in an intermediate
column (35 mm × 2 mm i.d.) by the valve-switching step. The substances
enriched in intermediate column were eluted and separated on the narrow
bore phenyl–hexyl column (100 mm × 2 mm i.d.) using acetonitrile-0.02M
potassium phosphate, pH 7, (33:67, v/v)[39].
2.2.8 X. Q. Liu, X. J. Chen, L. H. Zhao, J. H. Peng have reported HPLC assay
method for  the  de terminat ion  of  acec lofenac  in  p lasma and i t s
pharmacokinetics in dogs [40].
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3. Aim of Present Work
The aim of the present work is to developed analytical method for combine fixed
dose formulation, which is novel to the market. The work of interest is tramadol
hydrochloride and aceclofenac in the combine dosage form. There is no analytical method
reported for the simultaneous determination of tramadol hydrochloride and aceclofenac
in novel combination. Various publication are available regarding determination method
of tramadol hydrochloride  and aceclofenac but most of the methods are applicable to
alone tramadol hydrochloride  or aceclofenac  in pharmaceutical dosage form or in
bilogical fluids.
Our work deals with the development and validation of stability-indicating high
performance liquid chromatographic assay method for the determination of tramadol
hydrochloride and aceclofenac in commercial tablet formulation. The combination
formulation was subjected to ICH recommended stress condition like acid hydrolysis,
base hydrolysis, oxidation, thermal and photolytic stress. Thus validated method can
recommend for the routine quality control analysis and also stability sample analysis.
The aim and scope of the proposed work are as under
1. To developed suitable HPLC method for simultaneous determination tramadol
hydrochloride and aceclofenac in tablet formulation.
2. Forced degradation study of tramadol hydrochloride and aceclofenac under
stress condition.
3. To resolve all major impurities generated during the force degradation studies
of tramadol hydrochloride and aceclofenac.
4. Perform the validation for the developed method.
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4. Experimental
4.1 Materials
Pharmacopoeial grade standards of tramadol hydrochloride and aceclofenac were
provided by reputed pharma company.   A tablet containing 37.5 mg tramadol
hydrochloride and 100 mg aceclofenac was commercially available (HIFENAC-TL, Intas
Pharmaceuticals LTD.) HPLC grade acetonitrile, methanol and water were obtained
from Spectrochem Pvt. Ltd., Mumbai (India). Analytical grade hydrochloric acid, sodium
hydroxide pellets, glacial acetic acid and hydrogen peroxide solution (30% v/v) were
obtained from Ranbaxy Fine Chemical, New Delhi (India).
4.2 Instrumentation
LC-10ATvp HPLC system was used as describe as general chapter (5A).
4.3  Mobile Phase Preparation
The mobile phase was consisted of 0.01M-ammonium acetate buffer pH 6.5 -
acetonitrile (65:35, v/v). To prepare the buffer solution, 0.77 g ammonium acetate was
weighed and dissolves in 1000 ml HPLC grade water. 3 ml triethylamine was added and
then adjusted to pH 6.5 with glacial acetic acid. Mobile phase was filtered through a
0.45 µm nylon membrane (Millipore Pvt. Ltd. Benglore, India) and degassed in an
ultrasonic bath (Spincotech Pvt. Ltd., Mumbai).
4.4 Diluent Preparation
Diluent use during whole study was prepared with acetonitrile-water (50:50,v/v)
4.5 Standard Preparation
Standard solution containing tramadol hydrochloride (0.0375 mg/ml) and
aceclofenac (0.100 mg/ml) were prepared by dissolving 18.75 mg tramadol
hydrochloride and 50 mg aceclofenac in 50 ml volumetric flask by diluent (stock standard
solution). Pipette out 5 ml stock solution into 50 ml volumetric flask and dilute up to
mark with diluent (standard solution).
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4.6 Test Preparation
Twenty tablets were weighed and the average tablet weight was determined.
Tablets were crushed by mortar and pastel. Tablet powder was weighed equivalent
to five times of average weight and transfer in to 500 ml volumetric flask. About
50 ml methanol and 300 ml mobile phase was added and sonicated for of 20 min. time
interval with intermittent shaking. Content was brought back to room temperature and
dilute to volume with diluent (stock test solution). The stock solution was filtered through
0.45 µm nylon syringe filter. Pipette out 5ml filtered stock solution in to 50 ml volumetric
flask and dilute with diluent (test solution). The concentration obtain was 0.0375 mg/ml
of tramadol hydrochloride and 0.100 mg/ml of aceclofenac.
4.7 Chromatographic Conditions
Chromatographic analysis was performed on a Phenomenex Gemini C18
(250 mm ?  4.6 mm i.d., 5 µm particle size) column. The mobile phase was consisted of
0.01 M-ammonium acetate buffer pH 6.5 -acetonitrile (65:35, v/v). The flow rate of the
mobile phase was adjusted to 1.0 ml/min and the injection volume was 20 µl. Detection
was performed at 270 nm.
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5. Result and Discussion
5.1 Development and Optimization of the HPLC Method
In the presence work, an analytical method based on high performance liquid
chromatography using photodiode array detection was developed and validated for
assay determination of tramadol hydrochloride and aceclofenac in tablet formulation.
The analytical conditions were selected, keeping in mind the different chemical nature,
molecular weight and solubility of tramadol hydrochloride and aceclofenac. The
development trials were taken by using the degraded sample of each component was
done, by keeping them in various extreme conditions.
Tramadol hydrochloride and aceclofenac are dissolved in polar solvent hence
RP-HPLC was selected to estimate them. The column selection has been done on
the basis of backpressure, resolution, peak shape, theoretical plates and day-to-day
reproducibility of the retention time and resolution between tramadol hydrochloride
and aceclofenac peak. After evaluating all these factors, Phenomenex Gemini C18
(250 mm ×  4.6 mm i.d., 5 µm particle size) column was found to be giving satisfactory
results. The selection of buffer based on chemical structure of both the drugs. Our
preliminary trails with di-sodium hydrogen orthophosphate and ammonium acetate buffer.
Result obtain with 0.01 M-ammonium acetate buffer was quite satisfactory but after
adding triethylamine and changing pH from 2.5 to 7, at 6.5 pH excellent result were
obtain. Finally, by fixing 0.01 M ammonium acetate buffer with addition of 3 ml
triethylamine per 1000 ml of buffer, adjusted to pH 6.5 with glacial acetic acid and
keeping mobile phase composition as of 0.01 M-ammonium acetate buffer-acetonitrile
(65:35, v/v), best peak shape was obtained. Triethylamine was added to buffer to lower
the peak asymmetry. For the selection of organic constituent of mobile phase, acetonitrile
was chosen to reduce the longer retention time and to attain good peak shape. Optimize
mobile phase proportion was provide good resolution between tramadol hydrochloride
and aceclofenac and also for degradation product which is generated during force
degradation study. Figure 3 and Figure 4 represent the chromatograms of standard and
test preparation respectively.
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Figure 3: Chromatogram of standard preparation
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Figure 4: Chromatogram of test preparation
5.2 Degradation Study
In order to determine whether the analytical method or assay were stability-
indicating, tramadol hydrochloride and aceclofenac combine tablets were stressed under
various conditions to conduct forced degradation studies. Regulatory guidance in ICH
Q2A, Q2B, Q3B and FDA 21 CFR section 211 all require the development and validation
of stability-indicating potency assays. Unfortunately, the current guidance documents
do not indicate detailed degradation conditions in stress testing. However, the used forced
degradation conditions, stress agent concentration and times of stress, were found to
effect a degradation and not complete degradation of active materials. The discovery of
such conditions was based on development trial.
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The degradation samples were prepared by transferring powdered tablets,
equivalent to 37.5 mg tramadol hydrochloride and 100 mg aceclofenac into a 250
ml round bottom flask. Then prepared samples were employed for acidic, alkaline
and oxidant media and also for thermal and photolytic stress conditions. After the
degradation treatments were completed, the stress content solutions were allowed
to equilibrate to room temperature and diluted with mobile phase to attain 0.0375
mg/ml of tramadol hydrochloride and 0.100 mg/ml of aceclofenac concentration.
Specific degradation conditions were described as follows.
5.2.1  Acidic condition: Acidic degradation study was performed by refluxed the
drug content in 1 N HCl (50 ml) for 30 min and mixture was neutralized with 1 N
NaOH solutions. The drug content was found to be degrading up to 30.50% in
acidic condition (Figure 5).
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Figure 5: Chromatogram of acidic forced degradation study
5.2.2  Alkaline condition: Solutions of alkali degradation study were prepared in
0.05 N NaOH (50 ml) and the resultant solution analyzed 15 min after preparation,
around 8.49% of the drug degraded (Figure 6). Our second trail with 0.10 N
NaOH (50 ml) and the resultant solution analyzed 15 min after preparation, peak
of aceclofenac was disappear and major degradent peak was found at 11.3 min.
In alkali degradation, it was found that aceclofenac is highly unstable.
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Figure 6: Chromatogram of alkali forced degradation study
5.2.3  Oxidative condition: Oxidation degradation study was performed by refluxed
the drug content in 5% v/v H2O2 (50 ml) for 3 h. In oxidative degradation, it was
found that around 7.62% of the drug degraded (Figure 7).
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Figure 7: Chromatogram of oxidative forced degradation study
5.2.4 Thermal condition: Thermal degradation was performed by exposing solid drug
to dry heat of 80 0C in a convection oven for 72 h. Drug content was found
slightly stable under above specific condition. Only 3.0% drug content were
degraded (Figure 8).
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Figure 8: Chromatogram of thermal degradation study
5.2.5 Photolytic condition: Photolytic degradation study was performed by exposing
the drug content in sunlight for 72 h. There was 8.9% degradation observed in
above specific photolitic condition. Drug content was found to be more stable
than other stress condition (Figure 9).
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Figure 9: Chromatogram of sunlight degradation study
156Tramado l  Hydroch lo r ide  and  Acec l o f enac . .
Part -A (Seect ion-III )
5.3  Method Validation
5.3.1  Specificity: The specificity of the method was determined by checking the
interference of placebo with analyte and the proposed method were eluted
by checking the peak purity of tramadol hydrochloride and aceclofenac during
the force degradation study. The peak purity of the tramadol hydrochloride and
aceclofenac were found satisfactory under different stress condition. There was
no interference of any peak of degradation product with drug peak.
5.3.2 Linearity: For linearity, seven points calibration curve were obtained in a
concentration range from 0.015-0.060 mg/ml for tramadol hydrochloride and
0.040-0.160 mg/ml for aceclofenac. The response of the drug was found to
be linear in the investigation concentration range and the linear regression
equation for tramadol hydrochloride was y = 7030988.47x + 5215.35 with
correlation coefficient 0.9999 (Figure 10) and for aceclofenac was
y = 33843850.67x + 1174.16 with correlation coefficient 0.9999 (Figure 11).
Where x is the concentration in mg/ml and y is the peak area in absorbance unit.
Chromatogram obtain during linearity study were shown in Figure 12-18.
Linearity study of tramadol hydrochloride
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Figure 10: Linearity curve for tramadol hydrochloride
157Tramado l  Hydroch lo r ide  and  Acec l o f enac . .
Part -A (Seect ion-III )
Linearity study of aceclofenac 
y = 33843850.67x + 1174.16
R2 = 0.9999
0
1000000
2000000
3000000
4000000
5000000
6000000
0.00 0.05 0.10 0.15 0.20
Concentration (mg/ml)
Pe
ak
 a
re
a
Figure 11: Linearity curve for aceclofenac
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Figure 12: Linearity study chromatogram of level-1 (40%)
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Figure 13: Linearity study chromatogram of level-2 (60%)
158Tramado l  Hydroch lo r ide  and  Acec l o f enac . .
Part -A (Seect ion-III )
Minutes
0 2 4 6 8 10 12 14 16 18
m
A
U
0
50
100
150
Tr
am
do
l H
C
l
Ac
ec
lo
fe
na
c
Figure 14: Linearity study chromatogram of level-3 (80%)
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Figure 15: Linearity study chromatogram of level-4 (100%)
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Figure 16: Linearity study chromatogram of level-5 (120%)
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Figure 17: Linearity study chromatogram of level-6 (140%)
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Figure 18: Linearity study chromatogram of level-7 (160%)
5.3.3 LOD and LOQ: The limit of detection and limit of quantification were evaluated
by serial dilutions of tramadol hydrochloride and aceclofenac stock solution in
order to obtain signal to noise ratio of 3:1 for LOD and 10:1 for LOQ. The LOD
value for tramadol hydrochloride and aceclofenac were found to be 0.1 ppm and
0.1 ppm, respectively and the LOQ value 0.5 ppm and 0.4 ppm, respectively.
Chromatogram of LOD and LOQ study were shown in Figure 19-22.
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Figure 19: Chromatogram of LOD study of tramadol hydrochloride
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Figure 20: Chromatogram of LOD study of aceclofenac
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Figure 21: Chromatogram of LOQ study of tramadol hydrochloride
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Figure 22: Chromatogram of LOQ study of aceclofenac
5.3.4 Precision: Data obtain from precision experiments are given in Table 1 for
intraday and interday precision study for both tramadol hydrochloride and
aceclofenac. The RSD values for intra day precision study and interday precision
study was < 2.0% for tramadol hydrochloride and aceclofenac. Which confirm
that the method was precise.
Table 1: Results of precision study
Tramadol Hydrochloride 
(%Assay) 
Aceclofenac 
(%Assay) 
Set 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Intraday 
(n = 6) 
1 102.0 102.0 98.1 98.1 
2 102.7 101.6 98.1 98.1 
3 101.6 102.0 98.3 98.3 
4 103.1 101.8 99.2 98.5 
5 101.7 102.4 98.6 98.9 
6 102.4 101.8 99.1 98.6 
Mean 102.3 101.9 98.6 98.4 
Standard deviation 0.59 0.27 0.49 0.31 
% RSD 0.58 0.27 0.50 0.32 
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5.3.5    Accuracy: Recovery of tramadol hydrochloride and aceclofenac were determined
at three  different concentration levels. The mean recovery for tramadol
hydrochloride was 98.87-99.32% and 98.81-99.49% for aceclofenac (Table 2).
The result indicating that the method was accurate. Chromatogram obtain during
accuracy study were shown in Figure 23-25.
Table 2: Results of accuracy study
 
Level 
(%) 
 
Amount 
Added 
Concentrationa 
(mg/ml) 
Amount Found 
Concentrationa 
(mg/ml) 
% 
Recoverya 
% 
RSDa 
50 0.01985 0.01962 98.87 1.12 
100 0.03844 0.03811 99.14 0.16 
Tramadol 
Hydrochloride 
150 0.05746 0.05707 99.32 0.58 
50 0.05033 0.05008 99.49 0.42 
100 0.10040 0.09921 98.81 0.19 Aceclofenac 
150 0.15038 0.14955 99.45 0.06 
 
a Each value corresponds to the mean of three determinations.
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Figure 23: Accuracy study chromatogram of level-1 (50%)
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Figure 24: Accuracy study chromatogram of level-2 (100%)
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Figure 25: Accuracy study chromatogram of level-3 (150%)
5.3.6 Solution stability study: Table 3 shows the results obtain in the solution stability
study at different time intervals for test preparation. It was concluded that the
test preparation solution was found stable up to 48 h at 2 - 5 0C and ambient
temperature with the consideration of < 2.0% in % assay value difference of
interval value against initial value.
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Table 3: Evaluation data of solution stability study
% Assay for test solution stored 
at 2 –5 0C 
% Assay for test solution stored 
at ambient temperature 
Intervals 
Tramadol 
Hydrochloride 
Aceclofenac 
Tramadol 
Hydrochloride 
Aceclofenac 
Initial 102.4 98.9 102.4 98.9 
12 h 102.1 98.8 102.0 99.0 
24 h 102.0 98.8 101.9 98.8 
36 h 102.0 98.9 101.3 98.6 
48 h 101.8 98.8 101.0 98.4 
 
5.3.7 Robustness: The result of robustness study of the developed assay method
was established in Table 4 and Table 5. The result shown that during all
variance conditions, assay value of the test preparation solution was not
affected and it was in accordance with that of actual. System suitability
parameters were also found satisfactory, hence the analytical method would
be concluded as robust. Chromatogram obtain during robustness study were
shown in Figure 26-32.
Table 4: Evaluation data of robustness study of tramadol hydrochloride
% Assay System Suitability Parameters 
Robust Conditions 
 
Theoretical 
Plates 
Asymmetry % RSD 
Flow 0.9 ml/min 102.6 2827 1.22 0.98 
Flow 1.1 ml/min 102.0 2847 1.23 0.79 
Buffer- ACN (63:37,v/v) 102.3 3125 1.40 0.38 
Buffer- ACN (67:33,v/v) 103.2 2893 1.21 0.42 
Buffer pH 6.7 101.9 3184 1.31 1.81 
Buffer pH 6.3 103.0 3230 1.39 1.49 
Column change 102.4 2767 1.27 0.80 
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Table 5: Evaluation data of robustness study for aceclofenac
 System Suitability Parameters 
Robust Conditions % Assay Theoretical 
Plates 
Asymmetry % RSD Resolution 
Flow 0.9 ml/min 98.3 6918 1.35 0.48 20.06 
Flow 1.1 ml/min 97.8 6158 1.28 0.77 20.55 
Buffer-ACN (63:37,v/v) 97.7 6259 1.37 0.19 17.25 
Buffer-ACN (67:33,v/v) 97.9 6969 1.36 0.20 23.64 
Buffer pH 6.7 98.1 6131 1.26 1.85 19.12 
Buffer pH 6.3 98.6 7101 1.39 1.33 22.22 
Column change 98.2 6371 1.31 0.09 19.73 
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Figure 26: Standard chromatogram (0.9 ml/min flow rate)
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Figure 27: Standard chromatogram (1.1 ml/min flow rate)
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Figure 28: Standard chromatogram [Buffer-ACN (63: 37,v/v)]
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Figure 29: Standard chromatogram [Buffer-ACN (67: 33,v/v)]
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Figure 30: Standard chromatogram (pH 6.7)
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Figure 31: Standard chromatogram (pH 6.3)
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Figure 32: Standard chromatogram (Column change)
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5.3.8 System suitability: A system suitability test of the chromatographic system was
performed before each validation run. Five replicate injections of standard
preparation were injected and asymmetry, theoretical plate, resolution and %
RSD of peak area were determined for same. Acceptance criteria for system
suitability, asymmetry should not be more than 2.0, theoretical plate should not
be less then 2000 and  % RSD of peak area should not be more then 2.0, were
full fill during all validation parameters.
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6. Calculation and Data
Calculation formula used:
1. Calculation formula for % assay tramadol hydrochloride
WeightTest
500
50
5
50
WeightStandard
AreaStandardMean
AreaTestMean
Assay% ×××=
      StandardofPotencyClaimLable
WeightAverage
5
50 ×××
2. Calculation formula for % assay aceclofenac
WeightTest
500
50
5
50
WeightStandard
AreaStandardMean
AreaTestMean
Assay% ×××=
    StandardofPotencyClaimLable
WeightAverage
5
50 ×××
3. Relative standard deviation
100
sMeasurmentofvalueMean
sMeasurmentofDeviationStandard
RSD% ×=
4. Recovery
100
AddedAmount
FoundAmount
erycovRe% ×=
5. Amount found
ionConcentratStandard
AreaStandardMean
AreaTestMean
)ml/mg(foundAmount ×=
6. Amount added
Volume
Weight)ml/mg(addedAmount =
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Specificity Study for Analytical Method Validation of Tramadol Hydrochloride
Aceclofenac Tablets
¾ For Tramadol Hydrochloride
Standard Weight (mg) 18.2     
Standard Dilution 50 5 50   
Standard Potency 100.0 %     
Factor 1 -     
Factor 2 -     
Standard Concentration 
(mg/ml) 0.0364     
      
Replicate 1 2 3 4 5 
Standard Area 252026 258953 253404 250062 253524 
Mean Standard Area 253594     
Stdev. 3305.05     
% RSD 1.30     
 
Replicate Test Area 
1 272822 
2 270132 
Mean Area 271477 
Test weight (mg) 1184.2  
Label Claim (mg) 37.5  
Mean Test weight (mg) 232.8  
% Assay 102.1 % 
 
Calculation:
Prototype calculation for one set:
2.1184
500
50
5
50
2.18
253594
271477Assay% ×××= 100
5.37
8.232
5
50 ×××
                = 102.1 %
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¾ For Aceclofenac
Standard Weight (mg) 50.1     
Standard Dilution 50 5 50   
Standard Potency 99.30 %     
Factor 1 -     
Factor 2 -     
Standard Concentration 
(mg/ml) 0.1002     
      
Replicate 1 2 3 4 5 
Standard Area 3279160 3285344 3282303 3283417 3286086 
Mean Standard Area 3283262     
Stdev 2742.25     
% RSD 0.08     
 
Replicate Test Area 
1 3290447 
2 3291787 
Mean Area 3291117 
Test weight (mg) 1184.2  
Label Claim (mg) 100.0  
Mean Test weight (mg) 232.8  
% Assay 98.0 % 
 
Calculation:
Prototype calculation for one set:
2.1184
500
50
5
50
1.50
3283262
3291117Assay% ×××= 30.99
100
8.232
5
50 ×××
    = 98.0 %
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Linearity Study for Analytical Method Validation of Tramadol Hydrochloride
Aceclofenac Tablets
¾ For Tramadol Hydrochloride
 
Standard Weight 18.9 mg           
Standard Dilution 50 5 50   
Standard Potency 100.0 %     
Factor 1 -     
Factor 2 -     
Standard Concentration (mg/ml) 0.0378     
Concentration of Linearity Stock 
Solution (mg/ml) 0.3780     
      
Replicate 1 2 3 4 5 
Standard Area 261299 261449 266215 259101 258707 
Mean Standard Area 261354         
Stdev 2988.48         
% RSD 1.14         
Concentration 
Level (%) 
Volume of 
Linearity 
Stock Solution 
Taken (ml) 
Diluted to 
(ml) Con(
40 2.0 50 
60 3.0 50 
80 4.0 50 
100 5.0 50 
120 6.0 50 
140 7.0 50 
160 8.0 50 
  Correlation co-ef
  Slope 
  Intercept
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¾ For Aceclofenac
 
Standard Weight (mg) 51.0          
Standard Dilution 50 5 50   
Standard Potency 99.30 %     
Factor 1 -     
Factor 2 -     
Standard Concentration (mg/ml) 0.1020     
Concentration of Linearity Stock 
Solution (mg/ml) 1.0200     
      
Replicate  1 2 3 4 5 
Standard Area 3438103 3432879 3436263 3433501 3431984 
Mean Standard Area 3434546         
Stdev 2551.23         
% RSD 0.07         
Concentration 
Level (%) 
Volume of 
Linearity 
Stock Solution 
Taken (ml) 
Diluted to 
(ml) 
Final 
Concentration 
(mg/ml) 
Mean Area 
40 2.0 50 0.0408 1390024 
60 3.0 50 0.0612 2070748 
80 4.0 50 0.0816 2768981 
100 5.0 50 0.1020 3447377 
120 6.0 50 0.1224 4118809 
140 7.0 50 0.1428 4837026 
160 8.0 50 0.1632 5539765 
  Correlation co-efficient 0.9999 
  Slope 33843850.67 
  Intercept 1174.16 
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Precision Study for Analytical Method Validation of Tramadol Hydrochloride
Aceclofenac Tablets
¾ For Tramadol Hydrochloride
Standard Weight (mg) 18.3      
Standard Dilution 50 5 50   
Standard Potency 100.0 %     
Label Claim (mg) 37.5      
Mean Test Weight (mg) 232.8      
Factor 1 -     
Factor 2 -     
Standard Concentration 
(mg/ml) 0.0366     
      
Replicate 1 2 3 4 5 
Standard Area 259646 261779 261378 262747 259980 
Mean Standard Area 261106     
Stdev 1286.40     
% RSD 0.49     
 
Description Mean Area Test weight (mg) % Assay 
Set 1 273753 1168.1 102.0 
Set 2 275894 1169.3 102.7 
Set 3 272676 1167.9 101.6 
Set 4 274325 1157.9 103.1 
Set 5 271283 1161.0 101.7 
Set 6 273052 1160.1 102.4 
  Mean 102.3 
  Stdev 0.59 
  % RSD 0.58 
  Confidence Level (95.0%) 0.62 
 
Calculation:
Prototype calculation for one set:
1.1168
500
50
5
50
3.18
261106
273753Assay% ×××= 100
5.37
8.232
5
50 ×××
    = 102.0 %
175Tramado l  Hydroch lo r ide  and  Acec l o f enac . .
Part -A (Seect ion-III )
¾ For Aceclofenac
Standard Weight (mg) 51.8      
Standard Dilution 50 5 50   
Standard Potency 99.3 %     
Label Claim (mg) 100.0      
Mean Test Weight (mg) 232.8      
Factor 1 -     
Factor 2 -     
Standard Concentration 
(mg/ml) 0.1036     
      
Replicate 1 2 3 4 5 
Standard Area 3425238 3427707 3431001 3434049 3437656 
Mean Standard Area 3431130     
Stdev 4938.58     
% RSD 0.14     
 
Description Mean Area Test weight (mg) % Assay 
Set 1 3282936 1168.1 98.1 
Set 2 3286875 1169.3 98.1 
Set 3 3288107 1167.9 98.3 
Set 4 3289935 1157.9 99.2 
Set 5 3278731 1161.0 98.6 
Set 6 3293697 1160.1 99.1 
  Mean 98.6 
  Stdev 0.49 
  % RSD 0.50 
  Confidence Level (95.0%) 0.51 
 
Calculation:
Prototype calculation for one set:
1.1168
500
50
5
50
8.51
3431130
3282936Assay% ×××= 3.99
100
8.232
5
50 ×××
    = 98.1 %
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Intermediate Precision Study for Analytical Method Validation of
Tramadol Hydrochloride Aceclofenac Tablets
¾ For Tramadol Hydrochloride
Standard Weight (mg) 18.1      
Standard Dilution 50 5 50   
Standard Potency 100.0 %     
Label Claim (mg) 37.5      
Mean Test Weight (mg) 232.8      
Factor 1 -     
Factor 2 -     
Standard Concentration 
(mg/ml) 0.0362     
      
Replicate 1 2 3 4 5 
Standard Area 251119 259443 261032 261607 260211 
Mean Standard Area 258682     
Stdev 4306.80     
% RSD 1.66     
 
Description Mean Area Test weight (mg) % Assay 
Set 1 274319 1167.8 102.0 
Set 2 273491 1169.2 101.6 
Set 3 274349 1168.9 102.0 
Set 4 273198 1165.4 101.8 
Set 5 273605 1160.3 102.4 
Set 6 272697 1163.2 101.8 
  Mean 101.9 
  Stdev 0.27 
  % RSD 0.27 
  Confidence Level (95.0%) 0.29 
 
Calculation:
Prototype calculation for one set:
8.1167
500
50
5
50
1.18
258682
274319Assay% ×××= 100
5.37
8.232
5
50 ×××
    = 102.0 %
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¾ For Aceclofenac
Standard Weight (mg) 51.5      
Standard Dilution 50 5 50   
Standard Potency 99.3 %     
Label Claim (mg) 100.0      
Mean Test Weight (mg) 232.8      
Factor 1 -     
Factor 2 -     
Standard Concentration 
(mg/ml) 0.1030     
      
Replicate 1 2 3 4 5 
Standard Area 3299469 3423933 3436241 3436863 3432344 
Mean Standard Area 3405770     
Stdev 59647.36     
% RSD 1.75     
 
Description Mean Area Test weight (mg) % Assay 
Set 1 3278616 1167.8 98.1 
Set 2 3279877 1169.2 98.1 
Set 3 3287797 1168.9 98.3 
Set 4 3283409 1165.4 98.5 
Set 5 3282316 1160.3 98.9 
Set 6 3280094 1163.2 98.6 
  Mean 98.4 
  Stdev 0.31 
  % RSD 0.32 
  Confidence Level (95.0%) 0.33 
 
Calculation:
Prototype calculation for one set:
8.1167
500
50
5
50
5.51
3405770
3278616Assay% ×××= 3.99
100
8.232
5
50 ×××
                        = 98.1 %
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Comparison for Precision and Intermediate Precision Study for Analytical
Method Validation for Tramadol Hydrochloride Aceclofenac Tablets
¾ For Tramadol Hydrochloride
 Set %Assay 
1 102.0 
2 102.7 
3 101.6 
4 103.1 
5 101.7 
Precision study 
6 102.4 
1 102.0 
2 101.6 
3 102.0 
4 101.8 
5 102.4 
Intermediate precision study 
6 101.8 
 Mean 102.1 
 Stdev 0.47 
 % RSD 0.46 
 
¾ For Aceclofenac
 Set %Assay 
1 98.1 
2 98.1 
3 98.3 
4 99.2 
5 98.6 
Precision study 
6 99.1 
1 98.1 
2 98.1 
3 98.3 
4 98.5 
5 98.9 
Intermediate precision study 
6 98.6 
 Mean 98.5 
 Stdev 0.40 
 % RSD 0.40 
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Accuracy Study for Analytical Method Validation of Tramadol Hydrochloride
Aceclofenac Tablets
¾ For Tramadol Hydrochloride
Standard Weight (mg) 18.2          
Standard Dilution 50 5 50   
Standard Potency 100.0 %         
Factor 1 -         
Factor 2 -         
Standard Concentration 
(mg/ml) 0.0364         
      
Replicate 1 2 3 4 5 
Standard Area 271518 269386 275109 267286 268861 
Mean Standard Area 270432         
Stdev 3021.31         
% RSD 1.12       
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¾ For Aceclofenac
Standard Weight (mg) 49.6          
Standard Dilution 50 5 50   
Standard Potency 99.3 %         
Factor 1 -         
Factor 2 -         
Standard Concentration 
(mg/ml) 0.0992         
      
Replicate 1 2 3 4 5 
Standard Area 3420322 3421039 3421754 3424969 3425154 
Mean Standard Area 3422648         
Stdev 2261.94         
% RSD 0.07       
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Solution Stability Study for Analytical Method Validation of Tramadol
Hydrochloride Aceclofenac Tablets
¾ For Tramadol Hydrochloride
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 260392 261159 267935 264328 262170 
2 254901 260317 264968 265192 261927 
3 257240 256782 264130 263555 261336 
4 255518 261812 265905 266558 261331 
5 257058 258315 265036 266198 260358 
Mean 257022 259677 265595 265166 261424 
Stdev 2131.10 2085.68 1451.17 1255.08 700.41 
%RSD 0.83 0.81 0.55 0.47 0.27 
 
Solution stability for standard preparation at 2-8 °C 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours  
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 260392 260392 260392 260392 
2 254901 254901 254901 254901 
3 257240 257240 257240 257240 
4 255518 255518 255518 255518 
5 257058 257058 257058 257058 
1 255324 258861 259349 260494 
2 258516 257384 255916 258255 
Mean 256993 257336 257196 257694 
Stdev 1969.59 1870.29 2024.51 2182.52 
%RSD 0.77 0.73 0.79 0.85 
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Solution stability for standard preparation at room temperature 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours  
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 260392 260392 260392 260392 
2 254901 254901 254901 254901 
3 257240 257240 257240 257240 
4 255518 255518 255518 255518 
5 257058 257058 257058 257058 
1 261923 257993 259349 259334 
2 262795 255794 255916 261031 
Mean 258547 256985 257196 257925 
Stdev 3142.20 1853.27 2024.51 2376.19 
%RSD 1.22 0.72 0.79 0.92 
 
Solution stability for test preparation at 2-8 °C 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 260392 261159 267935 264328 262170 
2 254901 260317 264968 265192 261927 
3 257240 256782 264130 263555 261336 
4 255518 261812 265905 266558 261331 
5 257058 258315 265036 266198 260358 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 273065 271328 271516 272799 272447 
2 269238 274725 271750 275489 272828 
Mean 271152 273027 271513 274144 272638 
% Assay 102.4 102.1 102.0 102.0 101.8 
Standard weight (mg) 18.2 18.2 18.7 18.5 18.3 
Test weight (mg) 1164.0 1164.0 1164.0 1164.0 1164.0 
% Absolute difference 
compare to that of 
initial 
 0.3 0.4 0.4 0.6 
 
185Tramado l  Hydroch lo r ide  and  Acec l o f enac . .
Part -A (Seect ion-III )
Solution stability for test preparation at room temperature 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 260392 261159 267935 264328 262170 
2 254901 260317 264968 265192 261927 
3 257240 256782 264130 263555 261336 
4 255518 261812 265905 266558 261331 
5 257058 258315 265036 266198 260358 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 273065 274081 271265 272175 271087 
2 269238 271484 271580 272159 270236 
Mean 271152 272783 271423 272167 270662 
% Assay 102.4 102.0 101.9 101.3 101.0 
Standard weight (mg) 18.2 18.2 18.7 18.5 18.3 
Test weight (mg) 1164.0 1164.0 1164.0 1164.0 1164.0 
% Absolute difference 
compare to that of 
initial 
 0.4 0.5 1.1 1.4 
 
Calculation:
Prototype calculation for one set:
0.1164
500
50
5
50
2.18
257022
271152Assay% ×××= 100
5.37
8.232
5
50 ×××
    = 102.4 %
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¾ For Aceclofenac
System suitability of standard preparation for solution stability 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3347996 3382284 3385487 3391207 3316744 
2 3344176 3387704 3384372 3376527 3326361 
3 3358780 3388157 3383455 3385555 3331359 
4 3356068 3391170 3392057 3382404 3329634 
5 3357155 3390627 3384738 3385328 3331216 
Mean 3352835 3387988 3386022 3384204 3327063 
Stdev 6380.67 3526.13 3452.10 5345.72 6109.17 
%RSD 0.19 0.10 0.10 0.16 0.18 
 
Solution stability for standard preparation at 2-8 °C 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours  
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 3347996 3347996 3347996 3347996 
2 3344176 3344176 3344176 3344176 
3 3358780 3358780 3358780 3358780 
4 3356068 3356068 3356068 3356068 
5 3357155 3357155 3357155 3357155 
1 3364445 3370161 3355610 3380903 
2 3368077 3366295 3363435 3370000 
Mean 3356671 3357233 3354746 3359297 
Stdev 8435.62 9208.85 6549.26 12602.99 
%RSD 0.25 0.27 0.20 0.38 
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Solution stability for standard preparation at room temperature 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours  
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 3347996 3347996 3347996 3347996 
2 3344176 3344176 3344176 3344176 
3 3358780 3358780 3358780 3358780 
4 3356068 3356068 3356068 3356068 
5 3357155 3357155 3357155 3357155 
1 3360849 3359489 3355610 3362568 
2 3350173 3358676 3363435 3365092 
Mean 3353600 3354620 3354746 3355976 
Stdev 6192.34 6040.71 6549.26 7513.73 
%RSD 0.18 0.18 0.20 0.22 
 
Solution stability for test preparation at 2-8 °C 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3347996 3382284 3385487 3391207 3316744 
2 3344176 3387704 3384372 3376527 3326361 
3 3358780 3388157 3383455 3385555 3331359 
4 3356068 3391170 3392057 3382404 3329634 
5 3357155 3390627 3384738 3385328 3331216 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 3258806 3271689 3263250 3278056 3287915 
2 3270233 3276823 3283054 3281618 3284992 
Mean 3264520 3274256 3273152 3279837 3286454 
% Assay 98.9 98.8 98.8 98.9 98.8 
Standard weight (mg) 50.8 51.1 51.1 51.0 50.0 
Test weight (mg) 1164.0 1164.0 1164.0 1164.0 1164.0 
% Absolute difference 
compare to that of 
initial 
 0.1 0.1 0.0 0.1 
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Solution stability for test preparation at room temperature 
 Initial After 12 hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3347996 3382284 3385487 3391207 3316744 
2 3344176 3387704 3384372 3376527 3326361 
3 3358780 3388157 3383455 3385555 3331359 
4 3356068 3391170 3392057 3382404 3329634 
5 3357155 3390627 3384738 3385328 3331216 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 3258806 3285429 3274892 3269432 3274922 
2 3270233 3279243 3273532 3271832 3275400 
Mean 3264520 3282336 3274212 3270632 3275161 
% Assay 98.9 99.0 98.8 98.6 98.4 
Standard weight (mg) 50.8 51.1 51.1 51.0 50.0 
Test weight (mg) 1164.0 1164.0 1164.0 1164.0 1164.0 
% Absolute difference 
compare to that of 
initial 
 -0.1 0.1 0.3 0.5 
 
Calculation:
Prototype calculation for one set:
0.1164
500
50
5
50
8.50
3352835
3264520Assay% ×××= 3.99
100
8.232
5
50 ×××
    = 98.9 %
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STUDIES ON SYNTHESIS OF BIOACTIVE COMPOUNDS
INTRODUCTION
The chemistry of the heterocyclic compounds is as logical as that of aliphatic or
aromatic compounds. This study is of great interest both from the theoretical as well as
practical stand point. A heterocyclic compound is one which possesses acyclic structure
with at least two different kinds of atoms in the ring. The most common type, contain
largely carbon atom, nitrogen, oxygen and sulphur are the most common heteroatoms,
but many other elements, including even bromine, chlorine can also serve. The heterocyclic
compounds containing the less common atoms have been subject to much investigation
in recent years.
The variety of heterocyclic compounds is enormous, their chemistry is complex
and synthesizing them requires great skill. Among large number of heterocycles found in
nature nitrogen heterocycles are most abundant than those containing oxygen of sulphur
owing to their wide distribution in nucleic acid instance and involvement in almost every
physiological process of plants and animals.
Heterocyclic systems are encountered in many groups of organic compounds
possessing great applicability in industry as well as in our life in various ways i. e. most
of the sugars and their derivatives, including vitamin C, for instance, exist largely in the
form of five membered (Furanosied str.) or six membered (Pyranoised str.) ring containing
one oxygen atom. Most members of the vitamin B group possess heterocyclic rings
containing nitrogen; one example is vitamin B6 (Pyridoxine), which is a derivative of the
pyridine essential in amino acid metabolism. Many other examples of the importance of
heterocyclic compounds in biological systems can be given.
Natural products containing heterocyclic compounds such as alkaloids and
glycosides have been used since old age, as remedial agents. Febrifagl alkaloid from
ancient Chinese drug, Chang Shan, reserpine from Indian rouwopifia, Curen alkaloid
from arrow poison, codenine, j-tropine and strychnine are all examples of heterocyclic
compounds. Many antibiotics including penicillin, cephalosporin, norfloxacin,
streptomycin etc. also contain heterocyclic ring systems. Majority of the large number
of drugs being introduced in pharmacopeias in recent years are heterocyclic compounds.
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Many veterinary products like pyrantel and morantel are the drug of choice as
broad spectrum anthelmintics. The herbicides atrazine and simazine are well known
example of heterocyclic agrochemicals. Plant pigments such as indigo, hemoglobin and
anthiocyanins, chlorophyll has contributed much colour chemistry and many other
heterocyclic colouring matters are in use since prehistoric times. The heterocyclic
tetraselena fulvalene was the first ionic molecular crystal to demonstrate superconductivity.
Heterocyclic compounds are obtainable by the following methods.
a. Isolation from natural sources, i.e. alkaloids, amino acids, indigo dyes etc.
b. Degradation of natural products i.e. acridine, furfural, indol, pyridine, quinoline,
thiophene etc.
c. Synthesis: Synthesis methods for obtaining heterocyclic compounds may be
divided into ring closer reactions, addition reaction and replacement reaction.
Cyclisation is usually accomplished by elimination of some small molecules such
as water or ammonia from chain of suitable length.
Heterocyclic compounds have a great applicability as drugs because,
a. They have a specific chemical reactivity.
b. They resemble essential metabolism and can provide false synthons in biosynthetic
process.
The current interest in the creation of large, searchable libraries of organic
compounds has captured an imagination of organic chemists and the drug discovery
community. Efforts in numerous laboratories focused on the introduction of chemical
diversity have been recently reviewed and pharmacologically interesting compounds have
been identified for libraries of widely different compositions.
Research in the field of pharmaceutical has its most important task in the
development of new and better drugs and their successful introduction into clinical
practice. Central to these efforts, accordingly stand the search for pharmaceutical
substances and preparation which are new and original. In addition to these objectives
the searching for drug which exhibit a clear advantage over a drug already known. Such
advantages may be qualitative or quantitative improvement in activity, the absence of
undesirable side effect, a lower toxicity, improved stability of decreased cost.
It is important at the outset to note that drug discovery is not an unambiguous
term in the pharmaceutical R & D world. For example, it can be defined using either
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programmatic or organizational approaches (or both), with several options on each
category. Hence, it is important first to understand this variability and to adopt a specific
definition for the purpose of this discussion.
The contribution of organic chemistry to be development of scientific medicine in
the 19th century mainly from acyclic and carbocyclic compounds, although the pyrazoline
antipyrin (1) was introduced as an antipyretic and analgesic in 1984 and the first
barbiturate baritone (veranol) (2) in 1903. Guttmann treated, malaria with methylene
blue in 1891, with slight success, and in 1912 he introduced acriflavine as trypancide, it
has proved to be more valuable as an antiseptic. Phenazopyridini (pyridium) (3) was
introduced for the same purpose in 1926, and although it is relatively ineffective it has
continued to be used since it has some analgesic action.
N
N
CH3
Ph
O
NHNH
O
OO
Et Et
N NH2
N
N
Ph
1 2 3
Aims and objectives
Taking in view of the applicability of heterocyclic compounds, we have undertaken
the preparation of heterocycles bearing triazole and pyrimidines nucleus. The placements
of a wide variety of substituents of these nuclei have been designed in order to evaluate
the synthesized products for their pharmacological profile against several strains of
bacteria and fungi.
During the course of our research work, looking to the application of heterocyclic
compounds, several entities have been designed, generated and characterized using
spectral studies. The details are as under.
1. To generate several bioactive derivatives  of 2-thioxotetrahydropyrimidines and
their fused derivatives of thiazolo[3,2-a]pyrimidines.
2. To characterize these products for structure elucidation using various
spectroscopic techniques like IR, PMR and mass spectral analysis.
3. To evaluate these new products for better drug potential against different strains
of bacteria and fungi.
4. Purity of all compounds has been checked by thin layer chromatography.
Synthesis, Characterization and
Antimicrobial screening of
2-Thioxotetrahydropyrimidines
Part-[B]
(Section-I)
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SYNTHESIS CHARACTERIZATION AND ANTIMICROBIAL
SCREENING OF 2-THIOXOTETRAHYDROPYRIMIDINES
1 INTRODUCTION
Pyrimidine is the most important member of all the diazines as this ring system
occurs widely in living organisms. Purines, uric acid, barbituric acid, anti-malarial and
anti-bacterial agents also contain the pyrimidine ring. The chemistry of pyrimidine has
been widely studied. Pyrimidine was first isolated by Gabriel and Colman in 1899. Since
pyrimidine is symmetrical about the line passing C-2 and C-5, the positions C-4 and C-
6 are equivalent and so N-1 and N-3 are equivalent. When a hydroxyl or amino group is
present at the 2-, 4- or 6- position than they are tautomeric with oxo and imino
respectively (Figure-1).
Despite the importance of dihydroazines (particularly those containing the 1,4-
dihydropyrimidine and dihydropyridine moiety1) for clarifying a wide range of theoretical,
medicinal and biological problems, the chemistry of this group of compounds is still
extremely spotty.2-6 From the theoretical point of view, it is essential to predict the
structure, binding properties, chemical reactivity, etc. of dihydro compounds from the
number and positioning of nitrogen atoms in the ring, as well as from the disposition of
double bonds. Such quantum mechanical calculations also enable an evaluation of the
degree of aromatic character in potential homoaromatic and antiaromatic isomers.
Availability of novel model compounds for verifying these predictions would open up
new horizons in theoretical heterocyclic chemistry, particularly in clarifying the structures
leading to spontaneous isomerization of a derivative or in verifying its redox properties.
From the biochemical point of view, dihydroazines are of intense interest because
of presence of this group at the active site of the hydrogen transferring coenzyme
(nicotinamide adenine dinucleotied hdrogenase-NADH or reduced nicotinamide adenine
dinucleotide). This nucleotide, a central participant in metabolic processes in living
organisms, participates in the reduction of various unsaturated functionalities.
1. A. L. Weis;  Adv. Heterocycl. Chem., 38, 1 (1985).
2. S. Yasui, K. Nakamura, A. Ohno;  J. Org. Chem., 49, 878 (1984).
3. N. Baba, M. Amano, J. Oda, Y. Inouye;  J. Am. Chem. Soc., 106, 1481 (1984). Annular
Reports in Medicinal Chemistry. 19, 119 (1984).
4. U. Eisner, J. Kuthan;  J. Chem. Reu., 72, 1 (1972).
5. J. Kuthan, A. Kurfurst;  Jnd. Eng. Prod. Res. Deu., 21, 191 (1982).
6. D. M. Stout, A. I. Meyers,  J. Chem. Reu., 82, 223 (1982).
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In the area of drug development, dihydroazines show great promise, particularly
since the 4-aryldihydropyridines exhibit powerful vasodilation activity via modifying the
calcium ion membrane channel.7-11 Additionally, dihydropyridines have been found to
actively transport medication across biological membranes.12
Until recently, most of the information available on dihydroazines centered around
dihydropyridines, with very little data extending to the related dihydropyrimidines.
This lacuna has motivated our deep involvement in developing dihydropyrimidine
chemistry, particularly dihydropyrimidines containing no substituents on the ring nitrogen.13
These molecules have long been considered unstable for oxidation, polymerization or
disproportionation reactions.14
Figure (1) depicts the five possible isomeric structures of dihydropyrimidines,
exhibiting different dispositions of the double bonds.
        A        B        C        D        E
   
N
N
H
NH
N
H
N
N
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N
N
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3
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       1,2-       1,4-        1,6-         2,5-        4,5-
Figure-1
7. F. Bossert, W. Vater;  Naturwissenshaften,  58, 578 (1971).
8. W. Vater, G. Kronenberg; F. Hoffmeister, H. Keller, A. Meng, A. Oberdorf, W. Puls, K. Schlossmann, K.
Stoepel;  Arzneim. Forsch., 22, 1 (1972).
9. B. Loev, M. M. Goodman, K. M. Snader, R. Tedeschi, E. Macko,  J. Med. Chem., 17, 956 (1974).
10. P. H. Stone;  J. Cardiouasc. Med., 7, 181 (1982).
11. F. Bossert, H. Meyer, E. Wehinger;  Angew. Chem., Int. Ed. Engl., 20, 762 (1981).
12. N. Bodor; In Design of Biopharmaceutical Properties Through Prodrugs and Analogs; E. B. Roche,
Ed.; American Pharmaceutical Association: Washington, DC, 1977; p 98.
13. A. L. Weis, H. C. van der Plas,  Heterocycles, 24, 1433 (1986).
14. D. J. Brown,  In The Chemistry of Heterocyclic Compounds; A. Weissberger, Ed.; Wiley (Interscience):
New York, (1962). D. J. Brown,  In The Chemistry of Heterocyclic Compounds, Suppl. 1; A. Weissberger;
Ed.; Wiley: New York, (1970).
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However, these structures are not easy to synthesize and, as a result, most of the
known dihydropyrimidines have either 1,2- (A) or the tautomeric 1,4- (B) and 1,6- (C)
geometry (Figure 1). On the basis of data available in the literature,15,16 the
dihydropyrimidines can be conveniently divided into two groups, within each of which
interconversion between isomers is possible under thermal conditions, namely, the 1,4-
(B), 1,6- (C), and 4,5- (E) compounds, and the 1,2- (A) and 2,5- (D) isomers. It is
worthwhile to note that, while thermal interconversion between the two groups is not
observed, photochemical rearrangement of 1,4-(or 1,6-)dihydropyrmidines to 1,2-isomers
has been reported.17-18
It should be stressed that dihydroazines take part in various isomerization
processes, usually characterized by reversible or irreversible migrations within the ring,
the study of which is still in its infancy. Hydrogen migration, for example, is classified
either as rearrangement or tautomerism depending on its kinetic and thermodynamic
parameters; the former term is reserved for irreversible processes, while the latter is
used to describe fast reversible exchanges.19 A study of isomerization in
dihydropyrimidines provides an excellent opportunity for clarifying the factors regulating
these processes.
After successfully developing versatile synthetic techniques for obtaining a variety
of 1,4- and 1,6-dihydropyrimidines,20-22 as well as the observation of amidinic tautomerism
between the two,23-24 A. L. Weis et al.15 examining the possibility of preparative synthesis
of similarly N-unsubstituted 1,2-dihydro derivatives and studying their properties.
Particularly important goals of this study were the possible observation of the formally
allowed hydrogen shift of homoaromaticity25-26 or hydrogen shift of imine-enamine
tautomerism27 in these compounds, behaviors of which have been seen in other systems.
15. A. L. Weis, F. Frolow, R. Vishkautsan; J. Org. Chem., 51, 4623-4626 (1986).
16. A. L. Weis, R. Vishkautsan;  Heterocycles 23, 1077 (1985).
17. R. E. van der Stoel, H. C. van der Plas;  J. Chem. SOC., Perkin Trans.-1, 1288 (1979).
18. R. E. van der Stoel, H. C. van der Plas;  J. Chem. Soc., Perkin Trans.-1, 2393 (1979).
19. Y. I. Minkin, L. P. Olekhnovich, Y. A. Zhdanov; Acc. Chem. Res., 14, 210 (1981).
20. A. L. Weis;  Synthesis. 528 (1985).
21. A. L. Weis, F. J. Frolow;  Chem. Soc., Perkin Trans.-1, 83 (1986).
22. A. L. Weis, R. Vishkautsan;  Isr. J. Chem., in press.
23. A. L. Weis; Tetrahedron lett., 23, 449 (1982).
24. A. L. Weis, Z. Luz Porat; J. Am. Chem Soc., 106, 8021 (1984).
25. L. A. Paquette,  Angew. Chem., Int. Ed. Engl., 7, 565 (1968).
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To date few reports on the formation of 1,2-dihydropyrimidines exist in the
literature, and in those cases where a product could be isolated and characterized, the
material was either an N-substituted derivative or else it contained geminal disubstitution
at position 2, situations that prevent the molecule from oxidizing to the corresponding
pyrimidine.
 Pyrimidine ring carrying various substituents may be built up from two or three
aliphatic fragments by the principle synthesis or by a variety of other synthesis, which
are complimentary rather than alternative to it. A second type of synthesis is the
isomerisation or break down of another heterocycles such as hydration of purine but
such roots are frequently used.
26. L. A. Paquette; Acc. Chem. Res., 6, 393 (1973).
27. J. Armond, K. Chekir, J. Pinson;  Can. J. Chem., 52, 3971 (1974).
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2 SYNTHETIC ASPECTS
2.1 Biginelli Reaction
In 1893, Italian chemist Pietro Biginelli reported an acid catalyzed
cyclocondensation reaction of ethyl acetoacetate, benzaldehyde, and urea. The reaction
was carried out by simply heating a mixture of the three components dissolved in ethanol
with a catalytic amount of HCl at reflux temperature. The product of this novel one-pot,
three-component synthesis that precipitated on cooling of the reaction mixture was
identified correctly by Biginelli as 3,4-dihydropyrimidin-2(1H)-one.28
 
Me O
O
EtO2C
O H
+ NH2
NH2 O
N
NMe O
O
EtO2C
H
H
H
+
EtOH
Biginelli Dihydropyrimidine Synthesis
2.2 Alternative synthetic routes for better yield, shorter reaction time to
synthesize new analogs
Various modifications have been applied to Biginelli reaction to get better yield
and to synthesize biologically active analogs. Different catalysts have been reported to
increase the yield of the reaction. Microwave synthesis strategies have also applied to
shorten the reaction time. Solid phase synthesis and combinatorial chemistry has made
possible to generate library of DHPM analogs.
2.2-A Catalysts
Min Yang and coworkers29 have synthesized the different DHPMs by using
different inorganic salts as a catalyst. They found that the yields of the one-pot Biginelli
reaction can be increased from 20-50% to 81-99%, while the reaction time shorted for
28. P. Biginelli;  Gazz.Chem. Ital., 23, 360-416 (1893).
29. Y. Ma, C. Qiana, L.Wang, M. Yang; J. Org. Chem., 65, 3864-3868 (2000).
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18-24 hr to 20 min. This report discloses a new and simple modification of the Biginelli-
type reaction by using Yb(OTf)3 and YbCl3 as a catalyst under solvent free conditions.
One additional important feature of the present protocol is the catalyst can be easily
recovered and reused.
R CHO
O
NH2 NH2
O
R1 R2
O
+ +
Yb(OTf)3
100
NH
N
H
RO
R1
R2 O
Indium(III) chloride was emerged as a powerful Lewis catalyst imparting high
region and chemo selectivity in various chemical transformations. B. C. Ranu and
coworkers30  reported indium chloride(InCl3) as an efficient catalyst for synthesis of 3,4-
dihydropyrimidn-2(1H)-ones. A variety of substituted aromatic, aliphatic, and heterocyclic
aldehydes have been subjected to this condensation very efficiently. Thiourea has been
used with similar success to provide the corresponding dihydropyrimidin-2(1H)-thiones.
O
R
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R
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O
+ R3 CHO
X
NH2 NH2
+
InCl3
THF
NH
N
H
R
3
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R
2
R
1
X
Where X = O or S
Majid M. Heravi et al.32 have reported a simple, efficient and cost-effective method
for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones/thions by one pot three-component
cyclocondensation reaction of a 1,3-dicarbonyl compound, an aldehyde and urea or
thiourea using 12-tungstophosphoric acid31 and 12-molybdophosphoric acid as a
recyclable catalyst.
NH2 NH2
X
+
R1 H
O
+
CH3
O
R2
O 12-molybdophosphoric acid
12-tungstophosphoric acid OR
AcOH/reflux
NH
N
H
R1 H
R2COO
CH3 X
Where X = O or S
30. B. C. Ranu, A. Hajra, U. Jana; J. Org. Chem., 65, 6270-6272 (2000).
31. M. M. Heravi, F. Derikvand, F. F. Bamoharram; J. Mol. Catal., 242, 173-175 (2005).
32. M. M. Heravi, K. Bakhtiari, F. F. Bamoharram; Catal. Commun., 7, 373-377 (2006).
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A novel covalently anchored sulfonic acid onto the surface of silica was prepared
and investigated for the Biginelli reaction by Satya Paul and co-workers.33 The catalyst
is highly stable, completely heterogeneous and recyclable for several times.  The work-
up procedure is very simple and Biginelli compounds were obtained in good to excellent
yields.
CH3 O
O
OCH3
R
O H
+ NH2
NH2 X
Catalyst 1
Stirring at 80
o
C, 7
NH
N
H
R1 H
CH3 X
O
OCH3
Where X = O or S
An efficient three-component synthesis of 3,4-dihydropyrimidinones using
trichloroisocyanuric acid (TCCA) as mild, homogeneous and neutral catalyst for Biginelli
reaction in ethanol or DMF under reflux condition.34
33. R. Gupta, S. Pal, R. Gupta;  J. Mol. Catal., 266, 50-54 (2007) .
34. M. A. Bigdeli, S. Jafari, G. H. Mahdavinia, H. Hazarkhani; Catal. Comm., 8 , 1641-1644 (2007).
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Very recently, many researchers35-41 have investigated an efficient Biginelli reaction
under solvent-free conditions for one-pot synthesis of 3,4-dihydropyrimidi-2-(1H)ones/
thiones using various catalyst as described under.
R O
O
R1
O H
+ NH2
NH2 X
NH
N
H
R X
O
H
R1various catalyst
R
Where X = O or S
35. Yang Yu, Di Liu, Chunsheng Liu, Genxiang Luo, Bioorg. Med. Chem. Lett., 17, 3508–3510 (2007).
36. WeiYi Chen, SuDong Qin, JianRong Jin; Catal.Commun.,  8, 123–126 (2007).
37. A. Kumar, R. A. Maurya; J. Mol. Catal., 272, 53–56 (2007).
38. X. Wang, Z. Quan, Z. Zhang; Tetrahedron, xx, 1–7 (2007).
39. N. Ahmed, J. E. van Lier; Tetrahedron Lett., 48,  5407-5409 (2007).
40. N. S. Nandurkar, M. J. Bhanushali, M. D. Bhor, B. M. Bhanage; J. Mol. Catal., 271, 14-17 (2007).
41. F. Shirini, K. Marjani, H. T. Nahzomi,  Arkivoc, (i) 51-57 (2007).
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2.2-B Solid phase synthesis 
 The generation of combinatorial libraries of heterocyclic compounds by solid 
phase synthesis is of great interest for accelerating lead discovery and lead optimization 
in pharmaceutical research.42,43 Multicomponent reactions (MCRs) leading to 
heterocycles are particularly useful for the creation of diverse chemical libraries, since the 
combination of n≥3 small molecular weight building blocks in a single operation leads to 
high combinatorial efficiancy.42-44 Therefore, solid phase modifications of MCRs are 
rapidly becoming the cornerstone of combinatorial synthesis of small-molecule 
libraries.42-47 One such MCR that has attracted considerable attention in recent years is the 
Biginelli reaction, which involves the one-pot cyclocondensation of a b-ketoester with an 
aryl aldehyde and an urea/thiourea derivative.48   
The first actual solid-phase modification of the Biginelli condensation was reported by 
Wipf and Cunningham49 in 1995. In this sequence, g-aminobutyric acid-derived urea was 
attached to Wang resin using standard procedures. The resulting polymer-bound urea was 
condensed with excess β-ketoesters and aromatic aldehydes in THF at 55 °C in the 
presence of a catalytic amount of HCl to afford the corresponding immobilized DHPMs. 
Subsequent cleavage of product from the resin by 50% trifluoroacetic acid (TFA) 
provided DHPMs in high yields and excellent purity. 
O
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CH3R2
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O
NH2
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2. TFA, CH2Cl2 O
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42. A. Nefzi, J. M. Ostresh,  R. A. Houghton; Chem. Rev., 97, 449 (1997). 
43. J. W. Corbett;  Org. Prep. Proced. Int., 30, 489 (1998). 
44. I. Ugi;  J. Prakt. Chem., 339, 499 (1997). 
45. A. Doemling;  Combinatorial Chemistry & High Throughput Screening, 1,  1 (1998). 
46. L. F. Tietze, M. E. Lieb; Curr. Opin. Chem. Biol., 2, 363 (1998). 
47. S. L. Dax, J. J. McNally, M. A. Youngman;  Curr. Med. Chem., 6, 255 (1999). 
48. For a review on DHPMs, see: C. O. Kappe;  Tetrahedron, 49, 6937 (1993).  
49. P. Wipf, A. Cunningham;  Tetrahedron Lett., 36, 7819-7822 (1995). 
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Weiwei Li and Yulin Lam50 described the synthesis of 3,4-dihydropyrimidin-2-
(1H)ones/thions using sodium benzenesulfinate as a traceless linker. The key steps 
involved in the solid-phase synthetic procedure include (i) sulfinate acidification, (ii) 
condensation of urea or thiourea with aldehydes and sulfinic acid, and (iii) traceless 
product release by a one-pot cyclization-dehydration process. Since a variety of reagents 
can be used in steps-ii and iii, the overall strategy appears to be applicable to library 
generation. 
 
Recently, Gross et al51 developed a protocol for based on immobilized α-ketoamides to 
increase the diversity of DHPM. The resulting synthetic protocol proved to be suitable for 
the preparation of a small library using different building blocks. They found that the 
expected DHPM derivatives were formed in high purity and yield if aromatic aldehyde 
and α-ketoamide building blocks were used. The usage of an aliphatic aldehyde leads to 
an isomeric DHPM mixture. Purities and yields were not affected if thiourea was used 
instead of urea. 
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50. Li Weiwei, Lam Yulin;  J. Comb. Chem., 7, 721-725 (2005).  
51. G. A. Gross, Hanns Wurziger, Andreas Schober; J. Comb. Chem., 8, 153-155 (2006). 
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2.1-C Liquid phase synthesis
In the solid phase synthesis there are some disadvantages of this methodology
compared to standard solution-phase synthesis, such as difficulties to monitor reaction
progress, the large excess of reagents typically used in solid-phase supported synthesis,
low loading capacity and limited solubility during the reaction progress and the
heterogeneous reaction condition with solid phase.52
Recently, organic synthesis of small molecular compounds on soluble polymers,
i.e. liquid phase chemistry53 has increasingly become attractive field. It couples the
advantages of homogeneous solution chemistry with those of solid phase chemistry.
Moreover owing to the homogeneity of liquid-phase reactions, the reaction conditions
can be readily shifted from solution-phase systems without large changes, and the amount
of excessive reagents is less than that in solid-phase reactions.
In the recent years, Task Specific room temperature Ionic Liquids (TSILs) have
emerged as a powerful alternative to conventional molecular organic solvents or catalysts.
Liu Zuliang et al.54 reported cheap and reusable TSILs for the synthesis of 3,4-
dihydropyrimidin-2(1H)-ones via one-pot three component Biginelli reaction.
Ionic liquid-phase bound acetoacetate react with (thio)ureas and various aldehydes
with a cheap catalyst to afford ionic liquid-phase supported 3,4-dihydropyrimidin-2(1H)-
(thi)ones by Jean Pierre Bazureau and co-workers.55
3,4-Dihydropyrimidinones (Biginelli products) are synthesized in one-pot of
aldehydes, â-dicarbonyl  compounds and urea, catalyzing by non-toxic room temperature
ionic liquid 1-n-butyl-3-methylimidazolium  saccharinate (BMImSac).56
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52. P. M. Toy, K. D. Janda; Acc. Chem. Res., 33, 546-554 (2000).
53. (a) D. J. Gravert, K. D. Janda;  Chem. Rev., 97, 489 (1997). (b) P. Wentworth, K. D. Janda;  Chem. Rev.,
1917 (1999). (c) P. H. Toy; K. D. Janda;  Acc. Chem. Res., 33, 546 (2000).
54. Fang Dong, Luo Jun, Zhou Xinli, Ye Zhiwen, Liu Zuliang; J. Mol. Catal., 274, 208-211 (2007).
55. Jean Christophe Legeay, Jean Jacques Vanden Eynde, Loic Toupet, Jean Christophe Legeay; ARKIVOC,
(iii) 13-28 (2007).
56. Li Minga, Guo Wei-Si, Wen Li-Rong, Li Ya-Feng, Yang Hua-Zheng; J. Mol. Catal., 258, 133-138 (2006).
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2.2-D Microwave assisted synthesis
In general, the standard procedure for the Biginelli condensation involves one-
pot condensation of the three building blocks in a solvent such as ethanol using a strongly
acidic catalyst, that is, hydrochloric acid.57 One major drawback of this procedure,
apart from the long reaction times involving reflux temperatures, are the moderate yields
frequently observed when using more complex building blocks.
Microwave irradiation (MWI) has become an established tool in organic synthesis,
because the rate enhancements, higher yields, and often, improved selectivity, with respect
to conventional reaction conditions.58 The publication by Anshu Dandia et al.59 described
12 examples of microwave-enhanced solution-phase Biginelli reactions employing ethyl
acetoacetate, (thio)ureas, and a wide variety of aromatic aldehydes as building blocks.
Upon irradiation of the individual reaction mixtures (ethanol, catalytic HCl) in an open
glass beaker inside the cavity of a domestic microwave oven the reaction times were
reduced from 2–24 hours of conventional heating (80oC, reflux) to 3–11 minutes under
microwave activation (ca. 200–300 W). At the same time the yields of DHPMs obtained
by us were markedly improved compared to those reported earlier using conventional
conditions.
CH2
CH3 O
H5C2OOC
Ar
O H
+ NH2
RNH X
Microwaves
C2H5OH, H
+
NH
NCH3 X
H5C2OOC
Ar
R
57. G. A. Gross, H. Wurziger, A. Schober; J. Comb. Chem., 8, 153-155 (2006).
58. (a) S. Caddick;  Tetrahedron, 51, 10403 (1995). (b) S. Deshayes, M. Liagre, A. Loupy, J. Luche, A.Petit;
Tetrahedron, 55, 10851(1999). (c) P. Lidstrom,  J. Tierney, B. Wathey,  J. Westman; Tetrahedron, 57,
9225 (2001). (d) A. Kirschning, H. Monenschein, R. Wittenberg; Angew. Chem. Int. Ed., 73, 193,
(2001). (e) R.S. Varma;  Pure Appl. Chem., 73, 193 (2001). (f) A. Loupy; Microwaves in Organic
Synthesis; Wiley-VCH: Weinheim, 2002.
59. A. Dandia, M. Saha, H. Taneja,  J. Fluorine Chem., 90, 17 (1998).
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In recent years, solvent –free reactions using either organic or inorganic solid
supports60 have received increasing attention. There are several advantages to performing
synthesis in dry media: (i) short reaction times, (ii) increased safety, (iii) economic
advantages due to the absence of solvent. In addition, solvent free MWI processes are
also clean and efficient.
Activated fly ash, an industrial waste (pollutant) is an efficient and novel catalyst
for some selected organic reactions in solvent free conditions under microwave irradiation.
M. Gopalakrishnan and co-workers61 have reported Biginelli reaction under microwave
irradiation in solvent-free conditions using activated fly ash as a catalyst.
2.1-E Ultrasound assisted synthesis
Ultrasound as a green synthetic approach has gradually been used in organic
synthesis over the last three decades. Compared with the traditional methods, it is more
convenient, easier to be controlled, and consumes less power. With the use of ultrasound
irradiation,62 a large number of organic reactions can be carried out in milder conditions
with shorter reaction time and higher product yields.
Ultrasound irradiated and amidosulfonic acid (NH2SO3H) catalyzed synthesis of
3,4-dihydropyrimidi-2-(1H)ones have reported by Ji-Taai Li and co-workers63 using
aldehydes, á-ketoester and urea.
60. P. Diddams, M. Butters,  In Solid Supports and Catalysts in Organic Synthesis; K. Smith; Ed.; Ellis
Harwood and PTR Prentice Hall: New York and London, 1992, Chapters 1, 3 and 5.
61. M. Gopalakrishnan, P. Sureshkumar, V. Kanagarajan, J. Thanusu, R. Govindaraju;  Arikvoc, (xiii) 130-
141 (2006).
62. (a)  H. A. Stefani,  C. M. P. Pereira,  R. B. Almeida,  R. C. Braga,  K. P. Guzen, R. Cella;  Tetrahedron Lett.,
46, 6833 (2005). (b)  Z. L. Shen, S. J. Ji, S.Y. Wang , X. F. Zeng;  Tetrahedron, 61, 10552 (2005) .
63. Ji-Tai Li, Jun-Fen Han, Jin-Hui Yang, Tong-Shuang Li; Ultrasonics Sonochemistry 10, 119-122 (2003).
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Chenjiang Liu et al.64 have synthesized a novel series of 4-substituted pyrazolyl-
3,4-dihydropyrimidin-2(1H)-(thio)ones under ultrasound irradiation  using magnesium
perchlorate [Mg(ClO4)2] as catalyst, by the condensation of 5-chloro/phenoxyl-3-methyl-
1-phenyl-4-formylpyrazole, 1,3-dicarbonyl compound and urea or thiourea in moderate
yields. The catalyst exhibited remarkable reactivity and can be recycled.
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Sonication of aromatic aldehydes, urea and ethyl acetoacetate in presence of
solvent (ethyl alcohol) or solvent-less dry media (bentonite clay) by supporting-zirconium
chloride (ZrCl4) as catalyst at 35 kHz gives 6-methyl-4-substitutedphenyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylic acid ethyl esters proficiently in high yields reported
by Harish Kumar.65
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64. X. Zhang, Y. Li, C. Liu, J. Wang; J. Mol. Catal., 253, 207-211(2006).
65. H. Kumar, A. Parmar; Ultrasonics Sonochemistry, XXX, XXX (2003). Article in Press
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3 MICHANISTIC STUDY
In 1893 Biginelli reported the first synthesis of dihydropyrimidines by a simple
one-pot condensation reaction of ethyl acetoacetate, benzaldehyde and urea.66
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EtO2C
O H
+ NH2
NH2 O
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NMe O
O
EtO2C
H
H
H
+
EtOH
Despite the importance and current interest in dihydropyrimidines of the Biginelli
type, the mechanism of the classical three-component Biginelli condensation has not
been elucidated with certainty.67  Early work by Folkers and Johnson68  suggested that
N,N”-benzylidienebisurea (i.e. the primary bimolecular condensation product of
benzaldehyde and urea), is the first intermediate in this reaction.
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In 1973 Sweet and Fissekis69 proposed that a “carbenium ion mechanism”,
produced by and acid-catalyzed aldol reaction of benzaldehyde with ethyl acetoacetate,
is the key intermediate and is formed in the first and limiting step of the Biginelli reaction.
66. P. Biginelli;  Gazz.Chim. Ital., 23, 360-416 (1893).
67. C. O. Kappe;  Tetrahedron, 49, 6937-6963 (1993).
68. K. Folkers, T. B. Johnson;  J. Am. Chem. Soc., 55, 3784-3791 (1933).
69. F. Sweet, J. D. Fissekis;  J. Am. Chem. Soc., 95, 8741-8749 (1973).
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Kappe C. O.70 carried out a detailed reinvestigation of the mechanism of the
Biginelli condensation using 1H-NMR and 13C-NMR spectroscopy to identify possible
intermediates.
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70. C. O. Kappe; J. Org. Chem., 62, 7201-7204 (1997).
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Kappe have established that the key step in this sequence involves the acid-
catalyzed formation of an N-acyliminium ion intermediate of type (5) from the aldehyde
(2) and urea (3) precursors. Interception of the iminium ion (5) by ethyl acetoacetate
(1), presumably through its enol tautoer, produces an opean chain ureide (7) which
subsequently cyclizes to hexahydropyrimidine (10). Acid-catalyzed elimination of water
form (10) ultimately leads to the final DHPM product (11). The reaction mechanism can
therefore be classified as an á-amidoalkylation, or more specifically as an á-
uridoalkylation.71
71. H. Petersen; Synthesis,  243-292 (1973).
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4 BIOLOGICAL PROFILE
4-Aryl-1,4-dihydropyridines of the nifedipine type (DHPs, e.g nifedipine) are
the most studied class of organic calcium channel modulators. More than 30 years after
the introduction of nifedipine (12), many DHP analogs have now been synthesized and
numerous second-generation commercial products have appeared on the market (e.g.
nitrendipine, nicardipine and amlodipine).72
The aza-analogs such as dihydropyrimidines of type (13) (DHPMs) which show
a very similar pharmacological profile to classical dihydropyridine calcium channel
modulators.73-79 Over the past several lead-compounds were developed (e.g. 13, SQ
32926 and (14) SQ 32574)76-78  that are superior in potency and duration of
antihypertensive activity to classical dihydropyridine drugs, and compare favorable with
second-genera t ion  analogs  such  as  amlodip ine  and n icard ip ine .76,77
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72. F. Bossert, W. Vater,  Med. Res. Rev., 9, 291 (1989).
73. H. Cho, M. Ueda, K. Shima, A. Mizuno, M. Hayashimatsu, Y. Ohnaka, Y.Takeuchi, M. Hamaguchi, K.
Aisaka, T. Hidaka, M. Kawai, M. Takeda, T. Ishihara, K. Funahashi, F. Sarah, M. Morita, T. J. Noguchi;
Meal. Chem., 32, 2399-2406 (1989).
74. K. S. Atwal, G. C. Rovnyak, J. Schwartz, S. Moreland, A. Hedberg, J. Z. Gougoutas, ; M. F. Malley, D. M.
Floyd,  J. Med Chem., 33, 1510-1515 (1990).
75. K. S. Atwal, G. C. Rovnyak, S. D. Kimball, D. M. Floyd, S. Moreland, B. N. Swanson, J. Z. Gougoutas,
J. Schwartz, K. M. Smillie, Malley, M. F..1. Med. Chem., 33, 2629-2635 (1990).
76. K. S. Atwal, B. N. Swanson, S. E. Unger, D. M. Floyd, S. Moreland, A. Hedberg, B. C. O’Reilly;  J. Med.
Chem., , 34,  806-811 (1991).
77. G. C. Rovnyak, K S. Atwal, A. Hedberg, S. D. Kimball, S. Moreland, J. Z. Gougoutas, B. C O’Reilly, J.
Schwartz, M. F. Malley;  J. Med Chem., 35, 3254-3263 (1992).
78. G. J. Grover, S. Dzwonczyk, D. M. McMullen, C. S. Normadinam, P. G. Sleph, S. J. Moreland;  J.
Cardiovasc. Pharmacol. , 26, 289-294 (1995). M. Negwer,  Organic-Chemical Drugs and their
Synonyms; Akademie Verlag: Berlin, p. 2558 (1994).
79. G. C. Rovnyak, S. D. Kimball, B. Beyer, G. Cucinotta, J. D. DiMarco, J. Gougoutas, A. Hedberg, M.
Malley, J. P. McCarthy, R. Zhang, S.  Moreland, J. Med. Chem., 38, 119-129 (1995). For a discussion,
see: D. J. Triggle, S. Padmanabhan;  Chemtracts: Org. Chem., 8, 191-196 (1995).
80. C. O. Kappe, J. Birgit, P. Tetiana;  Molecules, 5, 227-239 (2000).
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Calcium ion plays a vital role in a large number of cellular processes, including
excitation-contraction and  stimulus-secretion.81,82 The regulation of the intracellular
concentration of this ion makes possible the control of such Ca2+-dependent processes.
One means of accomplishing this is by the use of agents known as calcium channel
antagonists, which inhibit the movement of calcium through certain membrane channel.83-85
K.S.Atwal86 prepared the 2-heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5
pyrimidinecarboxylic acid esters (15), which lack the potential C3 symmetry of
dihydropyridine calcium channel blockers, were prepared and evaluated for biological
activity. Biological assays using potassium-depolarized rabbit aorta and radioligand
binding techniques showed that some of these compounds are potent mimics of
dihydropyridine calcium channel blockers. The combination of a branched ester (e.g.
isopropyl, sec-butyl) and an alkylthio group (e.g. SMe) was found to be optimal for
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N
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3
MeR
2
X
R
1
N
N
H
COOEt
MeS
NO2
15 16
biological activity.  Dihydropyrimidines (15) were found to be 30-fold less active than
dihydropyridines. The solid-state structure of dihydropyrimidine analogue (16) shows
that these compounds can adopt a molecular conformation which is similar to the reported
conformation of dihydropyridine calcium channel blockers.
81. R. H. Kretsinger;  Adv. Cyclic Nucleotide Res., 11, 1 (1979).
82. J. W. Putney Jr; Pharmacol. Rev., 30, 209 (1978).
83. L. B. Rosenberger D. J. Triggle;   Calcium and Drug Action; G. B. Weiss, Ed.; Plenum Press: New York,
1978.
84. D. J. Triggle;  New Perspectives on Calcium Antagonists; G. B. Weiss, Ed.; American Physiological
Society: Bethesda, MD 1981.
85. A. Fleckenstein;  Annu. Rev. Pharmacol. Toxicol, 17, 149 (1977).
86. K. S. Atwal, C. Rovnyakg, J. Schwartz, S. Moreland, A. Hedberg, J. Z. Gougoutas, M. F. Malley, D. M.
Floyd;  J.Med. Chem., 33, 1510-1515 (1990).
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Atwal K. et  al.87  synthesized the 3-substituted 1,4-dihydropyrimidine (17) and
documented that vasorelaxant activity was critically dependent on the size of the C5
ester group, isopropyl ester being the best, a variety of substituents (carbamate, acyl,
sulfonyl, alkyl) were tolerated at N3. The dihydropyrimidines (17) are significantly more
potent than corresponding 2-heteroalkyl-l,4-dihydropyrimidines. Dihydropyridine
enantiomer usually show 10-15 fold difference in activity, while the enantiomers of
dihydropyrimidine (18) show more than a 1000-fold difference in activity. These results
strengthen the requirement of an enamino ester for binding to the dihydropyridine receptor
and indicate a nonspecific role for the N3-substituent.
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George C. Rovnyak et al.88 examined a series of novel dihydropyrimidine calcium channel
blockers that contain a basic group attached to either C5 or N3 of the heterocyclic ring.
One of these compounds was identified as a lead, and the individual enantiomers (19a)
(R) and (19b) (S) were synthesized. Dihydropyrimidine (19a) is equipotent to nifedipine
and amlodipine in vitro. In the spontaneously hypertensive rat, dihydropyrimidine (19a)
is more potent and longer acting than nifedipine and compares most favorably with the
long-acting dihydropyridine derivative amlodipine. Dihydropyrimidine (19a) has the
potential advantage of being a single enantiomer
87. K. S. Atwal, G. C. Rovnyak, D. S. Kimball, M. F. David, M. Suzanne, N. S. Brian, Z. G. Jack, S. Joseph, M.
S. Kaye, F. M. Mary;  J. Med. Chem., 33, 2629 (1990).
88. G. C. Rovnyak, K. S. Atwal, A. Hedberg, S. D. Kimball, S. Moreland: J. Z. Gougoutas, B. C. O’Reilly, J.
Schwartz, M. F. Malleys; J. Med. Chem., 35, 3254-3263 (1992).
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Selma Sarac and co-workers89,90 have synthesized 4-arlyl-3,4-dihydropyrimidin-
2(1H)-one/thione derivatives. The calcium channel blocker activities of all compounds
performed on isolated rat ileum. Product (20), 2-nitrophenyl-derivative and (21), 2-
bromophenyl-derivative have potent antispasmodic activity on BaCl2-stimulated rat ileum.
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N. Dhanapalan and co-workers91 have synthesized dihydropyrimidinones and
describe compound (22) have a high binding affinity (Ki = 0.2nM) for á 1a receptor and
greater than 1500 fold selectivity over á 1b and á 1d adrenoceptors. Modification of the
linker in (22) gave compounds (23) and (24)92 viz ì-opioid receptor. Both these compounds
showed good á 1a binding affinity (Ki = 0.2nM) and selectivity (>800-fold over á 1b and
á 1d), also showed good selectivity over several other recombinant human G-protein
89. I. S. Zorkun, S. Sarac, S. Celebib, K. Erolb; Bioorg. Med. Chem., 14, 8582–8589 (2006).
90. M. Yarym, S. Sarac, M. Ertan, O. Sarnyc Batu, K. Erol;  Il Farmaco, 54, 359–36 (1999).
91. N. Dhanapalan, M. Shou Wu,  L. Bharat, C. George, F. James, T. G. Murali, Z. Jack, T. Sriram, R. M.
Mohammad, Z. Fengq, C. W. Wai, S. Wanying, T. Dake, M. W. John; J. Med. Chem., 2, 4764-4777
(1999).
92. T. G. Murali, N. Dhanapalan, R. M. Mohammad, L. Bharat, C. W. Wai, C. George, T. Sriram, M. Shou Wu,
Z. Fengqi, S. Wanying, T. Dake, S. Quanrong, Z. Jack, M. W. John; J. Med. Chem., 42, 4778-4793
(1999).
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coupled receptors. They have also identify that compound (25)93 was a lead compound
with a binding and functional profile comparable to that of (22). Compound (25) has
negligible affinity for the ì-opioid receptor.
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The synthesis and differential antiproliferative activity of monastrol (26a), oxo-
monastrol (26b) and eight oxygenated derivatives (28a,b–31a,b) on seven human cancer
cell lines are described by Dennis Russowsky.94 For all evaluated cell lines, monastrol
(26a) was shown to be more active than its oxo-analogue, except for HT-29 cell line,
suggesting the importance of the sulfur atom for the antiproliferative activity. Monastrol
(26a) and the thio derivatives (28a), (29a) and (31a) displayed relevant antiproliferative
properties with 3,4-methylenedioxy derivative (31a) being approximately more than 30
times more potent than monastrol (26a) against colon cancer (HT-29) cell line.
93. L. Bharat , T. Dake ,  N. Dhanapalan, R. M. Mohammad , C. W. Wai, W. M.Shou , Z. Fengqi, S.
Wanying, C. George, F. James; J. Med. Chem., 42, 4794-4803 (1999).
94. D. Russowsky, R. F. S. Canto,  S. A. A. Sanches, M. G. M. DOca, A. de Fatima, R. A. Pilli, L. K. Kohn,
M. A. Antonio, J. E. de Carvalho; Bioorg. Chem., 34,  173–182 (2006).
2 - T h i o x o t e t r a h y d r o p y r i m i d i n e s
Part-B (Section-I)
219
NH
N
H
Me
O
EtO
X
OH
NH
N
H
Me
O
EtO
X
NH
N
H
Me
O
EtO
X
OMe
NH
N
H
Me
O
EtO
X
OMe
NH
N
H
Me
O
EtO
X
OMe
OMe
NH
N
H
Me
O
EtO
X
O
O
26a X = S Monastrol
26b X = O oxo-Monastrol 27b X = O 
28a X = S 
28b X = O 
29a X = S 
29b X = O 
30a X = S 
30b X = O 
31a X = S 
31b X = O 
27a X = S
Y. Mizutani and co-workers identify that dihydropyrimidine dehydrogenase (DPD)
is the rate-limiting enzyme in the pathway of uracil and thymine catabolism. DPD is also
the principle enzyme involved in the degradation of 5-fluorouracil, and anticancer
chemotherapeutic agent that is used clinically to treatment of bladder cancer95 and renal
cell carcinoma.96
95. Y. Mizutania, H. Wadab, M. Fukushimad, O. Yoshidac, O. Ukimura, A. Kawauchi, T. Mikia; Euro. J.
Cancer, 37, 569–575 (2001).
96. Y. Mizutania, H. Wadab, O. Yoshidac, M. Fukushimad, H. Nakanishia, M. Nakaoa, T. Mikia; Euro. J.
Cancer, 39,  541–547 (2003).
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5 NEW DRUG MOLECULES UNDER CLINICAL STUDY
Recently many new molecules which are under study from phase-I to phase-IV
clinical trials for different pharmacological action have shown that the basic characteris-
tic of morpholine to behave as hidden amine has attracted many medicinal chemists to
incorporate this feature in drug design. Some interesting compounds are as under.
Treatment of Hypertension
Calcium Channel Blokers
Drug Data Report, 8(1), 35 (1986).
Calcium Channel Blokers97
Company Name: Merck & Co.
Drug Data Report, 10(3), 200 (1988).
Moreover one compound (33) is very active against non-nucleoside inhibitor of
human hepatitis B virus (IC50 = 53 nM for reduction of HBV DNA in human hepatoma
HepG2.2.15 cells) with low cytotoxicity in uninfected cells (CC50 = 7 mcM). Compound
inhibited both viral DNA and viral cores in HepG2.2.15 cells and HBV-transfected cell
lines, whereas it did not affect the activity of endopolymerase and had no effect on other
DNA or RNA viruses. In vivo in a transgenic mouse model, oral doses of 3-100 mg/kg
b.i.d. or t.i.d. for up to 28 days dose-dependently.
Decreased viral DNA in the liver and plasma with efficacy comparable to
lamivudine. However, unlike lamivudine, compound reduced cytoplasmic HBV core
antigen (HBcAg) in the liver of mice. Pharmacokinetic studies in mice showed rapid
absorption, 30% bioavailability and dose-proportional plasma levels.
N
H
N
CH3 CH3
O
O
CH3
32
N
H
NH
O CH3
O
CH3
NO2
33
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Compound Code: Bay-41-4109
Anti Hepatities B Virus Drugs
Bayer
Drug Data Report, 24(2), 165, 2002.
Calcium Channel Blocker
Drug Data Report, 8(5), 465, 1986.
MAR-99
Leukotrine Antagonist251
Drug Data Report, 10(10), 826, 1988.
(Known anti-asthmatic agent, now reported to pos-
sess anti-ulcerative and gastric antisecretory activ-
ities, which inhibits hydrochloric acid-ethanol-,
stress- and indomethacin-induced ulcers in rat.
Calcium Channel Blocker
Drug Data Report, 10(11), 899, 1988.
Antifungal Agent.
253
Clin Microbiol Infect 2003, 9, 1504.
In vitro susceptibility of Candida species isolated
from cancer patients against some antifungal
agents.
N
H
NH
CH3
O
O
N
FF
CH3
Cl
F
34
N
N
O
OO
O
CH3 CH3
NO2
35
N
N
NH
OH
OO
O
CH3 CH3
MAR-99
36
N
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O
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CH3 S
N
CH3
NO2
CH3
CH3
N
NH
NH2
F
O
Flucytosine
(flurocytosine)
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Antimalarial Agent.
Iancet, 361 (9357), 577, 2003.
Acute Myocardial Infection
Treatment of Antiplatlet Therapy.
Immunosuppressants
Oncolytic Drug
Antibacterial Drugs
39th Intersci Conf Antimicrob Agents Chemother (Sept 26-
29, San Francisco) 1999, Abst F1808
In vitro activity of novel 6-anilinouracils targeted to DNA
polymerase III of Gram-positive bacteria
TNK-6123
Anti HIV Agent
Reverse Transcripase Inhibitors.
Non-nucleoside HIV-1 reverse transcriptase inhibitor
Compound was active not only against wild-type HIV-1
strains (IC50 = 3 nM against IIIB and NL4-3 HIV-1 strains)
but also showed nanomolar
N
N
NH2
NH2
Cl
CH3
Primethamine
N
N
N
N
N
N
N
N
OH
OH
OH
OH
Dipyridamole
N
NHNH
NH
N
Cl
Cl
Cl
Cl
O CH3
O
N
H
N
O
OH
NH
CH3 CH3
O
N
NH
S
CH3
CH3O
O
O
CH3
TNK-6123
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6 REACTION SCHEME
Step-1
NH2
Cl
O
H3CO
OCH3
+
Toluene
Reflux
Cl
Step-2
NH
O
OCH3
Cl
HO
R
NH2
NH2 S
+
H
+
Ethanol
NH
N
H
O
NH
Cl
SCH3
R
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7 EXPERIMENTAL
Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silicagel-G as stationary
phase. Ethyl acetate: Hexane (5:5) was used as a mobile phase. The other solvent system
like acetone: benzene was also employed.
Step-1 Synthesis of N-(4-chlorophenyl)-3-oxobutanamide.
A suspension of ethyl acetoacetate (0.01 mol, 1.16 gm) and 4-choloroaniline
(0.01 mol, 1.27 gm) in toluene (50 ml) containing catalytic amount of NaOH (0.05 ml,
40%) was refluxed on an oil bath for 8 hr. After completion of the reaction (TLC
monitoring) the solvent was removed under reduced pressure, separated solid was filtered
and washed with petroleum ether and crystallized from ethanol to give pure product.
Yield 67% m.p. 87-89 oC.
Step-2 Synthesis of N-(4-chlorophenyl)-6-methyl-4-phenyl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide.
The intimate mixture of N-(4-chlorophenyl)-3-oxobutanamide (0.01 mol, 2.11
gm), benzaldehyde (0.01 mol, 1.06 gm) and thiourea (0.01 mol, 0.76 gm) in ethanol (8
ml), containing 0.4 ml of concentrated HCl was heated under reflux for 6 hr. After
completion of the reaction, the reaction mixture was allowed to stand at 0 oC for several
hours and precipitation was obtained. The product was filtered, washed with chilled
methanol and isolated product crystalized from ethanol.Yield 53%. m.p. 272-273 oC,
Anal. Calcd. for C18H16ClN3OS Calcd: C, 60.14; H, 4.51; N, 11.74%, Found: C, 60.38;
H, 4.41; N, 11.81%.
Similarly, other N-(4-chlorophenyl)-6-methyl-4-aryl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamides were prepared and crystallized from appropriate
solvents, in some cases the products were purified by column chromatography. The reaction
time and percentage yields of the respective reactions are depicted in the physical data
Table-1a.
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Table-1a: Physical constatnt of N-(4-chlorophenyl)-6-methyl-4-aryl-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamides.
NH
N
H
O
NH
Cl
SCH3
R
.rS
.oN
noitutitsbuS
R
/alumroFraluceloM
thgiewraluceloM
.P.M
oC
dleiY
%
noitisopmoC%
dnuoF/.dclaC
C H N
a1 H C 81 H 61 NlC 3 SO58.753 372-272 35
14.06
83.06
15.4
14.4
47.11
18.11
b1 HCO-4 3
C 91 H 81 NlC 3O2S
88.783 142-042 25
38.85
67.85
86.4
66.4
38.01
97.01
c1 ON-3 2
C 81 H 51 NlC 4O3S
58.204 462-262 14
76.35
95.35
57.3
86.3
19.31
78.31
d1 lC-4 C 81 H 51 lC 2N3 SO03.293 672-572 24
11.55
60.55
58.3
97.3
17.01
37.01
e1 HCO(-4,3 3)2
C 02 H 02 lC 2N3 SO
09.714 142-042 64
84.75
83.75
28.4
67.4
50.01
30.01
f1 HCO(-5,2 3)2
C 02 H 02 NlC 3O3S
09.714 752-552 84
84.75
14.75
28.4
58.4
50.01
10.01
g1 HCO-2 3
C 91 H 81 NlC 3O2S
88.783 632-532 84
38.85
47.85
86.4
07.4
38.01
08.01
h1 HO-2 C 81 H 61 NlC 3O2S58.373 282-182 53
38.75
17.75
13.4
92.4
42.11
02.11
i1 ON-4 2
C 81 H 51 NlC 4O3S
58.204 562-462 94
76.35
06.35
57.3
17.3
19.31
58.31
j1 H6CO-3 5
C 42 H 02 NlC 3O2S
59.944 962-762 75
60.46
10.46
84.4
25.4
43.9
92.9
k1 F-4 C 81 H 51 NFlC 3 SO48.573 852-652 54
25.75
14.75
20.4
69.3
81.11
51.11
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7 SPECTRAL STUDIES
IR spectrum of N-(4-chlorophenyl)-6-methyl-4-(2-methoxyphenyl)-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide.
epyT edoMnoitarbiV mcycneuqerF 1-
HC-enaklA 3
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gnidneb.p.iH-C 5901
gnidnebp.oH-C 128
lynobraC O=C- 2761
enimA
.rtsHN- 7143
.fedHN- 0751
edilaH lC-C- 457
Instrument: Shimadzu FTIR-8400 using KBR DRS techniques. The percentage transmittance is
given in cm-1 and frequence range is between 400-4000cm-1.
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IR spectrum of N-(4-chlorophenyl)-6-methyl-4-(3-nitrophenyl)-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide.
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Instrument: Shimadzu FTIR-8400 using KBR DRS techniques. The percentage transmittance is
given in cm-1 and frequence range is between 400-4000cm-1.
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1H-NMR  spectrum of N-(4-chlorophenyl)-6-methyl-4-(4-methoxyphenyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
Instrument: BRUKER 400 MHz (Avance - II), Internal reference: TMS,
Solvent: DMSO [d6].
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Assignment of proton vlues of N-(4-chlorophenyl)-6-methyl-4-(4-methoxyphenyl)-
2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
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O
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1H-NMR spectrum of N-(4-chlorophenyl)-6-methyl-4-(2-methoxyphenyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
Instrument: BRUKER 400 MHz (Avance - II), Internal reference: TMS,
Solvent:DMSO [d6].
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1H-NMR spectrum of N-(4-chlorophenyl)-6-methyl-4-(3-nitrophenyl)-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide.
Instrument: BRUKER 400 MHz (Avance - II), Internal reference: TMS,
Solvent: DMSO [d6].
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9 ANTIMICROBIAL ACTIVITY
Method : Cup-Plate97
Gram positive bacteria : Staphylococcus aureus ATCC 6538
Staphylococcus epidermidis ATCC 12228
Gram negative bacteria : Escherichia coli ATCC 8739
Pseudomonas aeruginosa ATCC 1539
Fungi : Aspergillus niger ATCC 16888
Concentration : 1000 µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Ciprofloxacin, Cephalexin,
Erythromycin, Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,
Ciprofloxacin, Cephalexin, Erythromycin and antifungal activity was compared with viz
Greseofulvin. The inhibition zones measured in mm.
(a) Antibacterial activity
The purified products were screened for their antibacterial activity using cup-
plate agar diffusion method. The nutrient agar broth prepared by the usual method was
dispensed in 50 ml quantities of different conical flasks. Then, add the 0.5 ml culture of
each bacteria (Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC
12228, Escherichia coli ATCC 8739 and Pseudomonas aeruginosa ATCC 1539) in
nutrient agar broth and inoculate at 37 oC for 24 hr.
The nutrient agar was melted at 100 oC and after cooling to 56 oC, was poured
into petri plates of 13 cm diameter in quantities of 20 ml, and left on a flat surface to
solidify and the surface of the medium was dried at 37 oC. Then, above subcultures of
each bacteria pipetted in to the nutrient agar plate. The cups (10 mm diameter) were
formed by the help of borer in agar medium and filled with 0.04 ml (40 ì g) solution of
sample in DMF. The plates were incubated at 37 oC for 24 hr. and the control was also
maintained with 0.04 ml of DMF in a similar manner. After the completion of incubation
period, the zone of inhibition of growth in the form of diameter in mm was measure and
recorded in Table-1b
97. A. L. Barry; The antimicrobial susceptibility test: Principle and practices, edited by llluslea
& Febiger, (Philadelphia), USA, 180; Biol. Abstr., 64, 25183 (1977).
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(b) Antifungal activity
Aspergillus niger ATCC 16888 was employed for testing antifungal activity using
cup-plate agar diffusion method. The culture was maintained on sabourauds agar slants,
sterilized sabourauds agar medium was inoculated with 72 hr. old 0.5 ml suspension of
fungal spores in a separate flask.
The sabourauds agar was melted at 100 oC and after cooling to 56 oC, was
poured into petri plates of 13 cm diameter in quantities of 20 ml, and left on a flat
surface to solidify and the surface of the medium was dried at 37 oC. Then, above
subculture of fungi pipetted in to the sabourauds agar plate. The cups (10 mm diameter)
were formed by the help of borer in agar medium and filled with 0.04 ml (40 ì g) solution
of sample in DMF. The plates were incubated at 30 oC for 48 hr. and the control was
also maintained with 0.04 ml of DMF in a similar manner. After the completion of
incubation period, the zone of inhibition of growth in the form of diameter in mm was
measure and recorded in Table-1b
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SYNTHESIS CHARACTERIZATION AND ANTIMICROBIAL
SCREENING OF THIAZOLO[3,2-a]PYRIMIDINES
1 INTRODUCTION
In section one, importance of DHPM moiety and various modifications applied
to Biginelli reaction for better yield, shorter reaction time and to synthesize various
analogs is surveyed in detail. The biological profile of this heterocyclic moiety is also
briefly reported in section one.
Biginelli reaction is not only important to synthesize analogs of DHPM ring using
different building block as potent bioactive heterocycles, but also various scaffolds can
be synthesized from this heterocyclic scaffold.
Tetrahydro/dihydropyrimidine-2-thiones are the key intermediate for the synthesis
of fused pyrimidines. They have become of considerable interest during the last forty
years1-12. Many of these compounds have proved to be active anticancer5-10, antipyretic
and antiinflammatory agents,8-12 calcium antagonist,13-15 analgesic,16 antitumor,17,18
antidepresant,19 antibacterial and antifungal20-22 agents.
1. M. Reimlinger, M. A. Reiren, R. Merenyi; Chem. Ber., 103, 3252 (1970).
2. Q. Hayashi; Yakugaku Zasshi, 85, 442 (1965); Chem Abstr., 63, 5644 (1965).
3. M. H. Elangdi, S. A. Abdalla; J. Pract. Chem., 315, 1009 (1973).
4. M. H. Elangdi, M. Ohta, Bull. Chem. Soc. Japan, 46, 1830 (1973).
5. Y. Masisumi; Japanese Patent 13, 640 (63); Chem. Abstr., 60, 531 (1964).
6. Y. Masisumi; Japanese Patent 13, 641 (63); Chem. Abstr., 60, 531 (1964).
7. Y. Masisumi; Japanese Patent 7, 982 (62); Chem. Abstr., 59, 8764 (1963).
8. A. Takamizawa; Y. Hamashima; Japanese Patent 14, 423 (66); Chem. Abstr., 65, 20144b (1966).
9. A. Takamizawa; Y. Hamashima; Japanese Patent 17, 595 (65); Chem. Abstr., 63, 19112h (1965).
10. Ito, Japan, 7030, 101 (1970); Chem. Abstr., 74, 22827e(1971).
11. V. Sprio, S. Plescia, J. Heterocyclic Chem., 9, 951 (1972).
12. A. Takamizawa, H. Sato, Japanese Patent 72, 45,595 (1972); Chem. Abstr., 78, 58454c (1973).
13. A. Balkan, M. Ertan, T. Burgemeister; Arch. Pharm., (Weinheim), 325, 499 (1992).
14. A. Balkan, S. Uma, M. Ertan W. Wiegrebe; Pharmazie, 47, 687 (1992).
15. A. Balkan, B. Tozkoparan, M. Ertan, Y. Sara, N. Ertekin; Boll. Chim. Farm., 135, 648 (1996).
16. J. Baetz; Brit., 1,334,628 (1973); Chem. Abstr., 80, 48028u (1974).
17. B. Dash, M. Patra, P.K. Mohapatra; J. Inst. Chem., 52, 92 (1980); Chem. Abstr., 93, 239353z (1980).
18. Teijin Ltd., Jpn. Kokai Tokkyo Koho JP, 58, 24,590 [83, 24,590] (1983); Chem. Abstr., 98, 215611j (1983).
19. D. Bigg (Synthelabo S.A.); Fr. Demande FR, 2,479,831 (1981); Chem. Abstr., 96, 162725z (1982).
20. J. Mohan, V.K. Chadha, H.S. Chaudhary, B.D. Sharma, H.K. Pujari; Indian J. Exp. Biol., 10, 37 (1972).
21. S.N. Dehuri, A. Nayak; J. Ind. Chem. Soc., 60, 970 (1983).
22. H.R. Champaneri, S.R. Modi, H.B. Naik; Asian J. Chem., 6, 737 (1994); Chem. Abstr., 121, 300842y
(1994).
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The parent ring systems of known thiazolopyrimidine derivatives are shown in
structures 1-4.
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2 SYNTHETIC ASPECTS
The following routs have been employed for the synthesis of thiazolopyrimidines.
2.1  Azole Approaches
Starting from the thiazole ring (5) and subsequent construction of the pyrimidine
ring in the terminal step.
? Thiazolo[3,2-a]pyrimidine (7) was prepared in 30% yield by the reaction of 2-
aminothiazole (5) with ethyl cyanoacetate (6) in a sodium ethoxide/ethanol mixture
or using polyphosphoric acid23 or acetic acid.24,25
? However, oxothiazolopyrimidine (9) was obtained upon treatment with
phosphorous pentoxide and methanesulfonic acid (8).23
? The reaction of (5) with ethyl acetoacetate (10) at 140–150 oC resulted in the
formation of (11) that was then converted to the Z-isomer upon heating at 250 oC
and cyclized to give (12).26
? 2-Aminothiazole (5) cyclized with acetylacetone (13) at 100 oC, in the presence
of methanesulfonic acid-phosphorus pentoxide or formic acid–phosphorus
pentoxide, followed by treatment with 70% perchloric acid, to give the
thiazolopyrimidin-4-ium salt (14).27
? The ester (16) was obtained from 2-aminothiazole (5) with an excess of methyl
methanetricarboxylate (15) in 61% yield.28
? Cyclocondensation of (5) with diethyl ethoxymethylene malonate (17) in acetic
acid followed by hydrolysis of the ester (18) gave (19).29-30
? Similarly, 2-aminothiazole (5) reacted with (20) in ethanol to give (21).31
? Stanovink et al.32-36 reported the synthesis of a series of thiazolopyrimidine
derivatives upon reacting 2-aminothiazole with a variety of different reagents.
Thus, dimethylaminobut-2-enoate (or pentenoate), (22a–d), reacted with (5) to
give thiazolopyrimidines (23a–d) (Chart 1).
23. T. Tsuji;  J. Heterocycl. Chem., 28, 489 (1991).
24. M. A. Jacobson, R. Norton; PCT Int. Appl. WO 97 33,879 (1997); Chem. Abstr., 127, 293241v (1997).
25. M.M. El-kerdawy, M.A. Moustafa, L.M. Gad, S.M.E. Badr; Bull Fac. Pharm. (Cairo Univ.), 31(1), 67
(1993); Chem. Abstr., 121, 57472b (1994).
26. S. Sharma, M.S. Khanna, C.P. Garg, R.P. Kapoor, A. Kapil, S. Sharma; Indian J. Chem. Sec. B, 32B(6),
693 (1993).
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27. K. Takenaka, T. Tsuji; J. Heterocycl. Chem., 33, 1367 (1996).
28. A. Kutyrevand, T. Kappe; J. Heterocycl. Chem., 36, 237 (1999).
29. D. R. Shridhar, M. Jogibhukta, V. S. Krishnan; Indian J. Chem. Sec. B, 25B(3), 345 (1986).
30. T. Shioiri, K. Ninomija, S. Yamada; J. Am. Chem. Soc., 94, 6203 (1972).
31. T. Mishina, N. Tsuda, A. Inui, Y. Miura; Jpn. Kokai Tokkyo Koho JP 62, 169, 793; (1987); Chem. Abstr.
108, 56120e (1988).
32. L. Selic, S.G. Grdadolnik, B. Stanovnik; Heterocycles, 45(12), 2349 (1997).
33. G. Sorsak, S.G. Grdadolnik, B. Stanovnik; J. Heterocycl. Chem., 35, 1275 (1998).
34. L. Selic, B. Stanovnik; J. Heterocycl. Chem., 34, 813 (1997).
35. G. Sorsak, A. Sinur, L. Golic and B. Stanovnik; J. Heterocycl. Chem., 32, 921 (1995).
36. B. Stanovnik, H. Van de Bovenkamp, J. Svete, A. Hvala, I. Simonic, M. Tisher; J. Heterocycl. Chem.,
27, 359 (1990).
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? The reaction of 2-aminothiazole (5) with 2-hydropolyfluoroalk-2-enoate (24) in
basic medium gave two isomers, 7-oxo (25) and its isomeric 5-oxo (26). The
structure of both (25) and (26) was established through 1H NMR, 19F NMR and
mass spectra.37
? 2-Aminothiazole derivatives (5), (R1¼H, CO2Et; R2¼Ph, aryl, Me), reacted with
the acetylenic derivative (27) and ester derivative (28) in ethanol and
polyphosphoric acid, respectively, to give the isomeric oxothiazolopyrimidine
derivatives (29) and (30), in 5–32% and 8–97% yield, respectively.38
? Condensation of 2-aminothiazole (5) in absolute ethanol with the sodium salt of
ethyl oximinocyanoacetate (31) gave after acidification (pH 6) with diluted
hydrochloric acid, the nitroso derivative (32) in 92% yield.39
? Treatment of the 2-aminothiazaole derivatives (5) with the hydrazone derivatives
(33) gave the oxothiazolo [3,2-a] pyrimidine derivatives 34.40
? Compound (37) was prepared in 70–95% yield by thermal (160 oC) condensation
of  ary laminobis th iazole  (35)  wi th  two equivalents  of  b is (2 ,4 ,6-
trichlorophenyl)methyl malonate (36)41 (Chart 2).
37. Y.-S. Liu, W.-Y. Huang; J. Chem. Soc. Perkin Trans., 1(6), 981 (1997).
38. D. Janietz, B. Goldmann, W.-D. Rudorf ; J. Prakt. Chem., 330(4), 607 (1988).
39. M.R.D. Giudice, A. Borioni, C. Mustazza, F. Gatta, B. Stanovnik; J. Heterocycl. Chem., 32, 1725 (1995).
40. M. A. Metwally, A. M. Ismaiel, Y. M. Yousif, F. Eid; J. Indian Chem. Soc., 66(3), 179 (1989).
41. G.O. Mbagwa, R. Garland; J. Heterocycl. Chem., 25, 571 (1988).
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2.2 Azine Approaches
Starting from pyrimidine ring and subsequent construction of the thiazole in the
terminal step.
Pyrmidinethione derivatives (37-39) were alkylated with monochloroacetic acid
or chloroacetyl chloride and then cyclized to give thiazolopyrimidine derivatives.42-56
Thus, pyrimidinethione (37) reacted with (40) or (41) in DMF42 or in an acetic anhydride/
pyridine mixture44,46 to give thiazolo-pyrimidines (42) and (43). Alkylation with (40) in
the presence of an aromatic aldehyde42-44, 47, 49-52, 54 gave the ylidene derivatives (44).
Similarly, pyrimidinethione derivatives (38) and (39) reacted with monochloroacetic acid
in acetic acid/acetic anhydride/sodium acetate mixture47,48 or with chloroacetyl chloride
in dry dioxane to give the corresponding thiazolopyrimidines. Table I summarizes the
pyrimidine-thione derivatives (37-39) used in the synthesis of various thiazolopyrimidines.
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42. S.A. Abdel-Aziz; Phosphorus, Sulfur Silicon Relat. Elem., 116, 39 (1996).
43. F.M. Manhi, A.M. Abdel-Fattah Egypt. J. Pharm., 33(5–6), 825 (1992); Chem. Abstr., 121, 83254b
(1994).
44. J.M. Parmar, A.R. Parikh; Heterocycl. Commun., 4(5), 463 (1998).
45. M. Ghorab, Y.A. Mohamed, S.A. Mohamed, Y.A. Ammar; Phosphorus, Sulfur Silicon Relat. Elem.,
108(1–4), 249 (1996).
46. K.M. Ghoneim, M.Y.H. Essawi, M.S. Mohamed, A.M. Kamal; Pol. J. Chem., 72(7), 1173 (1998).
47. M.R. Mohamoud, A.Y. Soliman, H.M. Bakeer; Indian J. Chem. Sec. B, 29B(9), 830 (1990).
48. H.R. Champaneri, S.R. Modi, H.B. Naik; Asian J. Chem., 6(3), 737 (1994); Chem. Abstr., 121, 300842y
(1994).
49. H.Y. Moustafa;  Indian J. Heterocycl. Chem., 7(4), 273 (1998).
50. M.A. Salama, H.H. Mousa, M. Al-Shaikh; Orient. J. Chem., 7(4), 185 (1991); Chem. Abstr., 116, 151713z
(1992).
51. M.A.F. Sharaf, F.A. Abdel Aal, A.M. Abdel Fattah, A.M.R. Khalik; J. Chem. Res. (S), 354 (1996).
52. B. Tozkoparan, M. Ertan, P. Kelicen , R. Demirdamar; Farmaco, 54(9), 588 (1999).
53. M.S. Akhtar, M. Seth, A.P. Bhaduri; Indian J. Chem. Sec. B, 26B(6), 556 (1987).
54. M.A. Salama, H.H.A Mousa, S.A. El-Essa; Orient. J. Chem., 7(3), 128 (1991); Chem. Abstr., 116, 41405t
(1992).
55. R.M. Abdel-Rahman, M. Fawzy, I. El-Baz; Pharmazie, 49, 729 (1994).
56. C.D. Kappe, P. Roschger; J. Heterocycl. Chem., 26, 55 (1989).
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The Hantzsch-type condensation of dihydropyrimidines (39) with a substituted
2-bromophenylacetaldehyde (45) led to the thiazolopyrimidine derivatives (46).57,58
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Thiazolo[3,2-a]pyrimidine derivatives (48) were prepared by refluxing
pyrimidinethione derivative (38) with phenacyl bromide (47) in glacial acetic acid.59-61
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Reaction of pyrimidinethiones (37) with 1,2-dibromoethane (49) gave the
oxothiazolopyrimidine derivatives (50) in the presence of DMF/K2CO3 at 70–80 
oC.62-65
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57. G. Adam, S. Kolczewski, V. Mutel, J. Wichmann; Eur. Pat. Appl. Ep 891, 978, (1999); Chem. Abstr., 130,
125087t (1999).
58. J. Wichmann, G. Adam, S. Kolczewski, V. Mutel, T. Woltering; Bioorg. Medi. Chem. Lett., 9, 1573 (1999).
59. A. Balkan, S. Uma, M. Ertan, W. Wiegrebe; Pharmazie, 47(9), 687 (1992).
60. A. Balkan, M. Ertan, T. Burgemeister Arch. Pharm. (Weinheim, Ger.), 325(8), 499 (1992).
61. S.A. Abdel-Aziz, H.A. Allimony, H.M. El-Shaaer, U.F. Ali, R.M. Abdel-Rahman; Phosphorus, Sulfur
Silicon Relat. Elem., 113, 67 (1996).
62. V.J. Ran, A. Goel, M. Nath, P. Srivastava; Bioorg. Med. Chem. Lett., 4(22), 2653 (1994).
63. V.J. Ram; Arch. Pharm. (Weinheim, Ger.), 324(11), 837 (1991).
64. A. Mobinikhaledi, N. Foroughifar, F. Goodarzi; Phosphorus, Sulfur Silicon Relat. Elem., 179, 507-512
(2004).
65. A. Mobinikhaledi, N. Foroughifar, B. Ahamadi; Phosphorus, Sulfur Silicon Relat. Elem., 180, 339-345
(2005).
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2.3 Retro Diels-Alder reaction
Both azole and azine approaches were considered as major methods for synthesis
of the thiazolopyrimidines. Whereas, the retro Diels-Alder reaction was considered a
minor method. Other reported methods include: (i) cyclization of propargylthiopyrimidines
in the presence of Pd(II) salts, (ii) metabolism of a N-allylpyrimidine and (iii) reaction of
thiazole derivative with isocyanates.
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3 BIOLOGICAL PROFILE
Thiazolo[3,2-a]pyrimidines have generated recently interest due to their
interesting biological and pharmaceutical activities. Thus, these ring systems have following
significant activities.
Various derivatives of thiazolo[3,2-a]pyrimidine (51) have been synthesized by
B. Tozkoparan et al.66 and tested for their anti-inflammatory activities at the 100 mg/kg
dose level compared with indomethacin.
N
N S
H3COOC
CH3
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R
R'
51
Krzysztof Danel and co-workers67 have been synthesized substituted 2,3-dihydro-
7H-thiazolo[3,2-a]pyrimidin-7-ones and considered as annulated analogues of HEPT.
2,3-Dihydro-5-[(3,5-dimethylphenyl)methyl]-3-ethoxy-6-ethyl-7H-thiazolo[3,2-
a]pyrimidin-7-one (52) were found most active against HIV-1.
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66. B. Tozkoparan, M. Ertan, P. Kelicen, R. Demirdamar; Il Farmaco, 54, 588–593 (1999).
67. K. Danel, E. B. Pedersen, C. Nielsen; J. Med. Chem. 41, 191-198 (1998).
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Antimicrobial activity of thiazolo[3,2-a]pyrimidine (53, 54) have been screened
by H. M. Sayed et al.68 against various gram positive, gram negative pathogens and
fungi.
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68. H. H. Sayed, A. H. Shamroukh, A. E. Rashad; Acta Pharm., 56, 231–244 (2006).
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4 REACTION SCHEME
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5 EXPERIMENTAL
Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silicagel-G as stationary
phase. Ethyl acetate: Hexane (5:5) was used as a mobile phase. The other solvent system
like acetone: benzene was also employed.
Step-1 Synthesis of N-(4-chlorophenyl)-3-oxobutanamide.
As per Part-B (Section-I), page No.224.
Step-2 Synthesis of N-(4-chlorophenyl)-6-methyl-4-phenyl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide.
As per Part-B (Section-I), page No.224.
Step-3 Synthesis of N-(4-chlorophenyl)-7-methyl-5-phenyl-2,3-dihydro-5H-
thiazolol[3,2-a]pyrimidine-6-carboxamide.
1,2-Dibromoethane (0.011 mol, 1.88 gm) was added to a boiling solution of N-
(4-chlorophenyl)-6-methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxamide (0.01 mol, 3.57 gm) in dimethyl formamide (5 ml) and then refluxed for 50
minutes. After completion of the reaction, the reaction mass was poured into ice cold
sodium bicarbonate solution and precipitated were isolated by filtered through a Buchner
funnel and purified by column chromatography. Yield 82%. m.p. 205-206 oC, Anal. Calcd.
for C20H18ClN3OS Calcd: C, 62.57; H, 4.73; N, 10.95%, Found: C, 62.66; H, 4.68;
N, 10.87%.
Similarly, other N-(4-chlorophenyl)-7-methyl-5-aryl-2,3-dihydro-5H-
thiazolol[3,2-a]pyrimidine-6-carboxamide were prepared and crystallized from
appropriate solvents, in some cases the products were purified by column chromatography.
The reaction time and percentage yields of the respective reactions are depicted in the
physical data Table-2a.
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Table-2a: Physical constatnt of N-(4-chlorophenyl)-7-methyl-5-aryl-2,3-dihydro-
5H-thiazolol[3,2-a]pyrimidine-6-carboxamides.
N
N
O
NH
Cl
SCH3
R
.rS
.oN
noitutitsbuS
R
/alumroFraluceloM
thgiewraluceloM
.P.M
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dleiY
%
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dnuoF/.dclaC
C H N
a2 H C 02 H 81 NlC 3 SO98.383 602-502 28
75.26
66.26
37.4
86.4
59.01
78.01
b2 HCO-4 3
C 12 H 02 NlC 3O2S
29.314 702-602 18
49.06
98.06
78.4
87.4
51.01
60.01
c2 ON-3 2
C 02 H 71 NlC 4O3S
49.654 202-102 96
10.65
19.55
00.4
11.4
60.31
10.31
d2 lC-4 C 02 H 71 lC 2N3 SO33.814 612-412 08
24.75
63.75
01.4
71.4
40.01
60.01
e2 HCO(-4,3 3)2
C 22 H 22 NlC 3O3S
49.344 002-991 77
25.95
64.95
99.4
78.4
74.9
24.9
f2 HCO(-5,2 3)2
C 22 H 22 NlC 3O3S
49.344 312-212 28
25.95
84.95
99.4
98.4
74.9
54.9
g2 HCO-2 3
C 12 H 02 NlC 3O2S
29.314 322-222 97
49.06
88.06
78.4
87.4
51.01
12.01
h2 HO-2 C 02 H 81 NlC 3O2S98.993 022-912 67
70.06
10.06
45.4
74.4
15.01
34.01
i2 ON-4 2
C 02 H 71 NlC 4O3S
49.654 091-981 57
10.65
59.55
00.4
70.4
60.31
99.21
j2 CO-3 6H5
C 62 H 42 NlC 3O2S
00.874 732-532 87
33.56
03.56
60.5
10.5
97.8
27.8
k2 F-4 C 02 H 91 NFlC 3 SO09.304 512-512 27
74.95
44.95
47.4
07.4
04.01
63.01
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6 SPECTRAL STUDIES
IR spectrum of N-(4-chlorophenyl)-7-methyl-5-(4-methoxyphenyl)-2,3-dihydro-
5H-thiazolol[3,2-a]pyrimidine-6-carboxamide.
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Instrument: Shimadzu FTIR-8400 using KBR DRS techniques. The percentage transmittance is
given in cm-1 and frequence range is between 400-4000cm-1.
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IR spectrum of N-(4-chlorophenyl)-7-methyl-5-phenyl-2,3-dihydro-5H-
thiazolol[3,2-a]pyrimidine-6-carboxamide.
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given in cm-1 and frequence range is between 400-4000cm-1.
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1H-NMR spectrum of N-(4-chlorophenyl)-7-methyl-5-phenyl-2,3-dihydro-5H-
thiazolol[3,2-a]pyrimidine-6-carboxamide.
Instrument: BRUKER 400 MHz (Avance - II), Internal reference: TMS,
Solvent: DMSO [d6].
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Assignment of proton vlues of N-(4-chlorophenyl)-7-methyl-5-phenyl-2,3-dihydro-
5H-thiazolol[3,2-a]pyrimidine-6-carboxamide.
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